2004

Citizen Coalition Denounces I-330: Insurance Lobby Initiative Seeks to Limit Patient Rights: PRNewswire - December 28, 2004; SEATTLE, Dec. 28 /PRNewswire/ -- Today, Citizens for Better Safer Healthcare, a coalition of consumer and patient rights groups, denounced Initiative 330 (I-330) -- an initiative backed by the insurance industry and the state medical association -- that would drastically limit the rights of patients across the state of
FDA Approves PRIALT(R) (ziconotide intrathecal infusion) for Severe Chronic Pain: Novel Non-Narcotic Treatment Based on Marine Snail Peptide Blocks Pain Signals: PRNewswire - December 28, 2004; -- PRIALT is Approved for Use Only in The Medtronic SynchroMed(R) EL, SynchroMed(R) II Infusion System and Simms Deltec Cadd Micro(R) External Microinfusion Device and Catheter NEW YORK, Dec. 28 /PRNewswire/ -- This is a MultiVu special report. There is a new alternative for patients who suffer from severe chronic pain
Kurt Salmon Associates Highlights 2004's Eight Significant Issues in the Health Care Industry: U.S. political landscape, flu vaccine shortage, and potholes in information superhighway: PRNewswire - December 28, 2004; NEW YORK, Dec. 28 /PRNewswire/ -- From the re-election of George W. Bush to the closure of key emergency rooms, significant moments in 2004 health care provider history will significantly shape the future of the U.S. health care industry, says Kurt Salmon Associates (KSA) Health Care Consulting Group. * Re-election of
FDA Issues Not Approvable Letter to Cellegy Pharmaceuticals for Cellegesic(TM): PRNewswire - December 23, 2004; SOUTH SAN FRANCISCO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY) announced that it received late today a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment). Cellegesic was the
Epimmune Provides Update on Cancer and HIV Clinical Development Programs: PRNewswire - December 21, 2004; SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today provided an update of ongoing clinical development programs with its EP-2101 therapeutic cancer vaccine and its EP-1090 therapeutic HIV vaccine. Cancer Vaccine Clinical Development Epimmune conducted two Phase 1 clinical trials of its EP-21
Former Regional Director for Sales for Serono Laboratories, Inc. Pleads Guilty to Offering Kickbacks to Doctors, Reports U.S. Attorney: PRNewswire - December 21, 2004; BOSTON, Mass., Dec. 21 /PRNewswire/ -- A Hewlett, New York man pleaded guilty today in federal court to offering kickbacks to three New York City doctors by offering them an all expenses paid trip to attend a medical conference in Cannes, France in April of 1999, in return for writing prescriptions of Serostim, a brand
Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines: First Collaboration to Develop a Once-Daily Antiretroviral Fixed-Dose Regimen: PRNewswire - December 20, 2004; NEW YORK and FOSTER CITY, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences , Inc. (Nasdaq: GILD) today announced details of a joint venture to develop and commercialize the fixed-dose combination of Bristol-Myers Squibb s
AIDS Action Committee Manages Utility Assistance for People Living with HIV/AIDS in Seven Area Counties: PRNewswire - December 20, 2004; BOSTON, Dec. 20 /PRNewswire/ -- The AIDS Action Committee of Massachusetts, Inc. is administering a Utility Assistance Program for people living with HIV/AIDS in Suffolk, Middlesex, Plymouth, Norfolk, Bristol, Worcester and Essex Counties. The project is being funded by the Boston Public Health Commission (BPHC). Effec
U.S. FDA Approves New 500 mg Tablet Formulation of INVIRASE(R) -- New tablet reduces number of INVIRASE pills for HIV patients; approved after six-month FDA priority review --: PRNewswire - December 20, 2004; NUTLEY, N.J. -- Roche today announced U.S. Food and Drug Administration ( FDA ) approval of a new 500 mg film-coated tablet formulation of its HIV protease inhibitor INVIRASE(R) (saquinavir mesylate), designed for use in combination with a small dose of ritonavir and other anti-HIV drugs for the treatment of HIV infect
Celebrex, Vioxx Scandals Prompt AIDS Group to Call for Ban on Consumer Drug Advertising: AIDS Healthcare Foundation Says New Independent Panel Should Oversee All Drug Research: PRNewswire - December 17, 2004; What: MEDIA AVAILABILITY -- AHF Calls for Emergency Ban on Direct to Consumer Drug Advertising & Creation of a New Panel to Review Drug Research Who: Michael Weinstein, President, AIDS Healthcare Foundation Contact: Ged Kenslea, AHF Communications Director, 323.860.5225(w) 323.791.5526(m) LOS ANGELES, Dec.
Mymetics Receives NIH Approval to Advance HIV Vaccine Into Late Preclinical Studies: PRNewswire - December 17, 2004; NYON, Switzerland , Dec. 17 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) announced today that it has received approval from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to begin advanced preclinical testing of the Company s tri
Tides Foundation Receives $1 Million From the World Health Organization for Collaborative Fund for HIV Treatment Preparedness: PRNewswire - December 16, 2004; -- WHO Grant Supports HIV Treatment Advocacy and Education Efforts in Communities Around the World SAN FRANCISCO, Dec. 16 /PRNewswire/ -- Tides Foundation has been awarded a $1 million grant from the World Health Organization (WHO) in support of the Collaborative Fund for HIV Treatment Preparedness to support community
Secretary Thompson Announces PACHA Co-Chair: PRNewswire - December 16, 2004; WASHINGTON, Dec. 16 /PRNewswire/ -- HHS Secretary Tommy G. Thompson today announced Anita Smith as the co-chair of the Presidential Advisory Council on HIV/AIDS (PACHA). The PACHA provides the President and the Secretary with recommendations regarding programs and policies intended to anticipate and respond to the Worl
FIND and BD Combine International Efforts to Improve Rapid Tuberculosis Diagnosis for HIV-positive Patients in Developing Countries: PRNewswire - December 15, 2004; GENEVA, and FRANKLIN LAKES, N.J., Dec. 15 /PRNewswire-FirstCall/ -- FIND (Foundation for Innovative New Diagnostics) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced an international collaboration aimed at improving diagnosis of pulmonary tuberculosis (TB) in HIV-infected patients in developing countr
Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART: PRNewswire - December 15, 2004; MONTEGO BAY, Jamaica , Dec. 15 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD) demonstrated sustained viral suppression and safety over 120 weeks, according to data pres
You're Hired!!! Bid on Props and Memorabilia From 'The Apprentice' at www.Apprentice-auction.com December 16 - 29 to Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - December 14, 2004; -- Signed Items By Donald Trump, Show Contestants and More to Raise Funds for Lifesaving Pediatric Research SANTA MONICA, Calif., Dec. 14 /PRNewswire/ -- On Thursday, December 16, one lucky contestant on the NBC-TV phenomenon The Apprentice will receive the opportunity of a lifetime when Donald Trump utters the words w
US Needs Blue Ribbon Commission to Review All Drug Research Says AHF: Safety of AIDS Drug to Prevent Mother-to-Child Transmission of HIV Questioned: PRNewswire - December 13, 2004; -- As White House Prepared Launch of Global AIDS Program, NIH Officials Reportedly Kept Flawed Study Data From Administration. On Heels of Recent Scandals Involving the FDA and NIH, US Largest AIDS Group Says New Independent Panel Must Be Convened to Oversee All Drug Research What: MEDIA AVAILABILITY - Call for New Pan
Survivor: Vanuatu Props and Memorabilia Up for Bid on eBay December 12-26 to Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - December 13, 2004; -- Fans Are Encouraged to Visit http://www.Survivor-Auction.com and Out Last, Out Play and Out Bid All for a Great Cause SANTA MONICA, Calif., Dec. 13 /PRNewswire/ -- The warm waters of the South Pacific proved to be no vacation for the most unforgettable, quirky and controversial castaways the CBS-TV adventure series,
Panacos Pharmaceuticals Announces Initiation of Phase 2 Clinical Development of its HIV Drug Candidate, PA-457: PRNewswire - December 10, 2004; GAITHERSBURG, Md., Dec. 10 /PRNewswire/ -- Panacos Pharmaceuticals, Inc., today announced the initiation of a Phase 2a clinical trial of PA-457, the first in a new class of HIV drug candidates called Maturation Inhibitors. Institutional Review Board (IRB) and other approvals have been received and the study is now open
World Vision 'Gifts of Hope' Help Build a Better World for Children: More Than 120 Ways to Benefit the World's Children in the Name of Loved Ones: PRNewswire - December 9, 2004; SEATTLE, Dec. 9 /PRNewswire/ -- As harsh and perilous as many parts of the world are for impoverished children and families, there is hope. This hope arrives tangibly to hard-working people worldwide each year in the form of income -- producing animals, clean water, seeds and tools, and much more -- from the hearts of
MedMira Rapid HIV Test Ranked No. 1 in China: Accuracy of MiraWell(TM) Rapid HIV Test as Good as Traditional Tests: PRNewswire - December 9, 2004; HALIFAX, Dec. 9 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that its MiraWell(TM) Rapid HIV Test has been designated as the number one rapid HIV antibody test, according to results of the
Novel Antibiotic Shows Promise in Shortening Treatment Duration of Tuberculosis: PRNewswire - December 9, 2004; RARITAN, N.J., Dec. 9 /PRNewswire/ -- Scientists at Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) have identified a novel anti- tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection. Also, preliminary studies in healthy hum
MedMira Engages Distributor for Middle East: Rapid HIV Test to be Carried by Established Distributor: PRNewswire - December 7, 2004; HALIFAX, Dec. 7 /PRNewswire-FirstCall/ - MedMira Inc., ( MedMira ) (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has engaged the Prestige Group of Abu Dhabi, the medical device and pharmaceuticals division of the US $4.5 billion Al Jaber
China Can Avert Major AIDS Crisis and Beat TB Epidemic: But Drastic Scale-Up Necessary to Keep Ahead of Growing Pandemics: PRNewswire - December 6, 2004; BEIJING, Dec. 6 /Xinhua-PRNewswire/ -- In discussions with senior Chinese government officials, Richard Feachem, the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, praised China s recent response to its growing HIV/AIDS problem and its actions against tuberculosis. In China to discuss Gl
Ronald McDonald House Charities(R) (RMHC(R)) Marks World AIDS Day with Continued Support for Global Fight Against HIV/AIDS: PRNewswire - December 3, 2004; -- Grant to Elizabeth Glaser Pediatric AIDS Foundation Will Help Women and Children in Cameroon by Reducing Mother-to-Child Transmission of HIV OAK BROOK, Ill., Dec. 3 /PRNewswire/ -- Ronald McDonald House Charities today awarded a grant of US$300,000 (XAF 153,774,000 CFA franc) to the Elizabeth Glaser Pediatric AIDS F
Massachusetts Health Care Leaders Report State Government Lags Behind Changing Face Of AIDS: PRNewswire - December 3, 2004; BOSTON, Dec. 3 /PRNewswire/ -- In recognition of World AIDS Day, the Massachusetts Health Policy Forum (The Forum) convened state health care leaders on Wednesday to evaluate the progress made in combating AIDS in Massachusetts over the past 10 years. At the conference, the Forum released its report titled HIV/AIDS in
Healed of AIDS by Philip Savage: Catharsis Releases Astounding Test Results for Gay Businessman Who Has Won 10-Year Battle Against Incurable Immune Disease: PRNewswire - December 1, 2004; MONTGOMERY, Ala., Dec. 1 /PRNewswire/ -- Catharsis, a California not-for-profit corporation releases astounding HIV viral test results for Buz Crump, a 50-year-old gay businessman diagnosed as having HIV/AIDS for 10 years. Despite arsenals of medications, Crump suffered numerous infections, while his HIV viral load (a
World AIDS Day Chosen to Launch HIV/AIDS Radio Network, First All HIV/AIDS 'On Demand' Radio Network to Tackle AIDS: PRNewswire - December 1, 2004; SAN FRANCISCO, Dec. 1 /PRNewswire/ -- Aldagon Resources and the Affiliate Nanocasting Network (ANN) announced today the launch of the HIV/AIDS Radio Network -- the first on demand radio network dedicated to airing the voices of HIV and AIDS from around the world. The Network s pilot program, HIV and Me Talk Radio, pre
Roche Employees Walked 'Around the World' to Commemorate World AIDS Day in Second Annual Global Employee AIDS Walk Benefiting Charities Worldwide: PRNewswire - December 1, 2004; -- Six U.S. Roche sites join forces in supporting global fight against HIV/AIDS NUTLEY, N.J., Dec. 1 /PRNewswire/ -- More than 8,000 Roche employees from 33 countries and 60 sites collectively walked nearly 25,000 miles to raise funds today for local and international AIDS organizations. Funds raised by employee sponso
IPM Hails CAD $15 Million to Support Microbicide Research and Development to Protect Women Against HIV: PRNewswire - December 1, 2004; -- Canadian International Development Agency (CIDA) Makes Commitment on World AIDS Day - 2004 Theme is Women, Girls, HIV and AIDS SILVER SPRING, Md., Dec. 1 /PRNewswire/ -- The International Partnership for Microbicides (IPM) applauds the Canadian International Development Agency (CIDA) today for contributing CAD$ 15 m
Calypte Biomedical Initiates China Clinical Trials of Rapid Test Platform: PRNewswire - December 1, 2004; PLEASANTON, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has initiated a clinical trial program of its rapid HIV-1/2 test platform and HIV-1 Western blot supplemental tests in The Peoples Republic of China (China). The trial will evaluate the sensitivity an
New Program Offers Immediate Access to FUZEON(R) for Patients In Expanded Access Programs of Investigational HIV Therapies: PRNewswire - December 1, 2004; -- FUZEON Accelerated Simultaneous Access Program (ASAP) Addresses Critical Needs for Growing Number of Treatment-Experienced Patients NUTLEY, N.J. and DURHAM, N.C., Dec. 1 /PRNewswire/ -- To address the needs of treatment experienced patients living with HIV disease, Roche and Trimeris are launching the FUZEON Acceler
Boehringer Ingelheim Announces U.S. Expanded Access Program for Anti-HIV Drug Tipranavir: PRNewswire - November 30, 2004; -- Program Will Provide Drug to HIV-Infected Patients with Limited Treatment Options RIDGEFIELD, Conn., Nov. 30 /PRNewswire-FirstCall/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the opening of the tipranavir Expanded Access Program (EAP) in the U.S., following the recent review of the protocol (1) by
AIDS Healthcare Foundation Joins With The China Foundation in New Global AIDS Partnership in Shanxi Province, China: PRNewswire - November 30, 2004; -- HIV Testing, Treatment and Training Efforts Will Target Yuncheng City Residents in Province Where Blood Selling of Villagers Led to Widespread HIV Infections -- Partners Will Host Receptions in Washington, DC, Nov. 30th and Shanxi Province, China, on December 1st WASHINGTON, Nov. 30 /PRNewswire/ -- The China Foundat
Bristol-Myers Squibb Invites Yahoo!'s Global Audience to Shine a Light on the HIV/AIDS Crisis on World AIDS Day: PRNewswire - November 30, 2004; -- Light to Unite Campaign Helps Raise HIV/AIDS Awareness on Nine Yahoo! Front Pages NEW YORK, Nov. 30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) is working with Yahoo! to raise awareness of the global HIV/AIDS crisis through the Light to Unite initiative on World AIDS Day. The Company will spo
Statement by Tommy G. Thompson, Secretary of Health and Human Services Regarding World AIDS Day 2004, December 1, 2004: PRNewswire - November 30, 2004; WASHINGTON, Nov. 30 /PRNewswire/ -- The following is a statement by Tommy G. Thompson, Secretary of Health and Human Services regarding World AIDS Day 2004, December 1, 2004: World AIDS Day is an important opportunity to remember those lost to AIDS. Just as importantly, it is an opportunity to raise awareness of the gl
Women Living With HIV Break Their Silence on HIV and Me Talk Radio, the First 'On Demand' Radio Program Dedicated to HIV/AIDS: PRNewswire - November 30, 2004; SAN FRANCISCO, Nov. 30 /PRNewswire/ -- Two women who have been living with HIV/AIDS speak candidly on the HIV/AIDS Radio Network about how their lives have been affected by this disease. These guests shatter many of the misconceptions people have about HIV and AIDS being a disease that affects gay men and intravenous d
113 Abstracts on Recent Clinical Data for Thalomid(R), Revlimid(TM), Actimid(TM) and Alkeran(R) to be Presented at the American Society of Hematology 46th Annual Meeting: PRNewswire - November 30, 2004; -- Forty-Nine Abstracts on Thalidomide in Single and Combination Therapies in Newly Diagnosed Multiple Myeloma and Other Hematological Cancers WARREN, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators from leading cancer research centers will present
Update: CBS Bans Anti-Syphilis Ad: AHF Fears 'Chilling Effect of 'Moral Values' on Safer Sex Education'; Will Seek FCC Ruling: PRNewswire - November 30, 2004; -- Rejected Stop the Sores TV Spot for Syphilis Prevention Campaign has Already Run on Area Cable Outlets Such as CNN, Bravo and A&E; Campaign Targeting Gay & Bisexual Men in L.A. is Backed by Community Coalition Including AHF & LA County Health Dept. s Office of STD Program What: PRESS CONFERENCE-LA area B
Lil' Kim and Rosie Perez to be Special Guest Hosts at Move Against AIDS: Return of the Dance-a-thon: PRNewswire - November 29, 2004; NEW YORK, Nov. 29 /PRNewswire/ -- Hip-Hop icon Lil Kim and actress Rosie Perez, currently on Broadway in the smash hit Reckless, have signed on as special guest hosts of Move Against AIDS: Return of the Dance-a-thon, on December 11, 2004, at the Jacob Javits Convention Center in Manhattan. Lil Kim and Rosie Perez join
Viral Genetics Announces Publication of Study on Effects of VGV-1 in Antiretroviral Non-Responding HIV Infections: PRNewswire - November 29, 2004; -- Treatment of VGV-1 Given Over Two Months in Subjects Failing Antiretroviral Therapy -- 5/10 Patients Reach Undetectable HIV Virus Levels by Three Months -- One Log Drop in HIV Virus Levels Observed by Six Months AZUSA, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Viral Genetics (OTC Bulletin Board: VRAL), a drug discov
Lipid Sciences' Viral Advisory Board Reviews Viral Immunotherapy Research Program: Positive Preliminary Results Seen in Non-human Primate Study: PRNewswire - November 29, 2004; PLEASANTON, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) today announced positive new data related to the Company s Viral Immunotherapy program was reviewed at a meeting of the Lipid Sciences Viral Advisory Board held last month. In December 2003, the Company announced the completion of
Mobilizing Business Women Leaders in the Fight Against HIV/AIDS: PRNewswire - November 29, 2004; CHICAGO, Nov. 29 /PRNewswire/ -- Millions of girls are dying on our watch. With this compelling charge, Mary Robinson, former United Nations High Commissioner for Human Rights and president of Ireland , opened the inaugural meeting of the Steering Committee of the Business Women s Initiative Against HIV/AIDS (BWI).
Kenneth Cole to Become amfAR Chairman: amfAR Honors Outstanding Research Focused on Women and HIV/AIDS at World AIDS Day Luncheon: PRNewswire - November 29, 2004; NEW YORK, Nov. 29 /PRNewswire/ -- Kenneth Cole, Chairman-designate of the American Foundation for AIDS Research (amfAR) will join amfAR in honoring outstanding contributions to the field of women and HIV/AIDS at a luncheon tomorrow at the Time, Inc. Conference Center, co-sponsored by the Mailman School of Public Health
M.A.C Aids Fund Raises $40 Million in Ten Years for People Living With HIV/AIDS: PRNewswire - November 29, 2004; -- In 2004 Missy Elliott, Christina Aguilera, Chloe Sevigny, Boy George, Linda Evangelista Helped Raise $8 Million -- M.A.C President and M.A.C AIDS Fund Chairman John Demsey to speak at The International Center for Research on Women (ICRW) Conference In Washington, D.C. On World AIDS Day NEW YORK, Nov. 29 /PRNewswire/
India.Arie Explores the Worldwide Struggle Against HIV/AIDS in 'VH1 NEWS PRESENTS: Battling The Global AIDS Epidemic': PRNewswire - November 29, 2004; -- A Special Highlighting VH1 s Partnership With the Global Fund to Fight AIDS, Tuberculosis and Malaria NEW YORK, Nov. 29 /PRNewswire/ -- AIDS. The world s worst ever health crisis. As part of its continuing public affairs initiative VH1, invited India .Arie to come up close -- real close -- by spending time with thos
Nick News Talks With Kids Living With AIDS in a Special to Air on World AIDS Day: PRNewswire - November 29, 2004; -- Nick News Special Edition: Living With AIDS: A Story of Three Kids to Air Dec. 1, 2004, at 8:30 p.m. (ET/PT) on Nickelodeon NEW YORK, Nov. 29 /PRNewswire/ -- More than 14,000 kids in the United States are infected with the HIV virus, and more than 90 percent of the kids infected were born with the disease. For a ki
World AIDS Day: Americans Walking for Orphans: PRNewswire - November 29, 2004; -- From Appalachia to China s Great Wall, People Matching Steps to Number of Children Affected by Pandemic SEATTLE, Nov. 29 /PRNewswire/ -- On World AIDS Day (December 1), as on every day, 6,000 children will lose their parents. This year, several hundred Americans will take action to help these children with both thei
Bayer and Tsinghua University Inaugurate Public Health and HIV/AIDS Media Studies Program: PRNewswire - November 22, 2004; -- Improvement of Health Through Communications -- a National Platform for Healthcare Reporting BEIJING, Nov. 22 /Xinhua-PRNewswire/ -- Bayer China and Tsinghua University have inaugurated a groundbreaking new initiative today, the Tsinghua -- Bayer Public Health and HIV/AIDS Media Studies Program, designed to play a
A Skate for Remembrance and Hope - Blades Against AIDS 2, A World AIDS Day Benefit for Body Positive: PRNewswire - November 22, 2004; NEW YORK, Nov. 22 /PRNewswire/ -- Join Body Positive at its second annual World AIDS Day fundraiser Blades Against AIDS 2, co-produced by the New York City Gay Hockey Association, 64events.com and Out of Bounds. This event takes place on Wednesday, December 1 from 8pm to Midnight at the Sky Rink at Chelsea Piers, Pier
Remarks by President Bush at CEO Summit Closing Session: PRNewswire - November 20, 2004; WASHINGTON, Nov. 20 /PRNewswire/ -- The following is a transcript of remarks by President Bush at CEO Summit closing session: Casa Piedra Santiago, Chile 4:47 P.M. (Local) PRESIDENT BUSH: Thank you very much. Siente se. Gracias. Thank you for the warm welcome. It is such an honor to be in Chile. Whoever is responsible
Bentley Pharmaceuticals Reports Auxilium's Announcement of Study Results Demonstrating That Testim(R) Delivered Using Bentley's CPE-215 Technology is Effective in Treating HIV-Positive Hypogonadal Men - Testim(R) Treated Men Experienced Sexual Function Improvement versus AndroGel(R) -: PRNewswire - November 19, 2004; EXETER, N.H., Nov. 19 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company focused on advanced drug delivery technologies, which also manufactures and markets a growing branded and generic product line in Europe, today announced that Auxilium Pharmaceuticals (Nasdaq: A
AHF Says 'FDA Fiasco' Raises Questions About AIDS Drug Approvals for Developing World: PRNewswire - November 19, 2004; -- Current Crisis Over Merck s Drug, Vioxx, Raise Questions About US Agency s Role in Approval of Generic AIDS Drugs for Use in Africa and the Developing World; FDA s Approval, Then Recall of Arthritis Medication Dispels Drug Industry Spin That Branded Equals Safe LOS ANGELES, Nov. 19 /PRNewswire/ -- AIDS Healthcare Fo
HHS Awards $10.4 Million to Fight AIDS On Three Continents: PRNewswire - November 18, 2004; WASHINGTON, Nov. 18 /PRNewswire/ -- HHS Secretary Tommy G. Thompson today announced four new grants totaling $10.4 million to provide support for HIV/AIDS research in Peru , Thailand , Cambodia and Russia , four nations
Boehringer Ingelheim Announces 24-Week Interim Results From Second Phase 3 Pivotal Study of Tipranavir: PRNewswire - November 18, 2004; GLASGOW, Scotland, Nov. 18 /PRNewswire/ -- New data from a pivotal Phase 3 study (RESIST-2) show that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed
Updated Federal Guidelines Recommend RETROVIR + EPIVIR as Part of First-Line Therapy in ART Regimens: Recommended Drugs Available as COMBIVIR Fixed Dose Tablet: PRNewswire - November 18, 2004; RESEARCH TRIANGLE PARK, N.C., Nov. 18 /PRNewswire/ -- Revised federal guidelines recommend RETROVIR(R) (zidovudine, ZDV) and EPIVIR(R) (lamivudine, 3TC ) as one of the preferred dual nucleoside reverse transcriptase inhibitor (NRTI) backbones used as part of initial HIV combination therapy. RETROVIR and EPIVIR are ava
Auxilium Announces Study Results Demonstrating Testim(R)1% Effective in Treating HIV-Positive Hypogonadal Men: PRNewswire - November 17, 2004; -- Testim-Treated Men Experienced Sexual Function Improvement versus AndroGel(R) NORRISTOWN, Pa., Nov. 17 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals (Nasdaq: AUXL), a specialty pharmaceutical company that develops and markets products for urologic and sexual health, today announced top line study results compar
Study Reveals Widespread Use of Antacids and Other Heartburn Medications Among HIV Patients -- pH-altering Characteristics of these Drugs May Have Implications for the Clinical Management of HIV Patients: PRNewswire - November 17, 2004; GLASGOW, Scotland, Nov. 17 /PRNewswire/ -- A survey conducted among HIV- positive patients has uncovered frequent use of prescription and over-the- counter (OTC) medications for the treatment of heartburn, gastroesophageal reflux disease (GERD) and ulcers. Because these medications increase the pH level in the stomach,
The Immune Response Corporation Presents Preliminary Analysis of REMUNE Phase II Trial in HIV Positive, Drug Naive Patients - Data Show Positive Trends in Key Immune Response Markers at 28 Weeks -: PRNewswire - November 17, 2004; CARLSBAD, Calif., Nov. 17 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, presented preliminary data this week from an ongoing Italian Phase II study of REMUNE(R) treatment i
Public Interest Watch Condemns Doctors Without Borders for Creating New HIV Strains: Public Interest Watch Concerned French NGOs Use of Substandard Generics Could Lose Fight Against AIDS: PRNewswire - November 16, 2004; LOS ANGELES, Nov. 16 /PRNewswire/ -- Public Interest Watch (http://www.publicinterestwatch.org) today condemned French charity Doctors Without Borders (MSF) for its gross negligence in putting substandard AIDS drugs on the market in 27 countries, with the very real possibility of having caused new strains of drug-resis
VH1 Commemorates World AIDS Day on Wednesday, December 1 With Original Programming and PSAs That Re-Ignite Awareness About This Global Pandemic: PRNewswire - November 16, 2004; NEW YORK, Nov. 16 /PRNewswire/ -- As part of VH1 s ongoing public affairs initiative to generate awareness about the AIDS pandemic, the network will air the award-winning VH1 News Presents: AIDS: A Pop Culture History as well as original public service announcements (PSAs) and a VH1 News package throughout World AIDS D
United States Health and Human Services Secretary Tommy G. Thompson Applauds Effective Public-Private Partnership Advancing HIV/AIDS Care in Tanzania: PRNewswire - November 16, 2004; DAR ES SALAAM, Tanzania , Nov. 16 /PRNewswire-FirstCall/ -- Today Abbott welcomed United States Secretary of Health and Human Services Tommy G. Thompson to Muhimbili National Hospital in Dar es Salaam where the Secretary saw first-hand a view of the comprehensive health care management and infrastructure improvements t
Waxman and Kennedy Push for UN's Defective AIDS Drugs May Leave the Taxpayer Liable to Tort Claims: PRNewswire - November 15, 2004; FAIRFAX, Va., Nov. 15 /PRNewswire/ -- After an Indian company recalled all of its generic AIDS drugs from the market this week, there are considerable liability issues in play and the members of Congress who aggressively touted the dangerous and unproven medicines may leave American taxpayers footing the bill. India s
ESSENCE Magazine Makes 100% Commitment to the Fight Against HIV/AIDS Joins Forces With The Black Aids Institute In The Our People. Our Problem. Our Solution. Awareness Campaign: PRNewswire - November 15, 2004; -- Actress and Comedienne Mo Nique Will Serve As Campaign Spokesperson NEW YORK, Nov. 15 /PRNewswire/ -- ESSENCE will observe the holiday season with a special HIV/AIDS awareness campaign called, Our People. Our Problem. Our Solution. The preeminent magazine for African-American women has teamed up with The Black AIDS
KNOW HIV/AIDS Teams Up With Hip-Hop Sensation Common to Promote HIV Testing: PRNewswire - November 15, 2004; -- Viacom and Kaiser Family Foundation s Initiative Supports World AIDS Day Through HIV/AIDS-Related Television Programming, PSAs, News Specials and Events NEW YORK, Nov. 15 /PRNewswire/ -- Viacom Inc. and the Henry J. Kaiser Family Foundation today announced the launch of a new set of public service advertisements (PS
GlaxoSmithKline Awards $250,000 in Research Grants to Three Scientists For Their Research to Develop Breakthrough Drug Therapies for HIV/AIDS: PRNewswire - November 15, 2004; RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire/ -- The 2004 GlaxoSmithKline (GSK) Drug Discovery and Development Research Grants have recently been awarded to three scientists working on novel approaches to combat HIV, the virus that causes AIDS. The recipients, who will share equally in a total of $250,000 in grant
Nick News Talks With Kids Living With AIDS in a Special to Air on World AIDS Day: PRNewswire - November 11, 2004; Nick News Special Edition: Living With AIDS: A Story of Three Kids to Air Dec. 1, 2004, at 8:30 P.M. (ET/PT) on Nickelodeon NEW YORK, Nov. 11 /PRNewswire/ -- More than 14,000 kids in the United States are infected with the HIV virus, and more than 90 percent of the kids infected were born with the disease. For a kid g
Pharmasset Initiates Racivir(R) Phase II HIV Study: PRNewswire - November 10, 2004; ATLANTA, Nov. 10 /PRNewswire/ -- Pharmasset, Inc. has initiated a Phase II clinical study to assess the safety, tolerability, and antiviral effect of substituting Racivir (RCV) for Epivir (R) (lamivudine, 3TC ) in treatment- experienced HIV-infected individuals.
AHF Commends Sheriff's Department for Successful HIV Prevention and Testing Project in LA County Jails: PRNewswire - November 10, 2004; -- The LA County Board of Supervisors on Tuesday Recognized the Sheriff s Department for Its Successful HIV Prevention and Testing Program in LA County Jails and Correction Facilities. AIDS Healthcare Foundation and Other County HIV Prevention and Testing Programs Join in This Success. LOS ANGELES, Nov. 10 /PRNewswire/
Trinity Biotech Receives CLIA Waiver for Uni-Gold(TM) Recombigen(R) HIV Test: PRNewswire - November 10, 2004; DUBLIN, Ireland , November 10 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) today announced that the US Food & Drug Administration ( FDA ) has approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for the Uni-Gold(TM) Recombigen(R) HIV test.
Fourth Annual Black AIDS Institute Gala Celebration Honors African-Americans in the Fight Against AIDS: Star-Studded Event Scheduled to Take Place in Hollywood Nov. 12: PRNewswire - November 10, 2004; LOS ANGELES, Nov. 10 /PRNewswire/ -- On November 12th, the Black AIDS Institute will unveil the portraits of the 2004 Heroes in the Struggle at the fourth annual Gala Reception and Awards Ceremony at the Directors Guild of America in Hollywood. Heroes in the Struggle is a photographic tribute to people of African desce
Medical Services Moves VScan Test Kits Into Russia: PRNewswire - November 9, 2004; EDMONTON, Alberta, Nov. 9 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that it has signed an agreement with a distributor in Russia to distribute the VScan test kits in Russia and surrounding countries. The Distributor already has a well defined distribution
TNX-355 Among HIV Therapies Highlighted at International Meeting of the Institute of Human Virology: PRNewswire - November 9, 2004; HOUSTON, Nov. 9 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) Medical Director Dr. Stanley Lewis recently presented findings from the Phase I clinical trial of TNX-355 for the treatment of human immunodeficiency virus (HIV) at the 2004 International Meeting of the Institute of Human Virology (IHV) in Baltimore,
A.L.B.R.C. Set to Oppose Continued Domination of $18 Billion Domestic HIV/AIDS Relief Funds by 'Gay Power Elite': PRNewswire - November 9, 2004; -- With Bush Receiving 16% of the Black Vote in Ohio; A.L.B.R.C. Calls for Significant Changes in the Ryan White Care Act and Other AIDS Relief Programs DALLAS, Nov. 9 /PRNewswire/ -- Stating that the A.L.B.R.C. shares the general opinion of most political pundits: marriage for gays probably cost the Democrats the elec
Panacos Pharmaceuticals Amends Merger Agreement with V.I. Technologies - Reports Accelerated Development of PA-457, Lead HIV Drug Candidate: PRNewswire - November 8, 2004; GAITHERSBURG, Md., Nov. 8 /PRNewswire/ -- Panacos Pharmaceuticals, Inc., a privately-held company developing novel therapeutics for the treatment of HIV and other major human viral diseases, today announced that it has amended the terms of its merger agreement with Watertown, MA-based V.I. Technologies, Inc. (Nasdaq: V
Research and Markets: Investigate Today's HIV Competitive Landscape: PRNewswire - November 4, 2004; DUBLIN, Ireland , Nov. 4 /PRNewswire/ -- The world-wide HIV competitive landscape, involves more than 110 drug developing companies and this report has reviewed its last ten years, 1994-2004, of business interactions, ranging from licensing deals to M&As. From 66 carefully selected business interactions, we have cr
AHF Says California Studies on HIV Rates Among Mexican Migrant Workers Require Targeted Prevention & Treatment Efforts to Better Contain Epidemic: PRNewswire - November 2, 2004; -- Two Studies in Fresno and San Diego Counties Show HIV Incidence Among Mexican Migrant Workers at Three Times the Level of the General Population in U.S. and Mexico LOS ANGELES, Nov. 2 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS organization, which operates free AIDS treatment clinics in the
Human Genome Sciences Characterizes Panel of Novel Human Monoclonal Antibodies That Specifically Antagonize the CCR5 Receptor and Block HIV-1 Entry: PRNewswire - November 2, 2004; -- Candidate Antibody Selected for Further Evaluation of Anti-HIV/AIDS Properties -- Data Presented at 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has identified and chara
Chinese Blood Centres To Use MedMira's Rapid HIV Tests: Increases Presence in China Public Health Initiative: PRNewswire - November 2, 2004; HALIFAX, Nov. 2 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that it has shipped 100,000 MiraWell(TM) Rapid HIV Tests to one of its distributors in the People s Republic of
Whole Foods Market(R) to Raise Funds for the Boston Living Center to Provide Meals for People Living With HIV/AIDS: PRNewswire - November 1, 2004; BOSTON, Nov. 1 /PRNewswire/ -- This month, shoppers at the 13 greater Boston-area locations of Whole Foods Market (formerly Bread and Circus) can provide meals to people living with HIV who might otherwise go hungry. During the month-long promotion, people can Buy a Meal for Someone Living with HIV/AIDS by making a tax
Land O'Lakes Partners With Hoops4Africa to Combat Africa's HIV/AIDS Pandemic: PRNewswire - November 1, 2004; ARDEN HILLS, Minn., Nov. 1 /PRNewswire/ -- At a reception last Thursday evening in Washington, DC, Land O Lakes, Inc., a leading U.S. food and agricultural cooperative, and top NBA and WNBA players formally launched a unique partnership of combining their assets and expertise in the fight against the HIV/AIDS pandemic
THE LION SINGS TONIGHT: Company Members of Disney's The Lion King to Perform an Evening of Song and Dance to Benefit AIDS Action: PRNewswire - November 1, 2004; BOSTON, Nov. 1 /PRNewswire/ -- On Monday, Nov. 15th only, members of the cast of Disney s The Lion King will donate their time and talent to shake loose and sing some of their favorite songs from the world of cabaret, pop, rock and R&B, at a special performance called The Lion Sings Tonight as a benefit for AIDS Ac
Longest Study of Kaletra(R) (Lopinavir/Ritonavir) Based Regimen Demonstrated Favorable Resistance Profile for Patients Through Six Years of Initial HIV Therapy: PRNewswire - November 1, 2004; WASHINGTON, Nov. 1 /PRNewswire/ -- Study data presented showed no primary protease inhibitor (PI) resistance was reported in anti-retroviral-naive patients taking a Kaletra (R) ( lopinavir / ritonavir )-based regimen through six years (300 weeks) of
City HIV/AIDS Expert, Dr. Marjorie Hill, Joins Gay Men's Health Crisis: PRNewswire - November 1, 2004; NEW YORK, Nov. 1 /PRNewswire/ -- Gay Men s Health Crisis (GMHC) today announced that Marjorie J. Hill, Ph.D., a prominent leader in the HIV/AIDS community, will join the agency to expand its work directed at women and families in the AIDS epidemic. Prior to joining GMHC, Dr. Hill was Assistant Commissioner for HIV/AIDS
Boehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study: PRNewswire - November 1, 2004; WASHINGTON -- New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs)
Clinical Study Results Build Case for Expanded Use of FUZEON(R) -- Data, Together with New HIV Treatment Guidelines, Support Use in Broad Range of Treatment-Experienced Patients: PRNewswire - October 31, 2004; WASHINGTON, Oct. 31 /PRNewswire-FirstCall/ -- Earlier use of FUZEON(R) ( enfuvirtide ) in treatment-experienced HIV patients results in better treatment outcomes and preserves future drug options, according to new data presented today at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
GlaxoSmithKline Perspective on Data Involving Combivir Presented at ICAAC: PRNewswire - October 31, 2004; WASHINGTON, Oct. 31 /PRNewswire/ -- A significant number of abstracts that include Combivir (R) (lamivudine 150 mg and zidovudine 300 mg) Tablets are being presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C. Among these is one abstract with data from a 24-week ana
New Information About TRIZIVIR Presented at ICAAC: PRNewswire - October 31, 2004; At a Glance -- The quad NRTI regimen of TRIZIVIR + tenofovir shows efficacy in treatment-naive patients; may preserve future treatment options. -- Patients who achieved viral suppression on an initial ART regimen retain viral suppression when switched to a simplified regimen of TRIZIVIR alone, or COMBIVIR +
Evidence That HIV Protease Inhibitor, LEXIVA Plus Ritonavir (RTV) May Replace AGENERASE + RTV Without Pharmacokinetic Impact Presented at ICAAC: PRNewswire - October 30, 2004; At a Glance According to preliminary data presented at ICAAC: -- Ritonavir (RTV) increased plasma PK parameters to a similar extent when co-administered with LEXIVA or APV. -- LEXIVA is the first PI with flexible dosing and no food or fluid restrictions, which may help simplify ART regimens for some patients.
Increases in HDL Cholesterol Observed in Patients Taking LEXIVA, According to New Data Presented at ICAAC: PRNewswire - October 30, 2004; According to 48-week data presented at ICAAC: -- Levels of HDL-C, were increased in patients taking LEXIVA who had low HDL-C at baseline. -- There were minimal changes in TC/HDL-C ratios. Additional results seen at 120 weeks were presented last week at the International Workshop on Adverse Drug Reactions and Lipodystro
ViroLogic Announces Presentations at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): PRNewswire - October 29, 2004; SOUTH SAN FRANCISCO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that Christos J. Petropoulos, Ph.D., Vice President of Research and Development at ViroLogic, will be making an oral presentation on Viral Fitness at the invitation of the organizing committee of the 44th Inter
Docs Without Drugs: APUA Report Reveals Urgency of Drug Resistance Worldwide - Describes impending loss of front-line antimicrobials, a major public health threat: PRNewswire - October 29, 2004; WASHINGTON -- A new report released at a meeting of the American Society for Microbiology (ASM), describes the ominous presence of disease-causing microorganisms resistant to today s front- line drugs. Shadow Epidemic: The Growing Menace of Drug Resistance presents up-to-date findings from major groups tracking resista
MedMira Donates Rapid HIV Tests In China: Supports National Government HIV Prevention Strategy: PRNewswire - October 27, 2004; HALIFAX, Oct. 27 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that it has made donations of 25,000 MiraWell(TM) Rapid HIV Tests to two organizations in the People s Republic of
Pediatric HIV/AIDS Medical Centers to be Built in African Nations of Lesotho and Swaziland: Funding Provided by Bristol-Myers Squibb's SECURE THE FUTURE(R) Program: PRNewswire - October 27, 2004; JOHANNESBURG, South Africa , Oct. 27 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY), New York; Baylor College of Medicine, Houston, Texas; and the governments of Lesotho and Swaziland announced that medical centers focused on caring for children with HIV/AIDS
Condomania(R) Awards Over 30,000 'Madonna Condoms' to Nonprofits: PRNewswire - October 27, 2004; -- Douglas County AIDS Project and Planned Parenthood Are the Big Winners in Condomania s Madonna Condom Giveaway LOS ANGELES, Oct. 27 /PRNewswire/ -- Condomania (http://www.condomania.com), America s First Condom Store, announced today the winners of its Madonna Condom Giveaway. Condomania produced the contest to enco
BET's Rap-It-Up Heads to Newark for Celebrity Health Forum on November 6: Campaign Educates Young Adults About Safe Sex Practices; Promotes HIV/AIDS Awareness: PRNewswire - October 26, 2004; WASHINGTON, Oct. 26 /PRNewswire/ -- BET s Rap-It-Up, the cable network s national HIV/AIDS public awareness initiative, comes to the city of Newark, New Jersey to host a health forum in partnership with the University of Medicine/Dentistry of New Jersey (UMDNJ). The purpose of the health forum is to offer a platform fo
AHF Lauds Schwarzenegger's Work on AIDS Issues During First Year: PRNewswire - October 26, 2004; -- The Nation s Largest AIDS Organization Gives Schwarzenegger a Good Grade for His Work on AIDS Issues LOS ANGELES, Oct. 26 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US, which treats nearly 6,000 Californians living with HIV, applauds the efforts of Governor Schwarzenegger,
RxAmerica to Team With ADAP to Help HIV-Positive Utahns: PRNewswire - October 26, 2004; SALT LAKE CITY, Oct. 26 /PRNewswire/ -- The AIDS Drug Assistance Program (ADAP) of Utah announced it has chosen RxAmerica to manage its prescription benefit services. The HIV Treatment & Care Program is a federally funded drug assistance program, administered by the Utah Department of Health. The group accepted a m
Dynamics Research Corporation Wins $4.8 Million Contract to Support the Navy's HIV Management System: PRNewswire - October 26, 2004; -- Contract Leverages Extensive Military Medical IT Experience from Recent Acquisition of Impact Innovations ANDOVER, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Dynamics Research Corporation (Nasdaq: DRCO) announced today that a $4.8 million contract to support the National Navy Medical Center s Navy Central HIV Program
AIDS Organizations Warn State that Voter Challenges Will Result in Voter Inaccessibility: PRNewswire - October 26, 2004; -- Election Day Challenges May Cause Long Waits and Discourage Eligible Voters CLEVELAND, Oct. 26 /PRNewswire/ -- Today the AIDS Taskforce of Greater Cleveland, with support from a national coalition of AIDS organizations, demanded that elections officials provide full and equal access to people living with disabilitie
Theratechnologies to present results from its HIV-associated lipodystrophy Phase II study on ThGRF at scientific conferences in the U.S. and Italy: PRNewswire - October 25, 2004; MONTREAL, Oct. 25 /PRNewswire-FirstCall/ - Theratechnologies (TSX :TH) is pleased to announce that the results of its Phase II clinical trial on ThGRF in HIV- related lipodystrophy will be the subject of oral presentations by Dr. Steven Grinspoon, Lead Investigator in the United States , and by Dr. Julian Falutz, Lead
Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir: Priority Review Requested for Investigational Anti-HIV Agent: PRNewswire - October 25, 2004; RIDGEFIELD, Conn., Oct. 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for tipranavir. The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review o
Theratechnologies to present results from its HIV-associated lipodystrophy Phase II study on ThGRF at scientific conferences in the U.S. and Italy: PRNewswire - October 25, 2004; MONTREAL, Oct. 25 /PRNewswire-FirstCall/ -- Theratechnologies (TSX :TH) is pleased to announce that the results of its Phase II clinical trial on ThGRF in HIV- related lipodystrophy will be the subject of oral presentations by Dr. Steven Grinspoon, Lead Investigator in the United States , and by Dr. Julian Falutz, Lead
Calypte Biomedical to Begin Shipping HIV-1 Incidence Test: PRNewswire - October 25, 2004; PLEASANTON, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (AMEX:HIV) today announced that it will begin shipping its HIV-1 BED Incidence EIA test (Incidence Test) this week. The first shipment is destined for South Africa , and the Company currently has initial orders for approximately 12,000
Yes on Proposition 71 Launches Statewide Ad Featuring Christopher Reeve: PRNewswire - October 22, 2004; LOS ANGELES, Oct. 22 /PRNewswire/ -- Proponents of Yes on Proposition 71, the California Stem Cell Research and Cures Initiative, today announced the launch of a new television ad featuring Christopher Reeve that calls on voters to support the initiative. The 30-second television ad features actor/patient advocate Chri
THAT '70S SHOW and QUEER AS FOLK Among Winners at 20th SHINE Awards: PRNewswire - October 22, 2004; HBO Films Picks Up Special Honors; Laura Innes, Michael Beach, Debi Mazar, Callum Blue and Lupe Ontiveros Among Presenters at Fun-Filled Event; Hosted by Writer/Comedienne Julie Brown LOS ANGELES, Oct. 22 /PRNewswire/ -- Whether highlighting classic scenarios of parents having The Talk or a young person s coming out o
Health Canada Approves New MedMira Rapid HIV Test Achieves Second North American Regulatory Success: PRNewswire - October 21, 2004; HALIFAX, Oct. 21 /PRNewswire-FirstCall/ -- MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that it has received approval from Health Canada to market and sell its enhanced MedMira(TM) Rapid HIV Test for detection of
'Open Access' Medical Journal Provides New Model for Publishing Original, Peer-Reviewed Research: PLoS MEDICINE Launched on Internet This Week: PRNewswire - October 20, 2004; -- Free Online Journal Answers Call of Congress, NIH, Nobel Laureates for Increased Access to Biomedical Research SAN FRANCISCO, Oct. 20 /PRNewswire/ -- A new general medical journal launched this week with a non-traditional publishing model is the latest top- tier venue for publishing important, peer-reviewed biomedic
Health Secretary Announces $1 Million Grant for HIV Prevention: Philadelphia HIV/AIDS Rates 3 Times Higher Than State Average: PRNewswire - October 19, 2004; HARRISBURG, Pa., Oct. 19 /PRNewswire/ -- Health Secretary Dr. Calvin B. Johnson today joined Senator Vincent Hughes to announce $1 million for HIV prevention and education for minority youth in Philadelphia County. By targeting funding for proven HIV prevention services to the county with the highest HIV prevalence in
U.S. FDA Grants Traditional Approval for FUZEON(R), First and Only Fusion Inhibitor for the Treatment of HIV: PRNewswire - October 15, 2004; -- Designation Follows March 2003 Accelerated Approval and Further Confirms Safety and Efficacy at 48 Weeks NUTLEY, N.J. and DURHAM, N.C., Oct. 15 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that the U.S. Food and Drug Administration ( FDA ) has granted traditional approval to FUZE
Xilinx Rallies for the Walk for AIDS Silicon Valley: Company's Commitment to Silicon Valley AIDS Coalition Spans 13 Years: PRNewswire - October 13, 2004; SAN JOSE, Calif., Oct. 13 /PRNewswire/ -- As the sole Red Ribbon sponsor for the Walk for AIDS Silicon Valley, Xilinx, Inc. (Nasdaq: XLNX), today announced the company expects more than 300 walkers affiliated with Xilinx will participate in the 15th annual Walk for AIDS Silicon Valley, Sunday, October 17, 2004 at 9:00
Los Angeles Steps Up Support for 2004 AIDS Walk Marking 20th Year of the World's First AIDS Walk: PRNewswire - October 13, 2004; -- APLA Commemorates Inaugural Event, Honors AIDS Walk Founder LOS ANGELES, Oct. 13 /PRNewswire/ -- On Sunday, October 17, more than 25,000 people are expected to take to the streets for the 20th annual AIDS Walk Los Angeles, which benefits AIDS Project Los Angeles and other local AIDS organizations. AIDS Walk Los Ange
The United Nations Association San Diego Chapter Honors QUALCOMM Incorporated for Its Philanthropic Community Relations and Volunteer Contributions at San Diego's 2004 UN Day - 'Year of The Woman': PRNewswire - October 13, 2004; -- Actress Lindsay Wagner and Dr. Johns, UN New York Spokesperson, Among Those Attending the Event SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- The United Nations Association San Diego Chapter (UNA-SD), announced today that they will present their first ever UNA Global Corporate Citizenship Award to QUALCOMM Incorporat
Courteney Cox, David Arquette, Cynthia Nixon Among Celebrity Supporters of M.A.C AIDS Fund Holiday Card Program to Benefit Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - October 12, 2004; -- Children Affected by HIV/AIDS Created Artwork for Cards Which Support Services, Treatment for Kids Worldwide -- Kids Helping Kids Cards Perfect for Holiday Greetings, Stocking Stuffers NEW YORK, Oct. 12 /PRNewswire/ -- The M.A.C AIDS Fund Kids Helping Kids greeting cards is an annual project for the holiday season w
PowderMed Initiates a Phase I Clinical Trial for a Novel Therapeutic Herpes Simplex Type 2 (HSV2) DNA Vaccine: PRNewswire - October 12, 2004; OXFORD, England, October 12 /PRNewswire/ -- Phase I clinical trial in patients of therapeutic DNA vaccine for the treatment of HSV2 commences at The Centre for Clinical Studies in Houston, Texas using PowderMed s novel DNA-on-Gold technology PowderMed Ltd (PowderMed), a company focusing on the development of therapeuti
Generex Biotechnology Presents Information at the Euroconference Vaccines 3 Meeting of the Pasteur Institute in Paris on the Use of Novel Peptide Vaccine for Melanoma: PRNewswire - October 12, 2004; -- Transgenic Mice Studies with Genes for Human HLA-DR Support Potential Use of T-Helper Cell Peptide Vaccine for Cancers TORONTO, Oct. 12 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that Dr. Robert Humphreys, founder of its Antigen Express immunomedicines subsidiary, deli
AIDS NGOs Protest 40% Hikes in Drug Prices: PRNewswire - October 12, 2004; -- AIDS Advocates Ask Drug Companies to Incorporate South African Drug Pricing Regulations Without Increasing Single Exit Prices for NGOs & Further Limiting Access to Life-Saving Drugs DURBAN, South Africa, Oct. 12 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the United States largest AIDS organization which o
AHF Applauds L.A. County Supervisors' Vote for Names-Based Reporting of HIV Cases: PRNewswire - October 12, 2004; -- Board Votes 4 to 1 to Support Switch to Names-Based Reporting System to Replace Inefficient Unique Identifier Code-Based System Currently in Place; Move Now Requires Action by State Legislature -- Present System s Flaws Slow Tracking of HIV Case Numbers in L.A. & California; Inaccurate Numbers Contribute to Pote
UPDATE: AIDS Project Los Angeles, Celebrities to Honor AIDS Walk Founder and Commemorate 20 Years of the AIDS Walk Movement: PRNewswire - October 9, 2004; LOS ANGELES, Oct. 9 /PRNewswire/ -- AIDS Project Los Angeles (APLA) and hundreds of supporters, including a host of celebrities, will gather this Sunday to honor AIDS Walk originator Craig R. Miller, and mark the 20th year of the AIDS Walk movement. AIDS Walk Los Angeles, the world s first such event for HIV/AIDS, was
Health Journalism Seminar Scheduled for Buenos Aires, October 11-14, 2004: PRNewswire - October 8, 2004; BUENOS AIRES, Argentina , Oct. 8 /PRNewswire/ -- Leading international experts on HIV/AIDS will participate in a three-day seminar for Latin American journalists specializing in health coverage October 11-14, 2004. Among the speakers at the Journalism and Health seminar are Dr. Mario Valcarcel, an HIV/AIDS expert, Pan
POZ Magazine Says Bush-Cheney Continue to Ignore Truth About AIDS: November issue includes voter guide on HIV issues, endorses Kerry: PRNewswire - October 7, 2004; NEW YORK, Oct. 7 /PRNewswire/ -- In this week s debate, Vice President Richard Cheney admitted that he did not know the facts about the U.S. AIDS epidemic. Cheney said he was not aware of government statistics that African-American women are 13 times more likely to die of AIDS than their white peers. It was just one mo
FDA Grants Priority Review to Market Leader Pegasys(R) With Copegus(R) for Treatment of Hepatitis C in HIV Patients -- Signals Major Step Toward Satisfying Unmet Medical Need --: PRNewswire - October 6, 2004; NUTLEY, N.J., Oct. 6 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has granted a six-month Priority Review Status to the supplemental new biologics license application (sBLA) for Roche s combination therapy of Pegasys(R) (peginterferon alfa-2a) in combination with Copegus(R) (ribavirin, USP) for the tre
MedMira Hosts HIV/AIDS Seminars with Chinese CDC: Achieves Significant Progress in China Marketing Strategy: PRNewswire - October 6, 2004; HALIFAX, Oct. 6 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the global market leader in flow-through diagnostic technology, announced today that it has begun conducting a series of technical training seminars in collaboration with the Centers for Disease Control (CDC) in the Peop
AIDSVote.org Says Democrats and Republicans Still Need Aids 101 Education: Vice presidential debate highlights gap in understanding of U.S. epidemic: PRNewswire - October 6, 2004; NEW YORK, Oct. 6 /PRNewswire/ -- AIDSVote.org released the following statement today: When asked a clear, direct question by PBS Senior Correspondent Gwen Ifill about the U.S. HIV/AIDS epidemic during their debate, neither Vice President Cheney nor Senator Edwards gave a clear, direct answer. Both candidates responses
Fuzeon(R) Plus an Active Boosted Protease Inhibitor Doubles Long-Term Response in Treatment-Experienced HIV Patients: PRNewswire - October 5, 2004; NUTLEY, N.J., and DURHAM, N.C., Oct. 5 /PRNewswire-FirstCall/ -- Twice as many treatment-experienced patients who used Fuzeon(R) ( enfuvirtide ) with an active boosted protease inhibitor (PI) regimen experienced a significant virologic response when compared to patients on an active boosted PI regimen alone, according
Calypte Biomedical Announces Licensing Agreement with Ani Biotech: Agreement gives company worldwide freedom to operate for its rapid HIV platform: PRNewswire - October 5, 2004; PLEASANTON, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation today announced that it has entered into a worldwide licensing technology transfer and equipment purchase agreement with Ani Biotech (Ani). The agreement grants Calypte access to Ani s new patent pending rapid diagnostic test platform a
Life Extension Foundation Announces Its Support for the California Stem Cell and Cures Initiative - Proposition 71: PRNewswire - October 5, 2004; FORT LAUDERDALE, Fla., Oct. 5 /PRNewswire/ -- In agreement with major scientific organizations, dozens of Nobel Laureates and the majority of the scientific community, the non-profit Life Extension Foundation supports Proposition 71 -- the California Stem Cell and Cures Initiative. Life Extension stands firm in its eff
USAID Awards Global Alliance for TB Drug Development $8 Million Grant: PRNewswire - October 5, 2004; NEW YORK and WASHINGTON, Oct. 5 /PRNewswire/ -- The United States Agency for International Development (USAID) announced today an $8 million grant to the Global Alliance for TB Drug Development (TB Alliance) for research and development into new drugs to save lives and combat the rapid spread of TB infection, drug resi
Calypte Biomedical Receives Rapid Test HIV-2 Patent License From Bio-Rad: PRNewswire - October 4, 2004; PLEASANTON, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) announced today that it has entered into a worldwide, non-exclusive licensing agreement with Bio-Rad Laboratories (Amex: BIO and BIOb) for patents relating to the Human Immunodeficiency Virus, Type 2, or HIV-2. Bio-Rad is th
Medical Services' Shanghai Plant Begins Production for China: PRNewswire - October 4, 2004; EDMONTON, Alberta, Oct. 4 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has received permission to ship VScan HIV tests within China , prior to regulatory approval. The Company received an order for 50,000 VScan HIV test kits to be shipped within China.
AHF Disappointed That Schwarzenegger Vetoes Canadian Drug Bills: PRNewswire - September 30, 2004; SB 1333 (Perata, D, Oakland), Sponsored by AHF, Would Have Allowed Medi-Cal and the State s AIDS Drug Assistance Program (ADAP) to Reimburse Providers for Drugs Purchased From Canadian Pharmacies LOS ANGELES, Sept. 30 /PRNewswire/ -- California Governor Arnold Schwarzenegger today vetoed several pending OURx Bill of Ri
Female Condom Partners in China: PRNewswire - September 29, 2004; CHICAGO, Sept. 29 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) (FHC) announced that it has formed a new relationship with China s Beijing Zizhu Pharmaceutical Co. Ltd. (BZP). FHC and BZP signed a non-binding Letter of Understanding in which the two companies agreed to work together to
Trinity Biotech Receives FDA Approval for Uni-Gold(TM) Recombigen(R) HIV Test use With Fingerstick Wholeblood: PRNewswire - September 29, 2004; DUBLIN, Ireland , September 29 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) today announced it has received approval from the US Food & Drug Administration ( FDA ) for the use of its Uni-Gold(TM) Recombigen(R) HIV Test with finger stick whole blood samples.
The Immune Response Corporation Announces REMUNE(R) Restores HIV-1-Specific Activity of CD4+ and CD8+ T Cells, Similar to Anti-HIV Immune Responses Seen in Long-Term Nonprogressors - Results Published in September Issue of Journal of Experimental Medicine -: PRNewswire - September 28, 2004; CARLSBAD, Calif., Sept. 28 /PRNewswire-FirstCall/ -- An investigational treatment called REMUNE(R) (HIV-1 Immunogen) appears to boost both HIV-1-specific CD4+ and HIV-1-specific CD8+ T cell lymphocyte activity in chronically HIV-1 infected patients. The results are published in the September 20th issue of the Journal o
IPM enters into a Preliminary Agreement with GlaxoSmithKline to explore Potential of Anti-HIV Compounds as Microbicides: PRNewswire - September 24, 2004; SILVER SPRING, Md., Sept. 24 /PRNewswire/ -- The International Partnership for Microbicides (IPM) has announced that it has entered into a material transfer agreement with GlaxoSmithKline (GSK) under which GSK will select and provide proprietary anti-HIV compounds to be tested for possible use as microbicides. Gla
'Reducing the Probability of Error in HIV/AIDS Patient Care: A Workshop on Patient Safety, Medical Errors and Adverse Events': PRNewswire - September 24, 2004; Hyatt Regency San Francisco Hotel - September 24, 2004 San Francisco, California - 7:30 a.m. to 3:30 p.m. OAKLAND, Calif., Sept. 24 /PRNewswire/ -- The Institute of Medicine issued a landmark report several years ago that called for research and implementation of programs to avert preventable medical error. While there
IMF Undermines Fight Against AIDS, Says New Report: PRNewswire - September 23, 2004; WASHINGTON, Sept. 23 /PRNewswire/ -- In advance of the Annual Fall Meetings of the International Monetary Fund (IMF) and the World Bank, a new report accuses the IMF of undermining the fight against AIDS. The report by four humanitarian agencies says that despite the severity of the AIDS crisis, IMF restrictions on pub
Ukraine Will Improve Access to HIV/AIDS Treatment and Monitoring Through Partnership with Clinton HIV/AIDS Initiative: PRNewswire - September 23, 2004; KIEV, Ukraine , Sept. 23 /PRNewswire/ -- The Minister of Health of Ukraine, and the Clinton HIV/AIDS Initiative announced today that Ukraine has joined the Clinton HIV/AIDS Initiative Procurement Consortium. This partnership will pave the way for Ukraine to purchase high-quality AIDS medicines and diagnostics at the lo
South African Sales of MedMira Rapid HIV Tests Begin: Distributor Receives First Order and Launches Nationally: PRNewswire - September 23, 2004; HALIFAX, Sept. 23 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the international market leader in rapid flow- through diagnostic technology announced today that it has begun shipment of its MiraWell(TM) Rapid HIV Test to its distributor. Impilo Medical Supplies will be distributin
Bush Misleads UN about Support for Global Fund, Says Global AIDS Alliance: PRNewswire - September 21, 2004; WASHINGTON, Sept. 21 /PRNewswire/ -- Today at the United Nations President Bush is making a major speech highlighting his support for programs to address the global AIDS epidemic. Last Saturday in his Radio Address he proclaimed his support for the Global Fund, the world s premiere anti-AIDS effort, launched in 2001 at
Bush's UN Remarks on Global AIDS Program Seen as Window Dressing, Says AIDS Healthcare Foundation: PRNewswire - September 21, 2004; -- President s Remarks During UN Speech Mask PEPFAR s Dismal Performance to Date. $15B Relief Program Fails in Lives Saved ; ARV Treatment Goals Fall Far Short LOS ANGELES, Sept. 21 /PRNewswire/ -- At his speech during the opening of the United Nations General Assembly in New York this morning, President Bush touched b
MedMira Ships Rapid HIV Tests to Caribbean Distributor: Distributor Begins Active Sales of MedMira's Test to Hospitals: PRNewswire - September 21, 2004; HALIFAX, Sept. 21 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ: MMIRF) the market leader in flow-through diagnostics declared today it has begun shipment of it s MiraWell(TM) Rapid HIV Test to Caribbean Medical International (CMI). The rapid HIV test is intended for use in hospitals and c
Glaxo Drops Appeal in AIDS Drug Pricing Case, Says AHF: PRNewswire - September 21, 2004; -- British Drug Giant Backpedals on Vow to Appeal South African Competition Tribunal s Ruling Allowing Complaint Filed by AIDS Healthcare Foundation, US Largest AIDS Group, & South African AIDS Advocates to Proceed DURBAN, South Africa and LOS ANGELES, Sept. 21 /PRNewswire/ -- A landmark South African legal complai
AHF Hails California Governor for Signing Needle and Syringe Bill: PRNewswire - September 21, 2004; -- SB 1159 (Vasconsellos, D, Santa Clara) Creates Disease Prevention Demonstration Project Allowing Individuals to Purchase Up to 10 Hypodermic Needles & Syringes Without a Prescription. Governor Davis had Twice Vetoed Similar Measures; Schwarzenegger s Support Seen as Pragmatic Public Health Move LOS ANGELES, Sept
HIV Vaccine Trial moving to Enroll Last Cohort of Volunteers: PRNewswire - September 20, 2004; LOS ANGELES, Sept. 20 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced today that enrollment in the ongoing Phase I HIV vaccine clinical trial at UMMS is proceeding to the final cohort of participants.
ImmuKnow(TM), First and Only FDA-Cleared Cellular Assay For Measuring and Managing Immune System Health, Gains Attention at Prominent Conferences: PRNewswire - September 20, 2004; -- Cylex is First to Market with Test that Works to Lower the Cost of Healthcare and Improve Therapeutic Outcomes in Transplantation and Infectious Disease Markets COLUMBIA, Md., Sept. 20 /PRNewswire/ -- Cylex Incorporated, today announced that ImmuKnow(TM), the first and only FDA-cleared cellular assay for measuring a
Radio Address By President Bush to the Nation: PRNewswire - September 18, 2004; WASHINGTON, Sept. 18 /PRNewswire/ -- The following is a transcript of remarks by President Bush to the nation. THE PRESIDENT: Good morning. Three years after the attacks of September the 11th, our nation continues to confront the threats to our security. We re acting to protect the homeland, to track and disrupt terror
WHO Urges Member States to Act Now to Avoid a Major HIV/AIDS Epidemic: Fifty-Fifth Session of the WHO Regional Committee for the Western Pacific 13-17 September 2004, Shanghai, China: PRNewswire - September 17, 2004; SHANGHAI, China , Sept. 17 /Xinhua-PRNewswire/ -- Dr Shigeru Omi, World Health Organization Regional Director for the Western Pacific, has warned of the danger of HIV bridging into the general population from infected individuals with high-risk behaviour unless countries and areas in the Region act now to avoid a major
WHO: Urgent Action is Required to Meet 2005 Case Detection Target: Fifty-fifth Session of the WHO Regional Committee 13-17 September 2004, Shanghai, China: PRNewswire - September 17, 2004; SHANGHAI, China , Sept. 17 /Xinhua-PRNewswire/ -- Countries must accelerate their efforts now if the Western Pacific Region* is to reach the target of a 70% case detection rate by the end of 2005. This is a very important milestone. It is the first step towards the 2010 objective of reducing the burden of tuberculosis
WHO: Protect the Public From Contaminated Blood: PRNewswire - September 17, 2004; -- Fifty-fifth Session of the WHO Regional Committee 13-17 September 2004, Shanghai, China SHANGHAI, China, Sept. 17 /Xinhua-PRNewswire/ -- Urgent measures need to be taken to protect the public from contaminated blood transfusions, the World Health Organization (WHO) warned today. In the Western Pacific Region
Bush AIDS Plan Reaches 1.25% of Treatment Goal: PRNewswire - September 14, 2004; WASHINGTON, Sept. 14 /PRNewswire/ -- Global AIDS Alliance reacted today to the statement of the Bush Administration regarding its global AIDS programs. The Administration says it is providing AIDS treatment to 25,000 people through its own programs as well as its contributions to other AIDS programs. This figure repres
New Economic Study Demonstrates Proposition 71 Benefits to State Economy: Investment in Stem Cell Research Could Yield More Than $12 Billion in Returns: PRNewswire - September 14, 2004; Through Tax Revenues, Royalty Revenues, and Health Care Cost Savings LOS ANGELES, Sept. 14 /PRNewswire/ -- A new economic study, co-authored by a nationally-recognized economic research firm, the Analysis Group, and Stanford professor and economist Dr. Laurence Baker, has determined that Proposition 71, the stem cell r
Sangamo BioSciences Updates Investors on Status of Latest Developments in ZFP Therapeutics Programs: Details of Programs in Diabetic Neuropathy and HIV Announced: PRNewswire - September 14, 2004; RICHMOND, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Sangamo BioSciences (Nasdaq: SGMO) will provide an update today to investors on the status of the latest developments in several of its ZFP Therapeutics programs. Scientists from the Company will provide details on programs focused on diabetic neuropathy (DN) and a n
The Immune Response Corporation Presents New Phase II Clinical Data Indicating That REMUNE(R) Induces a HIV-Specific Immune Response: PRNewswire - September 14, 2004; -- Interim Results From Study in Italy in Drug-Naive HIV Patients Presented at HIV Meeting CARLSBAD, Calif., Sept. 14 /PRNewswire-FirstCall/ -- An investigational treatment, REMUNE(R) (HIV-1 Immunogen), induces HIV-specific immunity in drug-naive patients according to interim results from an ongoing multi-center Phase
The Philadelphia AIDS Consortium's Access to Care Through Service (ACTS) Will Provide Another Three Years of Excellent Service to the HIV/AIDS Community: PRNewswire - September 14, 2004; -- One Million Dollar Grant is Awarded to TPAC s ACTS AmeriCorps Program by the Corporation of National and Community Service PHILADELPHIA, Sept. 14 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC), a local nonprofit organization and major funder of support services to individuals with HIV/AIDS, announces offici
Bush Global AIDS Plan Results Called 'Failure' by AIDS Healthcare Foundation: Only 5% of Treatment Goal Set by Congress Has Been Met: PRNewswire - September 13, 2004; LOS ANGELES, Sept. 13 /PRNewswire/ -- AIDS Healthcare Foundation released the following statement in response to a Washington Post article noting 25,000 AIDS patients are in treatment under President Bush s global AIDS plan: Congress set global AIDS treatment goals in federal law last year, but today s numbers indicate
Gay Men's Health Crisis Compares Healthcare Positions of Presidential Candidates Bush and Kerry: PRNewswire - September 13, 2004; NEW YORK, Sept. 13 /PRNewswire/ -- Gay Men s Health Crisis (GMHC) today released a report that compares the health care reform proposals of President George W. Bush and Senator John Kerry. Entitled Prescriptions for Reform: A Comparison of the Bush and Kerry Health Care Access Proposals and their Impact on People with
Barnett Releases State Clinical Trial Requirements Reference Guide: PRNewswire - September 13, 2004; PHILADELPHIA, Sept. 13 /PRNewswire-FirstCall/ -- Barnett Educational Services, a division of PAREXEL International Corporation (Nasdaq: PRXL), has announced the release of State-by-State Clinical Trial Requirements Reference Guide. Designed for clinical research professionals, regulatory affairs professionals, clinical
The Immune Response Corporation Announces Clinical Trial for HIV Therapy IR103 Has Begun to Enroll: First HIV Patients Enrolled in New International Trial: PRNewswire - September 10, 2004; CARLSBAD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today the first patients have been enrolled at the Canadian site in its initial clinical
Chiron Announces Settlement with Roche in HIV Patent Dispute: Agreement Highlights Strength of Company's Intellectual Property Estate: PRNewswire - September 10, 2004; EMERYVILLE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under a licensing agreement related to its U.S. Pate
The U.S. Fund for UNICEF and Procter & Gamble Reunite To Help Children in Latin America: PRNewswire - September 9, 2004; -- Campaign Seeks to Raise Funds for UNICEF Programs in Latin America through the Purchase of Bounce(R), Bounty(R), Charmin(R), Dawn(R) and Downy(R) NEW YORK, Sept. 9 /PRNewswire/ -- For the fifth consecutive year, the U.S. Fund for UNICEF and Procter & Gamble (P&G) brands are coming together to provide childre
Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C: PRNewswire - September 7, 2004; CAMBRIDGE, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has successfully completed the dosing portion of a Phase Ia clinical trial for VX-950, an investigational oral protease inhibitor for the treatment of hepatitis C virus (HCV) infection. The study, i
Roche Files Application with FDA to Market Leading Hepatitis C Medication Pegasys(R) in Combination with Copegus(R) for People with HIV - Hepatitis C, a major killer of Americans with HIV, afflicts 30 percent of U.S. HIV population -: PRNewswire - September 2, 2004; NUTLEY, N.J., Sept. 2 /PRNewswire/ -- Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) in combination with Copegus(R) (ribavirin, USP) for the treatment of chronic hepatitis C in patien
AHF Sues Glaxo for AIDS Drug Price Gouging: PRNewswire - September 2, 2004; LOS ANGELES, CA USA 04/29/2003 - AIDS HealthCare Foundation Files Federal Action Seeking Damages From British Drug Giant Over Fraud in Glaxo s Drug Pricing Practices in US Government s 340B Drug Discount Program. AIDS Group Will Also Ask Senator Richard Alarcon to Spearhead State Legislative Audit Based on Glaxo s Agre
India's Swami Vivekananda Youth Movement (SVYM) Partners With AIDS Healthcare Foundation Global Immunity (AHF-GI) in New AIDS Treatment Clinics in Karnataka State, India: PRNewswire - September 1, 2004; LOS ANGELES, CA USA 04/29/2003 Partnership of US Largest AIDS Group, Respected Indian NGO, and Indian State Government Hospital to Bring Life-Saving ARVs to Patients in Mysore & Koppal LOS ANGELES, Sept. 1 /PRNewswire/ -- AIDS Healthcare Foundation, (AHF) the largest AIDS organization in the United States
Aids Vaccine '04 Conference Calls for a Coherent Research Strategy at European Level to Fight HIV Pandemic: Leading Scientists Urge EUROPEAN Countries to Greater Commitment: PRNewswire - September 1, 2004; LAUSANNE, Switzerland , September 1 /PRNewswire/ -- At the close of the AIDS VACCINE 04 Conference, leading scientists called for both a coherent research strategy to fight the HIV/AIDS pandemic and increased financial commitment with appropriate resources, planning and implementation at European Commission and EFTA co
Testing With Procleix(R) West Nile Virus Assay Initiated on Procleix(R) TIGRIS(R) System Under IND: Automated System Provides Blood Centers with Highest Process Control for Testing: PRNewswire - September 1, 2004; EMERYVILLE, Calif. and SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Chiron (Nasdaq: CHIR) and Gen-Probe (Nasdaq: GPRO) announced today that testing with the Procleix(R) West Nile Virus (WNV) Assay has been initiated under an investigational protocol on the Procleix(R) TIGRIS(R) System. The high-throughput, fully automa
United Nations Foundation President Articulates International Right to Protection: PRNewswire - September 1, 2004; Former US Senator Timothy E. Wirth Calls for Implementation of ICPD Action Plan to Alleviate Fear, Poverty; Urges Conference Attendees to Support Integrated Approach to Reproductive Health, HIV/Aids and Millennium Development Goals So All People Can Protect Themselves LONDON, Sept. 1 /PRNewswire/ -- Timothy E. Wirth, P
Epimmune Presents SIV Vaccine Study Data at AIDS Vaccine 2004 in Lausanne, Switzerland Showing Control of Virus Despite the Presence of Viral Mutations: PRNewswire - August 31, 2004; SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today presented preliminary data from its ongoing SIV rhesus macaque vaccine study at the AIDS Vaccine 2004 conference in Lausanne, Switzerland . SIV is the virus equivalent of HIV in many non-human primate species. Preliminary data presented sh
Remarks by Senator Sam Brownback on 'AIDS Initiative' as Prepared for Delivery at the 2004 Republican National Convention on Tuesday, August 31, Evening Session 7:00 - 11:15 P.M. EDT: PRNewswire - August 31, 2004; NEW YORK, Aug. 31 /PRNewswire/ -- The following are remarks by Senator Sam Brownback on AIDS Initiative as prepared for delivery at the 2004 Republican National Convention: My friends, it is a privilege to be with you. A fundamental principle of our democracy and our Republican Party is respect for the inherent dignity
AIDS VACCINE '04 Conference Calls for Increased Political and Financial Commitment: At Least 1 Billion Euros Yearly Required: PRNewswire - August 30, 2004; LAUSANNE, Switzerland , August 30 /PRNewswire/ -- At the opening ceremony of the Lausanne, Switzerland, AIDS VACCINE 04 conference, leaders in the field of AIDS vaccine research called for increased political and financial commitment to facilitate the development of preventive and therapeutic AIDS vaccines as a public
AIDS VACCINE '04 Conference Calls for Increased Political and Financial Commitment: At Least 1 Billion Euros Yearly Required: PRNewswire - August 30, 2004; LAUSANNE, Switzerland , August 30 /PRNewswire/ -- At the opening ceremony of the Lausanne, Switzerland, AIDS VACCINE 04 conference, leaders in the field of AIDS vaccine research called for increased political and financial commitment to facilitate the development of preventive and therapeutic AIDS vaccines as a public
Gay Issues and the 2004 Election: PRNewswire - August 27, 2004; WASHINGTON, Aug. 27 /PRNewswire/ -- The Human Rights Campaign (HRC) is the nation s largest gay, lesbian, bisexual and transgender advocacy organization, with 600,000 members, a 110-person staff, three governing boards, a national headquarters building in downtown Washington, D.C., and a $30 million annual budget. In 2
New Long-Term Data Provide Guidance on the Use of Sustiva(R) (Efavirenz) in HIV-Treatment-Naive Patients: PRNewswire - August 26, 2004; -- Package Insert to Include 168-Week Data on Long-Term Durability, Safety & Tolerability - PRINCETON, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that SUSTIVA(R) ( efavirenz ) has received approval from the U.S. Food and Drug Administration (
Theratechnologies presents results from its HIV-associated lipodystrophy Phase II study on ThGRF at the 12th International Congress of Endocrinology: PRNewswire - August 26, 2004; -- Additional presentations to be made before year end in Europe and the US MONTREAL, Aug. 26 /PRNewswire-FirstCall/ - Theratechnologies (TSX :TH) announced today that results of its Phase II clinical trial on ThGRF in patients with HIV-related lipodystrophy, a medical condition characterized by body composition change
Bavarian Nordic Announces Significant Progress in Safe Smallpox Vaccine: Company Strengthens its Position in Competition for NIH Award: PRNewswire - August 26, 2004; COPENHAGEN, Denmark and WASHINGTON, Aug. 26 /PRNewswire/ -- International biopharmaceutical company Bavarian Nordic announced today its interim results for the six-month period ending 30 June, 2004, and other key developments. Bavarian Nordic noted particular progress has been made to date on their safe, third generati
Leading AIDS Organizations Launch Absentee Ballot Drive: Requests for Ballots and Voter Registration Available Online at POZ.com: PRNewswire - August 25, 2004; NEW YORK, Aug. 25 /PRNewswire/ -- A coalition of leading AIDS organizations today announced the launch of a major absentee ballot drive for the 2004 elections through POZ.com. Using new interactive technology, visitors to POZ.com can now request absentee ballots, register to vote and change their registered addresses.
Viral Genetics Appoints Former U.S. Surgeon General Dr. Jocelyn Elders to Scientific and Medical Advisory Board: PRNewswire - August 25, 2004; AZUSA, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Viral Genetics (OTC Bulletin Board: VRAL) is pleased to announce the addition of Dr. Jocelyn Elders to its Scientific and Medical Advisory Board. Dr. Elders has a long and distinguished track record of public health service, most notably as Surgeon General of the U.S. Pu
HIV-Positive Children in Resource-Limited Setting Successfully Treated: PRNewswire - August 23, 2004; HOUSTON, Aug. 23 /PRNewswire/ -- Clinicians have been able to reduce mortality rates in HIV positive children from 15 to 3 percent in the largest group of children treated with highly active antiretroviral therapy (HAART) in any single center worldwide, according to a paper published in the August 2004 issue of The Ped
Medarex Announces Special Protocol Assessment Agreement with FDA to Initiate Phase III Clinical Trial for MDX-010 in Metastatic Melanoma: PRNewswire - August 23, 2004; -- Conference Call Scheduled for 11:00 AM ET Today to Discuss Phase III Trial PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration ( FDA ) for the initiation of a pi
Generex Biotechnology Expands HIV Vaccine Efforts With Leading MGH Investigator: Collaboration to Study Patient's Recognition of Novel Vaccine Stimulating T-Helper Cells: PRNewswire - August 18, 2004; TORONTO, Aug. 18 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that its wholly owned subsidiary, Antigen Express, has established a collaboration with Massachusetts General Hospital to use modified peptide antigens to stimulate immunity to HIV for both prevention and treatme
California Mayors & Local Elected Officials Endorse Proposition 71: Noting Measure's Promise to Save Lives and Boost Local Economies: PRNewswire - August 18, 2004; -- Los Angeles City Council Votes Unanimously to Lend Support to Prop. 71 LOS ANGELES, Aug. 18 /PRNewswire/ -- Supporters of Proposition 71, the California Stem Cell Research and Cures Initiative, today announced that mayors and local elected officials across California have endorsed the measure, adding to a growing, b
Nomination Introduces Red Ribbon Charm to Support The American Foundation for AIDS Research (amfAR): PRNewswire - August 18, 2004; NEW YORK, Aug. 18 /PRNewswire/ -- Nomination, the original creator of the composable charm bracelet, introduces the red ribbon charm link symbolizing AIDS prevention and awareness and support of amfAR -- the nation s leading nonprofit organization dedicated to the support of AIDS research. Nomination has planned a nati
MedMira Rapid HIV Tests Donated to African Orphanage: Supporting Canadian Hopes and Dreams Team to Provide HIV Testing for Orphaned Children in Kenya: PRNewswire - August 17, 2004; HALIFAX, Aug. 17 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the market leader in rapid flow-through diagnostic technology, announced today that it has donated MiraWell(TM) Rapid HIV Tests to the Hopes and Dreams Team for use in Kenya at an orphanage where over 700 orphaned child
Investigational Formulation of Invirase(R) Granted Priority Review Status by U.S. FDA - 500 mg Tablet to Simplify Drug Regimens -: PRNewswire - August 17, 2004; NUTLEY, N.J., Aug. 17 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration ( FDA ) has granted priority review status to the New Drug Application (NDA) for a 500 mg tablet formulation of its HIV protease inhibitor, Invirase (R) (saquinavir mesylate). If approved, the new formulation of In
2004 World Factbook Now Available From NTIS: Basic Intelligence on All Areas of the World Released by the CIA in One Handy Manual: PRNewswire - August 17, 2004; SPRINGFIELD, Va., Aug. 17 /PRNewswire/ -- The World Factbook, a popular Central Intelligence Agency reference manual, provides a wealth of information on over 260 separate nations and other entities, listed alphabetically, in over 700 pages. There are also 11 terrain maps and three world maps included. The World Factbo
AHF: Generic AIDS Medications Backed by California and Mexican Leaders: PRNewswire - August 13, 2004; -- NAFTA Issues Discussed at Legislative Forum: Pledge Made to Work Together to Lift Trade Barriers to Cost Effective, Life-Saving HIV Treatment SACRAMENTO, Aug. 13 /PRNewswire/ -- A special meeting of Legislators from the 3 Californias, yesterday pledged to advocate for access to low cost, generic AIDS medications in
MedMira Rapid HIV Test Number One In U.S. Hospitals: Recent CDC Study Shows MedMira is a Leader in the Point-Of-Care Market: PRNewswire - August 12, 2004; HALIFAX, Aug. 12 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the market leader in flow-through diagnostics today announced its Reveal(TM) Rapid HIV-1 Antibody Test is the number one choice of hospitals in the United States (where over 80% of HIV testing is conducted) according to
New Survey Reveals Surprising Insights into Parental Attitudes Toward Teenage Sexual Behavior: Parents Share Top Concerns About Their High Schoolers: PRNewswire - August 11, 2004; BLUE SPRINGS, Mo., Aug. 11,2004 /PRNewswire/ -- As an estimated four million American children make the transition from junior high/middle school to high school this fall, a new national survey conducted by the Society for Adolescent Medicine (SAM) reveals parents primary concerns as they ready their teenagers for the
New 3- Minute Rapid HIV Test Launched In United States: Reveal(TM) G2 Introduced at AACC in Los Angeles: PRNewswire - August 10, 2004; HALIFAX, Aug. 10 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the market leader in flow-through diagnostics today announced the U.S. launch of its newest FDA approved rapid HIV test, the Reveal(TM) G2 Rapid HIV-1 Antibody Test (Reveal(TM) G2) at the AACC (American Association for C
Detroit Area Artists Unite in the Fight Against AIDS: PRNewswire - August 10, 2004; FERNDALE, Mich., Aug. 10 /PRNewswire/ -- Over 300 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the ninth annual ART WORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 18, 2004 at Detroit s historic Masonic Temple to benefit the Midwest AIDS Pr
Calypte Biomedical Announces Signing of Sublicense Agreement with Abbott Laboratories: PRNewswire - August 9, 2004; PLEASANTON, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), announced today that it has signed a sublicense agreement with Abbott Laboratories , Inc. (NYSE: ABT) for certain worldwide rights to patents relating to the design, manufacture and sale of lateral-flow rapid
AHF AIDS Program Saves Florida $52 Million: PRNewswire - August 9, 2004; -- AHF is Shining Star in Otherwise Troubled Disease Management Initiative: Program Improved Patient Health Outcomes While Reducing State s Costs Significantly WHAT: Media Availability -- On $52M Savings to Florida s MediPass (Medicaid) Program and Improved Patient Outcomes by AIDS Healthcare Foundation s Disease Manag
FDA Advisory Committee Overwhelmingly Recommends Approval of Roche's COBAS AmpliScreen Hepatitis B Test for Use in Screening Donated Whole Blood: Test Is First Nucleic Acid Hepatitis B Blood Screening Test to Be Accepted For Review by FDA: PRNewswire - August 9, 2004; PLEASANTON, Calif., Aug. 9 /PRNewswire/ -- Roche Diagnostics announced that the Blood Products Advisory Committee (BPAC) of the United States Food and Drug Administration ( FDA ) voted overwhelmingly that the sensitivity and specificity of Roche s COBAS AmpliScreen HBV Test in a mini-pool format supported licensing as
Generic Drugs Work: Proof is Seen in the WHO's Pulling of Ranbaxy Drugs, Says AHF: PRNewswire - August 6, 2004; -- As the Heated Debate Over the Use of Generics in the Developing World Continues, the World Health Organization Takes Steps to Ensure the Health and Safety of Millions Living With HIV by Pulling Three Drugs off its List of Approved Medicines LOS ANGELES, Aug. 6 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the la
New Survey Finds Majority of African Americans Say U.S. is Losing Ground on HIV/AIDS: African Americans Name HIV/AIDS the Most Urgent Health Problem, While Latinos Place It the Second Most Urgent Behind Cancer: PRNewswire - August 4, 2004; WASHINGTON, Aug. 4 /PRNewswire/ -- A majority of African Americans (56%) say the U.S. is losing ground when it comes to the problem of HIV/AIDS -- an 18 percentage point increase since October 2003 -- according to a new national survey by the Kaiser Family Foundation, conducted this spring. By comparison, three in ten
Medical Discoveries Inc. Announces Multiple Clinical Development Priorities Under a Drug Master File: PRNewswire - August 4, 2004; TWIN FALLS, Idaho, Aug. 4 /PRNewswire-FirstCall/ -- Medical Discoveries, Inc. (OTC Bulletin Board as MLSC) announced today an addition in clinical development priorities to multiple indications, led by Cystic Fibrosis (CF) and HIV, as allowed under an FDA Drug Master File (DMF). The Company s clinical development objec
Viral Genetics Announces Enrollment for South African Clinical Trial of VGV-1: Clinical Trial Funding Support Tied to Distribution Agreement and Subsidiary Sale: Company to focus on development in USA: PRNewswire - August 3, 2004; AZUSA, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (OTC Bulletin Board : VRAL) (the Company ) today announced that enrollment has begun for a human clinical trial in South Africa on VGV-1. VGV-1 (formerly known as Thymus Nuclear Protein) is a purified protein extracted from bovine thymus gland that ha
AHF Thanks Governor and Legislature for Compromise on Funding for Vital AIDS Testing Program: 2004-2005 Budget Includes $4 Million for Essential Viral Load Monitoring: PRNewswire - August 3, 2004; LOS ANGELES, Aug. 3 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest HIV organization, welcomes the recent inclusion of $4 million to a General Fund program specifically earmarked for viral load and HIV resistance testing, in the final 04-05 budget. Last year, $7 million was cut from the $8 millio
Trinity Biotech Receives FDA Clearance for CAPTIA(TM) Herpes Simplex Virus (HSV) IgG Type Specific ELISAs: PRNewswire - August 3, 2004; DUBLIN, Ireland , August 3 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) announced that it has received clearance from the U.S.A. Food and Drug Administration ( FDA ) to market its CAPTIA(TM) HSV IgG Type Specific ELISAs in the United States .
FDA Approves EPZICOM - A New HIV Medication Combining Two Antiretrovirals in One Tablet Dosed Once a Day: PRNewswire - August 2, 2004; RESEARCH TRIANGLE PARK, N.C., Aug. 2 /PRNewswire/ -- EPZICOM(TM), a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration ( FDA ). EPZICOM combines two widely-used nucleoside rever
Epimmune Reports Data in The Journal of Immunology Showing Cellular Response Against Multiple HIV Variants and Subtypes With Epitope Vaccine: PRNewswire - August 2, 2004; SAN DIEGO, Aug. 2 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today announced the publication of data in the August 1 issue of The Journal of Immunology which showed that an epitope-based HIV-1 vaccine can be designed to induce cytotoxic T lymphocytes (CTL) capable of recognizing viruses from different parts
From Bangkok to Toronto: The Tough Road Ahead in The Campaign to Combat HIV/AIDS: PRNewswire - August 2, 2004; MANILA, Philippines , Aug. 2 /Xinhua-PRNewswire/ -- HIV/AIDS is still a major global emergency, which must remain at the forefront of policy-makers priorities. That was the over-riding message of the 15th International AIDS Conference in Bangkok, Thailand in July 2004 and it is a message that will be repeated
Giving Aid to the Children; Compassion International Expands AIDS Assistance to Children: PRNewswire - August 2, 2004; COLORADO SPRINGS, Colo., Aug. 2 /PRNewswire/ -- Compassion International, one of the world s largest child development organizations, is significantly increasing its help to children infected with the HIV/AIDS virus. The ministry intends to triple the amount of money it spends over the next three years, making new drug
Ranbaxy to File ARVs With the US FDA: PRNewswire - August 2, 2004; NEW DELHI, India , Aug. 2 /PRNewswire-FirstCall/ -- In response to the many enquiries the Company has been receiving in the recent past, Ranbaxy Laboratories Limited (Ranbaxy) has initiated a program to file its Anti Retroviral (ARV) range of products for the treatment of HIV/AIDS with the US
AIDS Healthcare Foundation Press Release; Schwarzenegger Vetoes AIDS Pharmacy Funds: PRNewswire - July 31, 2004; LOS ANGELES, July 31 /PRNewswire/ -- California Governor Arnold Schwarzenegger today used his line item veto power to kill a legislative effort protecting AIDS patients from across-the-board pharmacy budget cuts, according to the AIDS Healthcare Foundation, the US largest HIV organization. We are deeply disappointed to
GenVec and NIH Move HIV Vaccine Candidate Into Human Clinical Trials: NIH Initiates Phase I HIV Vaccine Trial: PRNewswire - July 28, 2004; GAITHERSBURG, Md., July 28 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC), announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has initiated a Phase I clinical study to test an HIV vaccine candidate
New England Journal of Medicine Publishes Results from Landmark Study Reporting the Highest Response Rates Ever Achieved for the Treatment of Hepatitis C in Co-infected Patients: PRNewswire - July 28, 2004; -- Study Findings Offer New Hope for the Estimated 300,000 Americans Co-infected With Hepatitis C and HIV NEW YORK, July 28 /PRNewswire/ -- A landmark study published in this week s New England Journal of Medicine reveals the highest efficacy rates ever reported among patients co-infected with hepatitis C and HIV treat
Landmark Study Published in New England Journal of Medicine Shows 40 Percent of People Infected with HIV and Hepatitis C had Sustained Response to Pegasys Hepatitis C Combination Therapy: PRNewswire - July 28, 2004; NUTLEY, N.J., July 28 /PRNewswire/ -- A landmark study published today in the New England Journal of Medicine showed that 40 percent of people with chronic hepatitis C co-infected with HIV who were treated with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin), achieved a sustained virological response (a p
Lingerie Bowl 2005 and AIDS Research Alliance of America Will Team on Super Bowl Sunday in the Fight Against AIDS: National Charity Will Benefit From PPV Broadcast: PRNewswire - July 27, 2004; LOS ANGELES, July 27 /PRNewswire/ -- Horizon Productions, Inc. is proud to announce that Pay-Per-View sales from the Lingerie Football League s (LFL) second annual Super Bowl halftime alternative Lingerie Bowl 2005 (http://www.lingeriebowl.com) will benefit the AIDS Research Alliance of America (http://www.aidsresearch
Generex Biotechnology Presents Research Abstract on the Use of Novel Peptide Vaccine for Melanoma at the 12th International Congress of Immunology: Late Preclinical Studies Support Potential Use of T-Helper Cell Peptide Vaccine for Cancers: PRNewswire - July 27, 2004; TORONTO, July 27 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), announced today the presentation of a research abstract by Cathy Blackwell of its Antigen Express immunomedicines subsidiary at the 12th International Congress of Immunology and 4th Annual Conference of FOCIS in Montreal. Cathy
The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103 - REMUNE(R) and IR103 Development on Track -: PRNewswire - July 27, 2004; CARLSBAD, Calif., July 27 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), presented research results at the International Congress of Immunology in Montreal demonstratin
10th Annual National HIV Testing Day Big Hit: Public-Private Partnership and National Community Support Vital to Success: PRNewswire - July 27, 2004; WASHINGTON, July 27 /PRNewswire/ -- Thousands of Americans received voluntary HIV counseling and testing across the country during the days leading up to and following June 27, making this year s National HIV Testing Day (NHTD) one of the most successful in the 10-year history of the event. The National Association of
Abbott Laboratories Announces Submission for Once-Daily Kaletra(R) (lopinavir/ritonavir) in United States, Europe - Application Seeks Use as Part of a Combination Regimen in HIV Treatment-Naive Patients: PRNewswire - July 26, 2004; ABBOTT PARK, Ill., July 26 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration ( FDA ) and a Marketing Authorization variation to the European Medicines Agency (EMA), seeking approval of once-daily d
BET'S Rap-It-Up Hosts David Deal Playday BET Teen Concert on August 4: PRNewswire - July 26, 2004; WASHINGTON, July 26 /PRNewswire/ -- BET s Rap-It-Up, the cable network s national HIV/AIDS public awareness initiative, comes to Fort Lauderdale to host the David Deal Playday/BET Teen Concert in partnership with the City of Fort Lauderdale and local radio station, 103.5 The Beat. BET s Rap-It-Up, along with the Browar
BET'S Rap-It-Up Sponsors Teen Forum & Testing for Tickets During Magic Johnson's 19th Annual 'A Midsummer Night's Magic' in LA, July 31 - August 1: PRNewswire - July 26, 2004; LOS ANGELES, July 26 /PRNewswire/ -- BET s Rap-It-Up, returns to Los Angeles with its award-winning, national HIV/AIDS initiative to host a teen forum during Earvin Magic Johnson s 19th Annual A Midsummer Night s Magic, July 30 - August 1. Committed to raising awareness about HIV/AIDS, Rap-It-Up will host a teen forum
BET, Black AIDS Institute and Kaiser Family Foundation Announce Winners of Rap-It-Up/Black AIDS Short Subject Film Competition: PRNewswire - July 26, 2004; WASHINGTON, July 26 /PRNewswire/ -- Concluding an extensive national call for submissions and thorough review process, Black Entertainment Television (BET), the Black AIDS Institute (The Institute), and the Kaiser Family Foundation proudly announce today the winners in the Rap-It-Up/Black AIDS Short Subject Film Compet
Gay Issues and the 2004 Election: PRNewswire - July 23, 2004; WASHINGTON, July 23 /PRNewswire/ -- The Human Rights Campaign (HRC) is the nation s largest gay, lesbian, bisexual and transgender advocacy organization, with 600,000 members, a 110-person staff, three governing boards, a national headquarters building in downtown Washington, D.C., and a $30 million annual budget. In 2
Viral Genetics Announces Results of Chinese Study of VGV-1 for the Treatment of AIDS: China Study Shows Sustained HIV Virus Suppression in Treatment-Naive AIDS Patients: PRNewswire - July 23, 2004; AZUSA, Calif., July 23 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (OTC Bulletin Board: VRAL) today announced the results of the human clinical trial conducted in China at the National AIDS Center located in Beijing Ditan Hospital. The results suggest that patients receiving no additional anti-HIV therapy had sustai
Stressgen Presents Data at International Immunology Congress -- Immunization with HspE7 Induces Strong and Durable Cellular Response to HPV E7 Protein in Normal and Immunocompromised Mice: PRNewswire - July 22, 2004; MONTREAL, July 22 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation (TSX:SSB) today presented data at the 12th International Congress of Immunology demonstrating that HspE7, the Company s lead immunotherapeutic, induces strong and durable cellular responses to the human papillomavirus (HPV) E7 protein in n
Roche Files for Application with FDA to Market Leading Hepatitis C Medication Pegasys(R) for Chronic Hepatitis B Treatment - CDC Estimates 1.25 Million in U.S. are Chronically Infected with Hepatitis B: PRNewswire - July 21, 2004; NUTLEY, N.J., July 21 /PRNewswire/ -- Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis B (CHB). Simultaneously, Roche has also filed with the Euro
Bioject Signs Agreement With Path to Develop and Evaluate a Disposable- Cartridge Jet Injection System for Global Immunization: PRNewswire - July 19, 2004; BEDMINSTER, N.J., July 19 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, announced today that it has signed a collaboration agreement with PATH, an international nonprofit organization whose mission is to improve the health of people
GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV: PRNewswire - July 16, 2004; LONDON, July 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received marketing approval from the European Commission for Telzir(R) ( fosamprenavir ) for the treatment of HIV infection in adults in combination with other anti-HI
AIDS Healthcare Foundation and Abbott Laboratories Agree to Collaborate on Programs to Support HIV Community; Resolve Lawsuits: PRNewswire - July 16, 2004; BANGKOK, Thailand , July 16 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) and Abbott Laboratories have agreed to work together on enhanced AIDS prevention, diagnosis and treatment programs. The agreement resolves the two lawsuits brought by AHF against Abbott over the company s price increase for its HIV/AIDS drug,
Bayer Healthcare Reaffirms Commitment to Community, People Living with AIDS; Lends Support for AIDS Walk San Francisco and 'KidZone': PRNewswire - July 16, 2004; TARRYTOWN, N.Y., July 16 /PRNewswire/ -- Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY), announced today that it is a proud sponsor of the San Francisco AIDS Walk. Specifically, Bayer HealthCare has provided the resources necessary for the group to implement KidZone, the first-ever family oriented initia
Calypte Biomedical Presents Results of Its Rapid HIV-1/2 Field Trial Tests at the XV International AIDS Conference in Bangkok: Overall Accuracy: Blood Rapid 100%, Oral Fluid Rapid 99.8%, Urine Rapid 99.6%: PRNewswire - July 15, 2004; PLEASANTON, Calif., July 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) announced today that it has completed the initial field trials of its rapid products currently under development and has distributed that study data at the XV International AIDS Conference in Bangkok,
Novation Signs Agreement With Bayer Diagnostics for Molecular Diagnostics Products: PRNewswire - July 15, 2004; IRVING, Texas, July 15 /PRNewswire/ -- Novation, the supply company of VHA Inc. and the University HealthSystem Consortium, has signed an agreement with Bayer HealthCare LLC, Diagnostics (NYSE: BAY) for molecular diagnostics products and accessories. The agreement took effect on June 15, 2004, and runs through June 14,
The Immune Response Corporation Presents Data Demonstrating IR103 HIV-Specific Immunologic Activity at XV International AIDS Conference - IR103 Produces HIV-Specific Immune Responses in Saline Formulation -: PRNewswire - July 15, 2004; CARLSBAD, Calif., July 15 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced that research results suggest its newest HIV product candidate, IR103, generated robu
Jewel to Perform at Summer Party(TM) for AIDS Project Los Angeles: PRNewswire - July 14, 2004; LOS ANGELES, July 14 /PRNewswire/ -- APLA s Summer Party(TM) is set to re-launch at a new location, Paramount Studios, on Saturday, July 24 from 7 P.M. until midnight. Singer/songwriter Jewel has signed on to headline a musical bill to include Robi Draco Rosa and Paul Lekakis. Master promoter Tom Whitman will present
Procleix(R) Ultrio(TM) Study Presented at International Society of Blood Transfusion Conference - Data Highlight the Value of Ultrio - Hepatitis B-Positive Blood Donation Detected: PRNewswire - July 14, 2004; EMERYVILLE, Calif., July 14 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced the results of a multicenter trial of the Procleix(R) Ultrio(TM) Assay presented at a symposium at the International Society of Blood Transfusion (ISBT) meeting in Edinburgh. The data, presented by Dr. Claudio Velati
Boehringer Ingelheim Reports Tipranavir Safety and Pharmacokinetics Data at International AIDS Conference - Interim Results Presented of First HIV Drug Development Program to Examine Dual-Boosted PI Therapy in Highly Treatment-Experienced Patients: PRNewswire - July 14, 2004; BANGKOK, Thailand , July 14 /PRNewswire/ -- Boehringer Ingelheim today announced new, interim findings from a Phase IIb study of tipranavir, a non-peptidic protease inhibitor, in HIV-positive patients with limited treatment options. The four-week results demonstrate that tipranavir is well tolerated when boosted with
Panacos Pharmaceuticals Presents Phase 1 Clinical Data on First-in-Class HIV-1 Maturation Inhibitor, PA-457, at XV International AIDS Conference, Bangkok, Thailand: PRNewswire - July 14, 2004; -- Additional Panacos Presentations Include Data on PA-457 s Molecular Target and the Discovery of Novel HIV Fusion Inhibitors GAITHERSBURG, Md., July 14 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today provides results of a recently completed Phase 1 clinical trial of its lead HIV drug candidate, PA-457, at the XV
Lower Frequency of Moderate to Severe Drug-Related Diarrhea Associated With LEXIVA Compared to Nelfinavir in Treatment-Naive HIV Infected Adults: PRNewswire - July 14, 2004; BANGKOK, Thailand , July 14 /PRNewswire/ -- The frequency of moderate to severe drug-related diarrhea was significantly lower in HIV-infected patients taking the protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium) compared to those taking the PI nelfinavir (NFV), according to 48-week data from SOLO and NEAT stu
Kaletra(R) (lopinavir/ritonavir) Based Regimens Demonstrate Favorable Resistance in Clinical Trials: PRNewswire - July 14, 2004; BANGKOK, Thailand , July 14 /PRNewswire-FirstCall/ -- In two clinical studies, no primary protease inhibitor (PI) resistance was reported in antiretroviral-naive patients taking a Kaletra (R) ( lopinavir / ritonavir
CytRx Corporation, Advanced BioScience Laboratories and University of Massachusetts Announce First Patients Enrolled in HIV Vaccine Trial: PRNewswire - July 14, 2004; LOS ANGELES, July 14 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced today that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine develo
REYATAZ(R) (atazanavir sulfate) Granted Approval For Use With Low-Dose Ritonavir in Treatment-Experienced HIV-Infected Patients - Package Insert to Include 48-Week Data Comparing Regimen Containing REYATAZ/Ritonavir to Kaletra(R) -: PRNewswire - July 14, 2004; PRINCETON, N.J., July 14 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that REYATAZ(R) ( atazanavir sulfate) has received approval from the U.S. Food and Drug Administration ( FDA ) to include new scientific data and dosing in its package insert, or label
Epimmune Presents Preliminary HIV Clinical Trial Data at XV International AIDS Conference in Bangkok: PRNewswire - July 13, 2004; SAN DIEGO, July 13 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today presented early data from one of the ongoing Phase I trials of its EP HIV-1090 therapeutic vaccine (EP1090) for HIV-infected patients. The available data were summarized in a poster presentation at the XV International AIDS Conference in Ba
New Invirase(R) Data Demonstrate Undetectable Viral Load in 91% of Patients; Clinical trial demonstrates high potency combined with good tolerability: PRNewswire - July 13, 2004; BANGKOK, Thailand , July 13 /PRNewswire/ -- Data from a new study with the HIV protease inhibitor Invirase (R) (saquinavir mesylate) has demonstrated the best HIV RNA response yet seen in a large group of HIV-infected patients given highly active antiretroviral therapy.(1-8) The data announced today at the XV Inter
United Nations-Supported Global Media AIDS Initiative Announces New Media Efforts to Address HIV/AIDS in Russia, India, China, Indonesia and U.S.: PRNewswire - July 13, 2004; BANGKOK, Thailand , July 13 /PRNewswire/ -- New HIV-focused public education efforts in Russia , India , China , Indonesia , and the United States were announced today by the United Nations-supported Gl
Sustained Virologic Responses With LEXIVA in Treatment-Naive Patients With High Viral Load and Low CD4 Counts at Entry in SOLO & NEAT: PRNewswire - July 13, 2004; BANGKOK, Thailand , July 13 /PRNewswire/ -- Treatment-naive HIV infected adults with high viral loads (VL) and low CD4 cell counts at baseline who took the protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once a day
Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC: PRNewswire - July 13, 2004; BANGKOK, Thailand , July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium, formerly GW433908, or 908) in combination with abacavir and lamivudine demonstrated sustained efficacy and safety after long-term treatment
GMHC Community Task Force Responds to the Emergent Increases of Crystal Meth Use and Syphilis Infections As They Relate to HIV Transmission: PRNewswire - July 13, 2004; NEW YORK, July 13 /PRNewswire/ -- Gay Men s Health Crisis (GMHC) today announced the findings of its broad-based New York City Task Force that was formed to develop strategic responses to the growing epidemic of crystal methamphetamine addiction and its connection to a recent resurgence of HIV and syphilis infections a
Patent Protection Crucial for Next Generation of HIV/AIDS Medicines: PRNewswire - July 13, 2004; BANGKOK, Thailand , July 13 /PRNewswire/ -- - New Innovative Medicines for People Living with HIV/AIDS Will be the Key to Sustain the Fight Against the Pandemic. - Overcoming Resistance is Critical for Future Safe and Effective Therapies. Intellectual property protection is essential to ensure the continued development
Primagen to Provide Quest Diagnostics with Retina Mitox Mitochondrial(TM) DNA Blood Test for Scientific Research use: PRNewswire - July 13, 2004; AMSTERDAM, July 13 /PRNewswire/ -- Primagen Holding B.V. (http://www.primagen.com), a provider of molecular diagnostic tests for infectious diseases, AIDS and cancer, announced that it will provide Quest Diagnostics Incorporated (NYSE: DGX) reagents and kits to perform its proprietary Retina(TM) Mitox(TM) test to quant
AIDS Healthcare Foundation, AIDS Therapeutic Treatment Now (ATTN) Advocates Host Colorful Procession During AIDS Conference Seeking Drug Company Commitments to the 'Treatment Access Pledge': PRNewswire - July 13, 2004; -- AIDS Advocates Press Drug Companies & Others to Sign Pledge to Stand Down on Enforcement of Drug Patents in Resource-Poor Countries, Improve Access & Reduce Barriers to Treatment in World s Least Developed Countries BANGKOK, Thailand , July 13 /PRNewswire/ -- At the international AIDS conference in Bangkok t
Drug Companies Close Booths, Flee Handful of AHF AIDS Advocates During AIDS Conference Procession Seeking Drug Company Commitments to the 'Treatment Access Pledge': PRNewswire - July 13, 2004; -- Gilead, Boehringer Ingelheim , Only Companies to Keep Conference Booths Open, Address Advocate s Concerns During Colorful Procession on Pledge to Stand Down on Drug Patents in Resource-Poor Countries. GSK, BMS, Merck and Roche Officials All Scatter BANGKOK, Thailand , July 13 /PRNe
Boehringer Ingelheim and GlaxoSmithKline to Develop Co-Package of Viramune(R) and Combivir(R) for the Developing World: PRNewswire - July 13, 2004; INGELHEIM, Germany , LONDON and PHILADELPHIA, July 13 /PRNewswire/ -- Boehringer Ingelheim and GlaxoSmithKline plc (GSK) announced today that the companies have signed a letter of intent for an accelerated development programme for a co-package for
New Mali Center Joins Five Other Novel HIV/AIDS Community-Based Treatment Support Programs: PRNewswire - July 12, 2004; -- Bristol-Myers Squibb s SECURE THE FUTURE HIV/AIDS Initiative Offers Preliminary Report on Sites Testing Models for Treatment and Care in Africa NEW YORK, July 12 /PRNewswire-FirstCall/ -- A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb s (N
Abbott Laboratories Shares Results and Key Learnings from Programs to Fight HIV/AIDS in Developing Countries: PRNewswire - July 12, 2004; BANGKOK, THAILAND, July 12 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) and the Abbott Laboratories Fund today announced that program results and key learnings from the company s Global Care Initiatives would be highlighted in more than 30 presentations at the XV International AIDS Conference taking place this week
Intensive Education and Support Lead to Successful HIV Treatment Outcomes with Fuzeon: PRNewswire - July 12, 2004; -- Model Program Empowers Patients and Physicians to Overcome Injection-Related Barriers BANGKOK, China , July 12 /PRNewswire/ -- An enfuvirtide (Fuzeon(R)) support program developed at the North Jersey Community Research Initiative (NJCRI) is showing remarkable success in helping physicians and patients to overcome in
Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI) - Experienced Patients: 48-Week Data Presented at IAC: PRNewswire - July 12, 2004; BANGKOK, July 12 /PRNewswire-FirstCall/ -- HIV treatment regimens containing the protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV
Number of Antiretroviral Development Strategies on the Increase Again, Reports Pharmaprojects: PRNewswire - July 12, 2004; RICHMOND, England and BANGKOK, Thailand , July 12 /PRNewswire/ -- On the occasion of the 15th International AIDS Conference, now underway in Bangkok, Thailand, Pharmaprojects, the world s leading database tracking R&D pipelines worldwide, reports a rise in the number of anti-HIV drug development strategies being ad
Medical Services International Inc. Completes Testing in the United States: PRNewswire - July 12, 2004; EDMONTON, Alberta, July 12 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has completed testing in the United States . The last independent testing was completed by the University of Maryland and demonstrated that the VScan HIV rapid test kit was 100% ac
IAVI: Progress Toward an AIDS Vaccine Outweighed by Challenges: PRNewswire - July 12, 2004; BANGKOK, Thailand , July 12 /PRNewswire/ -- Global efforts to develop a vaccine to prevent HIV infection and AIDS have intensified over the past few years, yet they continue to fall short of what is likely to be needed to achieve success, according to a new report by the International AIDS Vaccine Initiative (IAVI).
HIV Patients Continue to Respond Positively to Drug After Two Years: PRNewswire - July 12, 2004; NEW YORK, July 12 /PRNewswire/ -- New clinical research, presented at the XV International AIDS Conference in Bangkok, Thailand show that more than half the patients treated with Fuzeon(R) ( enfuvirtide ) continued to show positive results after almost two years of use. Fuzeon is the first and only fusion inhibitor
AHF to GSK: 'Voluntary Licensing is a Scam': PRNewswire - July 12, 2004; -- AIDS Healthcare Foundation Protests GlaxoSmithKline Over Voluntary Licensing Agreements With South African Generic Makers -- Since GSK s October 2001 Agreement With Aspen Pharmacare, Not One Pill has Been Produced in South Africa. AIDS Advocates Question GSK on Production Delays, Patent Royalties in the Agreement to
New Data Finds Fuzeon-Based Therapy Provides Significant Long-Term Benefit - AIDS Survivor Demonstrates Benefits of HIV Fusion Inhibitor -: PRNewswire - July 11, 2004; BANGKOK, Thailand , July 11 /PRNewswire/ -- Fuzeon(R) ( enfuvirtide ), the first and only fusion inhibitor for the treatment of HIV, durably suppresses HIV and provides continuous increases in immune (CD4) cells over a period of 96 weeks, according to new data presented today at the XV International AIDS Conference (IA
Members of Congress, Public Health Experts and Community Leaders Convene in Miami, Discuss Racial and Ethnic Health Disparities: Tobacco, Obesity, HIV/AIDS and Immigrant Health Addressed: PRNewswire - July 10, 2004; MIAMI, July 10 /PRNewswire/ -- Members of Congress, public health experts, community leaders and citizens of South Florida convened today to address racial and ethnic health disparities in the areas of tobacco, obesity, immigrant health and HIV/AIDS. The American Legacy Foundation, Pfizer and the Kellogg Men s
AIDS Orphans, All Orphans and Vulnerable Children: Innovative, Successful Low-Cost Efforts Offer Comprehensive Care for Children Orphaned and Affected by AIDS in Colombia, Brazil, Uganda and Rwanda: PRNewswire - July 9, 2004; -- The Association Francois-Xavier Bagnoud (AFXB) Will Present Four New Studies During Special Satellite Session in Bangkok on Rights and Costs: Advocacy and Sustainable Development for children, families and communities living with HIV/AIDS BANGKOK, Thailand , July 9 /PRNewswire/ -- Results of four successful low- cos
AnorMED announces new HIV entry inhibitor drug candidate to advance to Phase II clinical program: PRNewswire - July 9, 2004; -- Positive Phase Ia safety and oral bioavailability data presented at 2004 International AIDS Conference in Bangkok, Thailand . VANCOUVER, July 9 /PRNewswire-FirstCall/ - AnorMED Inc. (TSX:AOM) announced today that positive clinical data from healthy volunteers support continued clinical development of AMD070, as new
Beckman Coulter Forms Strategic Alliance With PointCare Technologies for Point-of-Care CD4 Monitoring for HIV/AIDS Patients: PRNewswire - July 9, 2004; FULLERTON, Calif., July 9 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) today announced it has entered into a strategic partnership agreement with PointCare Technologies, Inc. Under the terms of the agreement, Beckman Coulter has exclusive global sales and marketing responsibilities for the new PointCARE(
AIDS Healthcare Foundation Calls Congressional AIDS Vote 'Unacceptable': Expresses Concern Over Waiting Lists for Medications and Clinic Appointments: PRNewswire - July 9, 2004; LOS ANGELES, July 9 /PRNewswire/ -- In response to yesterday s vote by the House of Representatives Labor/HHS Appropriations Subcommittee to provide no new HIV/AIDS funding to Title I of the Ryan White CARE Act, the AIDS Healthcare Foundation -- the US largest non-profit HIV organization -- released the following state
VH1 and The Global Fund to Fight AIDS, Tuberculosis and Malaria Launch Unprecedented Multi-Year Media Partnership: PRNewswire - July 8, 2004; -- First Wave of On-Air Public Service Announcements to Launch July 13th in the U.S. on VH1 NEW YORK, July 8 /PRNewswire/ -- U.S. Television Network VH1 has teamed up with The Global Fund to Fight AIDS, Tuberculosis and Malaria to create an unprecedented collaborative public education campaign designed to raise awarene
AIDS Healthcare Foundation, AIDS Therapeutic Treatment Now Coalition to Unveil Ambitious Bangkok 2004 'Treatment Access Pledge': PRNewswire - July 8, 2004; -- In Addition to Joining in Treatment Access Marches, Hosting Protests and Rallies During Int l AIDS Conference, AIDS Advocates Will Now Press Drug Companies & Others to Sign Pledge that Each Will Stand Down on Enforcement of Drug Patents in Resource-poor Countries BANGKOK, Thailand , July 8 /PRNewswire/ -- In
AIDS Fight Must Not Ignore Orphans and Vulnerable Children: PRNewswire - July 7, 2004; WASHINGTON, July 7 /PRNewswire/ -- Relatively few sessions at next week s International AIDS Conference will focus directly on the plight of orphans and vulnerable children, even though the explosion in the number of abandoned children is a key consequence of the epidemic. The crisis is a focus of only a handful of wor
World Vision and AIDS 2004 World Conference - Bangkok July 11-16: Leading Christian Humanitarian Organization Mobilizes Church, Christian Community, in Fight Against HIV/AIDS Pandemic: PRNewswire - July 7, 2004; BANGKOK, Thailand , July 7 /PRNewswire/ -- World Vision is a Christian relief and development organization dedicated to helping children and their communities worldwide reach their full potential by tackling the causes of poverty. For more than a decade, AIDS has been the single greatest cause of poverty and suffering
WHO and Clinton HIV/AIDS Initiative Come Together To Support China's Efforts to Fight its Epidemic: PRNewswire - July 6, 2004; BEIJING, July 6 /Xinhua-PRNewswire/ -- At a time when China is stepping up its efforts to combat the spread of HIV/AIDS in the world s largest population, the World Health Organization and the Clinton HIV/AIDS Initiative have come together to lend China their support. On 1 July 2004, WHO and CHAI signed a trust fund ag
Erratic Rains, Civil Strife and Desert Locusts Seriously Threaten Food Security in Sub-Saharan Africa: PRNewswire - July 6, 2004; -- Crisis in Sudan Pushes Millions Off the Land; Elsewhere, Drought and AIDS Undercut Agricultural Production WASHINGTON and ROME, July 6 /PRNewswire/ -- Twenty-three countries in sub- Saharan Africa are facing food emergencies for the summer season, according to FAO s latest Africa Report, issued today. Despite an
Global Business Coalition on HIV/AIDS Announces New China Business And AIDS Working Group Beijing: PRNewswire - July 6, 2004; BEIJING, July 6 /Xinhua-PRNewswire/ -- Following meetings with Chinese Vice Minister of Health Wang Longde the Global Business Coalition on HIV/AIDS (GBC) announced today the formation of the China Business and AIDS Working Group. GBC Executive Director Trevor Neilson met with the Vice Minister of Health at his offices
The Swedish Government Provides Substantial Funding for a WHO Project On Comprehensive HIV/AIDS Prevention and Care in China: PRNewswire - July 2, 2004; BEIJING, July 2 /Xinhua-PRNewswire/ -- As China steps up its efforts to tackle the critical issue of HIV/AIDS, the Government of Sweden is providing substantial support for a key project, via the World Health Organization . On Friday, 2 July 2004, the Swedish International Development Agency (SIDA) and t
AHF Lauds Research Backing Generic AIDS Drug Safety & Efficacy: Calls on Bush Administration to Begin Purchasing Low-Cost Pills: PRNewswire - July 2, 2004; LOS ANGELES, July 2 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States and which operates HIV clinics in Uganda , South Africa and Honduras , issued the following statement to
The Immune Response Corporation Presents Preliminary Clinical Data, Further Demonstrating NeuroVax(TM) Immunological Activity, at European Neurological Society Meeting - Company Plans to Accelerate NeuroVax(TM) Clinical Program in Response to Encouraging Preliminary Results: PRNewswire - July 1, 2004; CARLSBAD, Calif., July 1 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced that data on the Company s MS treatment, NeuroVax(TM), was presented yesterday at the
Novavax, Inc. Provides Update on HIV Vaccine Programs: PRNewswire - July 1, 2004; COLUMBIA, Md., July 1 /PRNewswire-FirstCall/ -- NOVAVAX, INC. (Nasdaq: NVAX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has cancelled its five-year contract [NO1-AI-30042] for the development of human immunodeficiency v
News and Content Available Rights Free to Support Reporting on the XV International AIDS Conference: PRNewswire - July 1, 2004; News and Content Available Rights Free to Support Reporting on the XV International AIDS Conference: -- Receive Daily Conference Updates -- Put Conference Coverage on Your Web Site -- View key Sessions and interviews with Newsmakers such as Peter Piot, Executive Director UNAIDS , and Richard Gere MENLO PARK, Cal
Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC Project: PRNewswire - July 1, 2004; STRASBOURG, France , July 1 /PRNewswire-FirstCall/ -- Transgene today announced that it manufactured clinical lots of HIV vaccine candidates in the frame of EUROVAC (European Vaccine Effort against HIV/AIDS), a European cluster of 21 laboratories, funded since 2000 by the European Union under the 5th Framework Programm
Multivitamin Supplements Delay Progression of HIV Among Women, Provide effective low-cost means to slow need for antiretroviral drug therapy: PRNewswire - Wednesday, June 30, 2004; Boston, MA� A simple daily regimen of multivitamins can significantly delay the progress of the AIDS virus according to the results of a study of HIV infected women in Tanzania . Researchers from the Harvard School of Public Health and the Muhimbili University College of Health Services in Dar es Salaam, found that wom
State Budget Would Be Death Penalty for Small Pharmacies Says AHF: PRNewswire - June 30, 2004; Budget Move Would Wreak Havoc With California s Sickest Patients; Harm Mom & Pop Pharmacies Delivering Specialized Care to Patients: AIDS Healthcare Foundation Announces Intention to File Suit to Stop Illegal Funding Cuts to Pharmacy Providers Treating California Medicaid Patients Should Budget Pass AIDS Group Will
Trinity Biotech Receives CLIA Waiver for Uni-Gold Recombigen (TM) HIV Test: PRNewswire - June 30, 2004; DUBLIN, Ireland , June 30 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) today announced that the US Food and Drug Administration ( FDA ) has approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for the Uni-Gold Recombigen HIV test.
Epimmune Reports Vaccine Publication Data Supporting Use of PADRE(R) to Boost Immune Response: PRNewswire - June 29, 2004; -- Potential for Increased Efficacy, Less Costly Production, Wider Target Population SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today announced the publication of data in the June 23 issue of the journal Vaccine which demonstrates the use of PADRE(R), the Company s proprietary, synthetic,
Gay Men's Health Crisis and AIDS Project Los Angeles Join Forces to Establish National HIV Prevention Effort: Institute for Gay Men's Health is Created: PRNewswire - June 29, 2004; NEW YORK and LOS ANGELES, June 29 /PRNewswire/ -- Gay Men s Health Crisis (GMHC) and AIDS Project Los Angeles (APLA), two of the oldest HIV/AIDS service and advocacy organizations in the United States , today announced the formation of The Institute for Gay Men s Health, which will develop and promote a nationwide heal
The William J. Clinton Foundation Launches www.clintonpresidentialcenter.org, an Interactive and Educational Platform Providing Global Access to the Historical Records of President Clinton's Administration and Real-Time Information About His Ongoing Work: PRNewswire - June 28, 2004; -- The Website Features a Comprehensive, Searchable Database of Historical Documents and Multimedia Artifacts from the Clinton Administration, Educational Materials, News on his Current Activities, and Multimedia and Collaboration Capabilities NEW YORK, June 28 /PRNewswire/ -- The Clinton Presidential Center (CPC) Web
Narconon International Celebrates UN's Day Against Drug Abuse: PRNewswire - June 25, 2004; LOS ANGELES, June 25 /PRNewswire/ -- In celebration of the International Day against Drug Abuse and Illicit Trafficking, Narconon International President Clark Carr announced the successful completion of a campaign based on the 2003 theme, Let s Talk About Drugs. The International Day is a program of the UN Office of D
PA Health Secretary Urges HIV Testing During National HIV Testing Day; AIDS Factline Provides Free, Confidential and Anonymous Testing: PRNewswire - June 25, 2004; HARRISBURG, Pa., June 25 /PRNewswire/ -- Health Secretary Dr. Calvin B. Johnson today reminded Pennsylvanians that June 27 is National HIV Testing Day and urged those who are at risk for HIV to get tested at any of the state s free and confidential testing and counseling sites. It is imperative for those who are at ris
Immtech Reports Positive Efficacy Results of DB289's Phase II Trial for Pneumocystis carinii Pneumonia: PRNewswire - June 24, 2004; VERNON HILLS, Ill., June 24 /PRNewswire-FirstCall/ -- Immtech International, Inc. (Amex: IMM) announced today preliminary Phase II trial results of the oral drug DB289 for the treatment of Pneumocystis carinii Pneumonia ( PCP ). PCP is a respiratory fungal infection in immunosuppressed patients that can be fatal if not
NAPWA: President Bush, Citing National HIV Testing Day, Calls on All Americans At-Risk of HIV Infection to Get Tested: National HIV Testing Day is June 27: PRNewswire - June 24, 2004; WASHINGTON, June 24 /PRNewswire/ -- President George W. Bush, acknowledging the importance of HIV testing, made these remarks during a major policy address on AIDS yesterday in Philadelphia: Across America, June 27th is National HIV Testing Day. For the sake of their health and for the sake of the health of others, I u
Georgians P.A.U.S.E. to Get Tested for HIV: Promoting Awareness of HIV Using Safer Sex Education: PRNewswire - June 24, 2004; -- Statewide Campaign Launch Addresses Growing Number of African-American Men with HIV/AIDS; Coincides with National HIV Testing Day ATLANTA, June 24 /PRNewswire/ -- Today a new social marketing campaign, branded P.A.U.S.E., is being unveiled to address the growing HIV epidemic in Georgia. P.A.U.S.E. is an extensive st
Calypte's Rockville, Maryland Facility Receives Quality System Certification to ISO 13485:1996: Corporate Headquarters Moved to Pleasanton, California: PRNewswire - June 24, 2004; PLEASANTON, Calif., June 24 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Rockville, Maryland manufacturing facility has successfully passed its quality system audit to obtain certification of
ViroLogic Awarded $1.5 Million Grant to Fund Large-Scale Clinical Studies Evaluating Replication Capacity as a Predictive Tool for the Clinical Management of HIV: PRNewswire - June 24, 2004; SOUTH SAN FRANCISCO, Calif., June 24 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the company has been awarded a phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to assess HIV replication capacity (RC), a gauge of viral fitness, as a
UNICEF National Ambassador Laurence Fishburne Returns From His First Ever Visit to South Africa: Fishburne Visited Children Orphaned by AIDS in the Largest and Poorest Province in the Country: PRNewswire - June 24, 2004; NEW YORK, June 24 /PRNewswire/ -- Inspired by the strides made in educating and protecting orphans and children affected by HIV and AIDS in South Africa , UNICEF National Ambassador Laurence Fishburne said today that the world must continue to support programs benefiting children in Africa. The creation of an entire g
MedMira Announces FDA Approval for New Reveal(TM) G2 Rapid HIV-1 Antibody Test: New 3-Minute Rapid HIV Test Easier and More Efficient For Point Of Care Market in United States: PRNewswire - June 24, 2004; HALIFAX, NS, June 24 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the market leader in rapid flow-through diagnostic technology, announced today that it has received U.S. Food and Drug Administration ( FDA ) approval of its new Reveal(TM) G2 Rapid HIV-1 Antibody Test (Reveal(TM) G
AHF Criticizes Bush Over Global AIDS Program: PRNewswire - June 23, 2004; -- President s PEPFAR Program Fails in Lives Saved; Only 2,000 People Worldwide in ARV Treatment via $15B Relief Program: Despite $20M in New Money and Addition of Vietnam as First Asian PEPFAR Country, Much More Needs to Be Done LOS ANGELES, June 23 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS or
Remarks by President Bush on Compassion and HIV/AIDS: PRNewswire - June 23, 2004; WASHINGTON, June 23 /PRNewswire/ -- The following are remarks by President Bush on compassion and HIV/AIDS: People For People Philadelphia, Pennsylvania 10:42 A.M. EDT THE PRESIDENT: Thank you all. Thanks for coming. Please be seated. Thanks for coming. The person who introduces me in the White House better look out fo
VH1 Takes Home 'POP' Award For Outstanding AIDS/HIV Awareness Programming During Cable Positive's Third Annual Pop Awards: PRNewswire - June 23, 2004; -- VH1 News Presents: AIDS: A Pop Culture History Special Won in the Outstanding News Coverage Category NEW YORK, June 23 /PRNewswire/ -- VH1 took home its first-ever POP award last night during Cable Positive s third annual POP awards, winning in the category of Outstanding News Coverage for its AIDS/HIV cause-related
'Discovery Health Channel Medical Honors' Recognizes Top Innovators and Achievements in Medicine: PRNewswire - June 23, 2004; -- Red Carpet Gala Hosted by Regis Philbin to Premiere July 8 on Discovery Health Channel SILVER SPRING, Md., June 23 /PRNewswire/ -- Today, Discovery Health Channel, in association with the National Health Museum and in partnership with 11 of the country s preeminent health organizations, honors the nation s premier h
New Harrison's Principles of Internal Medicine Adds Free Online Resources to Help Improve Medical Treatment Worldwide: Full-Color Enhancements Included in Latest Edition: PRNewswire - June 23, 2004; NEW YORK, June 23 /PRNewswire-FirstCall/ -- McGraw-Hill Medical Publishing today released the new 16th edition of the world s best-selling medical reference guide, Harrison s Principles of Internal Medicine. The new 16th edition provides doctors, medical students and other healthcare professionals with the latest diagn
Background Briefing on the President's Pending HIV/AIDS Relief Announcements Via Conference Call By Senior Administration OfficialsBackground: PRNewswire - June 22, 2004; Briefing on the President s Pending HIV/AIDS Relief Announcements Via Conference Call By Senior Administration Officials WASHINGTON, June 22 /PRNewswire/ -- The following is a background briefing on the President s pending HIV/AIDS relief announcements: 5:05 P.M. EDT SENIOR ADMINISTRATION OFFICIAL: Thank you. Thanks e
The NAMES Project Foundation Presents 1,000 Blocks of The Aids Memorial Quilt in Washington, D.C.: PRNewswire - June 22, 2004; DISPLAY KICKS OFF A TWO-YEAR, 50-CITY NATIONAL TOUR ATLANTA, June 22 /PRNewswire/ -- WHAT: For the first time since 1996, The NAMES Project Foundation returns to our nation s capital with a large, 1,000 block display of The AIDS Memorial Quilt, featuring 8,000 panels to be presented for the first time in Washington, D.
Generex Biotechnology Presents Potential Uses of RapidMist(R) Technology in Transmucosal Vaccines at Merieux Conference in France: PRNewswire - June 22, 2004; -- Company Expands Aerosolized Delivery Applications Beyond Insulin TORONTO, June 22 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), announced today the presentation of a research abstract by Robert Humphreys, the Chief Scientific Officer of its Antigen Express immunomedicines subsidiary, at
Roche Submits Application to U.S. FDA for New Formulation of Invirase(R) - New 500 mg Tablet To Simplify Dosing Regimens -: PRNewswire - June 21, 2004; NUTLEY, N.J., June 21 /PRNewswire/ -- Roche today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for approval to market a new 500 mg tablet formulation of its HIV protease inhibitor Invirase (R) (saquinavir mesylate). The new formulation of Invirase is smaller
Remarks By The National Security Advisor at the Leon H. Sullivan Summit Awards Dinner: PRNewswire - June 18, 2004; WASHINGTON, June 18 /PRNewswire/ -- The following is a transcript of remarks made yesterday by the National Security Advisor at the Leon H. Sullivan Summit Awards Dinner: Marriott Wardman Park - Washington, D.C. June 17, 2004 DR. RICE: Thank you very much. I am deeply honored to be here with you this evening. And I am
WHO Statement on Removal of Two Aids Medicines From List of Prequalified Products: PRNewswire - June 18, 2004; GENEVA, June 18 /Xinhua-PRNewswire/ -- The World Health Organization (WHO) removed two antiretroviral products from the WHO List of prequalified products: Lamivudine 150mg tablet from Cipla Ltd, Kurkumbh, India .
Guilford Licenses U.S. Rights to GPI 1485 to Symphony Neuro Development Company: PRNewswire - June 18, 2004; BALTIMORE, June 18 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) announced today that it has licensed to Symphony Neuro Development Company, a newly formed Delaware corporation ( SNDC ), its rights to GPI 1485 for certain indications in the United States . SNDC will invest up to $40 million to
African Americans, Latinos Continue to Face High HIV Risk: All Risk Groups Urged to Get Tested at National HIV Testing Day Events: PRNewswire - June 17, 2004; WASHINGTON, June 17 /PRNewswire/ -- More than half of all Americans diagnosed with HIV each year are African American, and almost 13 percent are Latino. Members of these two at-risk groups, as well as others at increased risk -- including men who have sex with men, sexually active youth, and those who use injection dru
BET Network Leads in Cable Positive Pop Award Nominations; Premieres HIV/AIDS Special Featuring R&B Singer Brandy: BET Continues Original HIV/AIDS-Related Television Programming: PRNewswire - June 17, 2004; WASHINGTON, June 17 /PRNewswire/ -- BET, the nation s leading cable network dedicated to African Americans, continues its staunch commitment of providing extraordinary and unique HIV/AIDS related programming through its award-winning Rap-It-Up partnership with the Kaiser Family Foundation. On Tuesday, June 22, Cable Po
Panacos Pharmaceuticals to Present Phase 1 Data on Its Lead HIV-1 Drug Candidate, PA-457, at XV International AIDS Conference, Bangkok, Thailand: PRNewswire - June 17, 2004; -- Additional Presentations to be Made on PA-457 and Panacos HIV Fusion Inhibitor Discovery Program GAITHERSBURG, Md., June 17 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it will present the results of a recently completed Phase 1 clinical trial of the first-in-class HIV Maturation Inhibitor, PA-
Procyon Biopharma reports progress at annual meeting - Company on track to deliver on anticipated milestones - Further peer-recognition for Fibrostat(R) -: PRNewswire - June 17, 2004; MONTREAL, June 17 /PRNewswire-FirstCall/ - At its Annual and Special Shareholders meeting today, Procyon Biopharma Inc. (TSX: PBP) reviewed the highlights of Fiscal 2003 along with its strategy to build critical mass through the development of the Company s three near-term value drivers, namely, PCK3145, a treatment fo
'The People vs. Larry Flynt': Protest and Media Event Sponsored by AHF: AIDS Advocates Press for Condoms in Porn: PRNewswire - June 17, 2004; What: Protest, Rally & Press Conference: Condom use is not currently standard in the straight porn film industry and they are often not used. Larry Flynt s Hustler label is considered a condom optional production house but those in the business know what this really means: Condoms allowed but if you demand to use o
The Circle of Health to Host Three-Days of Latino Health, Fatherhood and Family Assessment With Conference and Fair: PRNewswire - June 17, 2004; -- Third Annual Fatherhood Conference Followed by Seventh Annual Male Health Fair Taps Into Father s Day Weekend LOS ANGELES, June 17 /PRNewswire/ -- Bienvenidos Children s Center, Inc., The National Latino Fatherhood & Family Institute and the National Compadres Network will host The Circle of Health (El Circulo D
Calypte Files Registration Statement: Registering Primarily Previously Issued Shares: PRNewswire - June 16, 2004; ALAMEDA, Calif., June 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a developer, manufacturer and marketer of HIV diagnostic tests, today announced that it has filed a registration statement (the Registration Statement ) with the Securities and Exchange Commission registering s
Women's Health Study Released by AllPoints Research: Sexual & cardio health for women over 40: PRNewswire - June 16, 2004; WINSTON-SALEM, N.C., June 16 /PRNewswire/ -- AllPoints Research today announced the results of a women s health study regarding behavior and perception about sexual and cardiovascular health by women aged 40 and older. Sexual health findings include: * Most married women over age 40 whose partners take an erectile d
AHF and Community Coalition to Premiere New STD Prevention PSA: 'Stop the Sores' Syphilis Prevention Campaign to Get World Premiere Treatment for First TV Spot: PRNewswire - June 16, 2004; -- AIDS Healthcare Foundation s Stop the Sores Is a Multi-Faceted Syphilis Prevention Campaign for Gay/Bisexual Men in Los Angeles WHAT: World Premiere Screening & Reception for the Stop the Sores Television Commercial WHEN: Thursday, June 17th 6:00pm - 8:00pm WHERE: here lounge - 696 N. Robertson, West Hollywood
New Women's Condom to be Released to All European Markets: PRNewswire - June 15, 2004; PETOSKEY, Mich., June 15 /PRNewswire/ -- Intellx Inc. announces the expansion of its distribution for the VA women s condom throughout Europe this summer, after a year of limited trial distribution in Germany and Spain . The world s only latex women s condom is to be distributed all over Europe the second half of 2004,
The Immune Response Corporation to Initiate First Clinical Study With IR103 in HIV Patients in a Multi-Center, International Clinical Trial: PRNewswire - June 15, 2004; -- Safety and Ability to Generate HIV-Specific Immune Reponses to be Investigated CARLSBAD, Calif., June 15 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced tod
Children Orphaned by AIDS Helped by Bill in Congress; Children's Advocates Praise Unanimous Passage by the House of Representatives: PRNewswire - June 15, 2004; WASHINGTON, June 15 /PRNewswire/ -- The US Congress has at last begun to address a humanitarian crisis that has moved the hearts of many Americans and raised alarm among security experts: the suffering of millions of children orphaned by the deadly AIDS epidemic. Last night, in a stunning display of bipartisanship, the
Popular AIDS Fundraising Thrift Store to Open New Location in Southern California: 'Buffy the Vampire Slayer' Props to Benefit AIDS Patients at Grand Opening of Los Angeles Area 'Out of the Closet' Superstore: PRNewswire - June 12, 2004; -- Donated Props & Set Pieces from Cult TV Show to Be Sold at Grand Opening Sat. June 12th -- Proceeds Benefit AIDS Healthcare Foundation (AHF), the Nation s LargestSpecialized Provider of HIV/AIDS Medical Care with Clinics in the U.S., Africa and the Caribbean What: Ribbon Cutting/Grand Opening Sale at Out of the
The Philadelphia AIDS Consortium Receives $1 Million Grant From AmeriCorps: PRNewswire - June 11, 2004; PHILADELPHIA, June 11 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC) announced last night during a community meeting of HIV/AIDS consumers that it was awarded a National Direct three (3) year, one (1) million dollar grant by The Corporation for National and Community Service. This highly competitive grant will
AHF Welcomes Federal 'False Advertising' Rebuke Against Drugmaker Abbott Over AIDS Drug Price Hike: PRNewswire - June 11, 2004; -- FDA Calls Drugmakers Ads Misleading, Issues Warning Letter : Same Claims Are Subject of AIDS Healthcare Foundation s Lawsuit LOS ANGELES, June 11 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) -- which recently sued drug maker Abbott Laboratories for publishing false statements deceiving the public about a 400
AIDS Healthcare Foundation Asks California DHS to Restrict Use of GSK's Trizivir by Patients Naive to ARV Therapy: PRNewswire - June 8, 2004; -- Advocates Want Trizivir Placed on Treatment Authorization Request Procedures (TAR); AHF Officials Voice Clinical Concerns, Note Fiscal Impact of Sub-par Treatments to ADAP, Medi-Cal LOS ANGELES, June 8 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the
Medical Services Completes Detailed Testing in China: PRNewswire - June 8, 2004; EDMONTON, Alberta, June 8 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has received the results of very detailed testing of the VScan HIV test kits in the People s Republic of China . The testing just completed by regulatory authorities was to verify t
Investigational Protease Inhibitor 640385 (VX-385) from GSK and Vertex Indicates Activity Against HIV, Including Protease Inhibitor-Resistant Strains: PRNewswire - June 8, 2004; LONDON, June 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data for an investigational Protease Inhibitor (PI) 640385 (VX-385) which appears to be active against HIV, including strains that have become resistant to multiple protease inhibitor drugs, a
Clinical Study Presented on THALOMID(R) Plus Temozolomide Oral Regimen as Adjuvant Therapy for Treating Patients With High Risk Advanced-Stage Metastatic Melanoma: PRNewswire - June 8, 2004; NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) today announced results of an ongoing clinical study using thalidomide in combination with temozolomide as an oral regimen for the adjuvant treatment of high-risk metastatic melanoma patients reported at the American Society of Clinical On
MedMira Receives 2nd Order For 3-Minute HIV Tests From Leading China Distributor: China Market Acceptance Prompts Increase of Annual Commitment: PRNewswire - June 7, 2004; HALIFAX, June 7 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) announced today the receipt of a second order for 100,000 MiraWell(TM) Rapid HIV Tests from its leading distributor in China to be shipped by mid June. This distributor has already sold the initial shipment of 100,000 tes
The Immune Response Corporation Presents New Data on REMUNE(R) and IR103 Suggesting HIV-1 Specific Immune Responses: PRNewswire - June 7, 2004; -- Preliminary Results From Ongoing Clinical Trial in Italy Suggest REMUNE(R) Has Activity in Drug-Naive Patients - -- Pre-Clinical Data Point to Potential of IR103 Combination to Boost This Effect CARLSBAD, Calif., June 7 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical com
Panacos Pharmaceuticals Presents Data on HIV Maturation Inhibitor PA-457 at 13th International Symposium on HIV & Emerging Infectious Diseases: PRNewswire - June 4, 2004; GAITHERSBURG, Md., June 4 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today presents its latest findings on the mechanism of action of PA-457, the Company s lead HIV drug candidate, which is the first in a new class of oral antiretroviral drugs called Maturation Inhibitors. In an invited presentation at the 13th Inte
Pfizer Sends Volunteers to Fight Diseases in Developing Countries as it Launches Second Wave of Global Health Fellows Program: PRNewswire - May 27, 2004; -- Company s Direct Approach to Serving Communities in Need Gains Momentum NEW YORK, May 27 /PRNewswire/ -- Pfizer Inc today announced the second class of Global Health Fellows, a group of fifteen physicians, scientists and other skilled Pfizer colleagues from around the world who are being loaned to non-governmental o
Bayer Diagnostics Europe and the Rome-Based Community of Sant' Egidio Sign Agreement for HIV-Infected Patients in Africa: PRNewswire - May 27, 2004; -- Collaboration Advances Sant Egidio s DREAM Project in Mozambique TARRYTOWN, N.Y., May 27 /PRNewswire-FirstCall/ -- The Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY) announced today that it has entered into a two-year agreement with the Rome-based Community of Sant Egidio to pr
Targeted Genetics to Present at the 7th Annual Meeting of the American Society of Gene Therapy: PRNewswire - May 26, 2004; -- Presentations Demonstrate Broad Potential of Company s AAV Technology SEATTLE, May 26 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation s (Nasdaq: TGEN) technology assets will be highlighted in 12 presentations during the 7th Annual Meeting of the American Society of Gene Therapy. The meeting will take place J
'DINE OUT DETROIT' Unites Area Restaurants in the Fight Against AIDS, on Friday, June 4': PRNewswire - May 26, 2004; FERNDALE, Mich., May 26 /PRNewswire/ -- DINE OUT DETROIT will give area residents the opportunity to fight AIDS by doing something they frequently do: GO OUT TO EAT! Nearly 120 metro Detroit area restaurants from over 30 local cities will participate in the ninth annual DINE OUT DETROIT benefit on Friday, June 4th. Lo
Music Publishing Community Raises More Than $150,000 for City of Hope at 'Songs of Hope III,' Hosted by Lionel Richie: PRNewswire - May 26, 2004; LOS ANGELES, May 26 /PRNewswire/ -- The Songs of Hope III charity event, hosted at the private home of Lionel Richie, five-time GRAMMY Award(R)-winner and one of music s most successful artists/producers/songwriters, was a must-attend party on May 19. The event brought together more than 330 music industry professional
Reminder - AHF Gen'l Counsel Available to Comment on NIH Hearings Tuesday on Abbott Labs' Norvir Pricing: PRNewswire - May 25, 2004; Abbott s 400% Price Hike on Key AIDS Drug in December Prompted AIDS Healthcare Foundation to File Anti-trust and False Advertising Lawsuits Over Pricing Issue WHAT: Media Availability with AHF General Counsel Tom Myers on NIH Hearings on Abbott Labs Norvir Price Hike WHEN: TUESDAY, MAY 25th NIH Hearing
Abbott Laboratories Comments at NIH Public Meeting Regarding Norvir and Bayh-Dole March-in Provisions: PRNewswire - May 25, 2004; BETHESDA, Md., May 25 /PRNewswire-FirstCall/ -- Following are remarks Jeffrey M. Leiden, M.D., Ph.D., president and chief operating officer, Pharmaceutical Products Group, Abbott Laboratories (NYSE: ABT), delivered today at the National Institutes of Health public meeting regarding the Bayh-Dole march-in provisions for
Calypte Developing HIV-1/2 Oral Fluid Rapid Tests: Launch Expected During Second Half Of 2004: PRNewswire - May 25, 2004; ALAMEDA, Calif., May 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a developer, manufacturer and marketer of HIV diagnostic tests, today announced that it has developed a rapid test for HIV-1/2 that can be performed on an oral fluid sample. HIV results are available from the ne
Zengen, Inc. Reports Positive Phase I/II Trial Results of its Proprietary Peptide Molecule for Vaginal Yeast Infection: PRNewswire - May 25, 2004; - High Efficacy Ratings Further Validate Research on Molecule s Anti-Infective and Anti-Inflammatory Properties - WOODLAND HILLS, Calif., May 25 /PRNewswire/ -- Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly kno
Medical Services Receives Additional Test Results in China: PRNewswire - May 21, 2004; EDMONTON, Alberta, May 21 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has received additional test results from the People s Republic of China related to its VScan HIV test kit. The results of an additional 1200 tests show that the test kit had a sens
Abbott Labs: 'Getting Fat on AIDS!' Says AHF: Protest at Drug Giant's Santa Clara Site to Protest 400% AIDS Drug Price Hike: PRNewswire - May 21, 2004; -- AIDS Healthcare Foundation & HIV/AIDS Patients & Advocates Join in Northern California Protest WHAT: Press Conference & AIDS Drug Price Protest WHEN: Monday, May 24th 8:30 AM PST WHERE: In front of Abbott Laboratories 5440 Patrick Henry Drive, Santa Clara, CA 95054 (cross street: Old Mountain View Alviso
AHF Applauds McCain, Senate Panel for Bipartisan Call on FTC to Investigate Abbott Labs for Anti-trust Over Norvir Price Hike: PRNewswire - May 20, 2004; -- Drug Giant s Actions Prompts Senate Panel to Call for Anti-trust Investigation: 400% Price Hike on Norvir Led to Huge Public Outcry by Doctors and AIDS Activists LOS ANGELES, May 20 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States w
National HIV Testing Day to Focus on Knowing HIV Status: PRNewswire - May 20, 2004; -- Community Groups Arrange for Thousands to Be Counseled and Tested WASHINGTON, May 20 /PRNewswire/ -- Thousands of communities across the country come together each June 27 to hold special awareness and testing events in support of National HIV Testing Day (NHTD). The theme of this year s campaign, It s Better to Kno
Biosyn, Inc. Initiates Phase 3 Pivotal Clinical Trial with 1% C31G Vaginal Gel for Prevention of HIV Transmission: PRNewswire - May 20, 2004; HUNTINGDON VALLEY, Pa., May 20 /PRNewswire/ -- Biosyn, Inc. today announced that it has commenced enrollment in a Phase 3 pivotal clinical trial of its lead drug candidate, 1% C31G vaginal gel, for the reduction of sexual transmission of human immunodeficiency virus (HIV). The study is being carried out with funding fr
State AIDS Drug Assistance Programs (ADAPs) Continue to Face Difficult Funding Challenges: 11 States Close Enrollment - 9 Have Waiting Lists to Receive HIV Drugs: PRNewswire - May 19, 2004; -- Wide Variation in Access to HIV Medications Across States -- To participate in the conference call release on Wednesday, May 19 at 12:30 p.m. EDT, Call 1-800-593-9038, the Password is ADAP WASHINGTON, May 19 /PRNewswire/ -- Despite a nine percent increase in the overall ADAP budget between FY 2002 and 2003, an incre
New Policy on AIDS Drugs a Slap to WHO and European Allies: PRNewswire - May 18, 2004; WASHINGTON, May 18 /PRNewswire/ -- Sixteen months after proposing an Emergency Plan to fight AIDS, the Bush Administration has finally declared its willingness to allow grant recipients to purchase AIDS drugs that combine various medications into one pill. Yet, the generic companies that make the combination must submi
Panacos Pharmaceuticals Closes $18.3M Series C Financing: PRNewswire - May 18, 2004; GAITHERSBURG, Md., May 18 /PRNewswire/ -- Panacos Pharmaceuticals Inc. today announced that it has closed a $18,300,000 Series C financing led by prior investors Ampersand Ventures and A. M. Pappas & Associates. New investors in this round include Mitsui & Co. Venture Partners, Inc., Novo A/S, New England Partn
Statement of the World Health Organization on United States Proposal for Rapid Review of Fixed Dose Combinations: PRNewswire - May 18, 2004; GENEVA, May 18 /Xinhua-PRNewswire/ -- The World Health Organization (WHO) welcomes the United States Government s announcement of its expedited process to review fixed-dose combination medicines and co-packaging of existing therapies for the treatment of HIV/AIDS in developing countries under programmes to be financed
PowderMed Launched in Spin Out of Powder Injection DNA Vaccine Programmes From Chiron Vaccines: PRNewswire - May 17, 2004; -- PowderMed closes 20 million pounds sterling ($34.5 million; euro 30 million) financing and enhances deal with Glaxo SmithKline OXFORD, England, May 17 /PRNewswire/ -- PowderMed Ltd (PowderMed), a new company focussing on the development of therapeutic DNA vaccines, was officially launched today. The Company has been
AIDS, Official Journal of the International AIDS Society, Publishes First Fuzeon(R) International Consensus Guidelines: PRNewswire - May 17, 2004; NUTLEY, N.J., and DURHAM, N.C., May 17 /PRNewswire-FirstCall/ -- International consensus guidelines for Fuzeon(R) ( enfuvirtide ), the first and only fusion inhibitor available for the treatment of HIV, were published today in AIDS(1), the official journal of the International AIDS Society. The international guideline
On World AIDS Vaccine Day, Progress and Challenges: PRNewswire - May 17, 2004; NEW YORK, May 17 /PRNewswire/ -- 18 May is World AIDS Vaccine Day, a global observance of the urgent need for a vaccine that prevents HIV infection and AIDS. Many scientists and world leaders agree that to end the epidemic, the world must develop a vaccine. Each day, 14,000 people become infected with HIV, and most go
MedMira Signs Canadian Distributor to Market Rapid HIV Test Kits: PRNewswire - May 17, 2004; HALIFAX/TORONTO, May 17 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) and Source Medical Corporation of Toronto, Ontario ( Source Medical ) today announced that they have reached an agreement for Source Medical to be the exclusive distributor of the MedMira Reveal(TM) Rapid HIV test within
AHF, AIDS Advocates Say: Save AIDS Services!: PRNewswire - May 17, 2004; -- AIDS Groups, Patients & Supporters to Protest in Front of Board of Supervisors Challenging County on AIDS Funding Cuts; AIDS Advocates Say Cut the Red Tape Not the Care What: Protest, Rally & Press Conference: AIDS Advocates and Patients from AIDS Healthcare Foundation, Bienestar Health Services, Southern Ca
AIDS Responsibility Project Applauds Bush Administration Move to Fast Track New Treatments: PRNewswire - May 17, 2004; WASHINGTON, May 17 /PRNewswire/ -- The AIDS Responsibility Project (ARP) today praised the Department of Health and Human Services announcement creating an expedited review process expanding access to HIV/AIDS medications. The announcement Sunday by HHS Secretary Tommy Thompson allows for the Food and Drug Administrati
May 20: Biggest DC AIDS Protest in a Decade: PRNewswire - May 17, 2004; Activists, Front-Line Providers Demand Candidates, Congress, Administration Wake Up and Act to End AIDS: Election Year Issue Focus Hundreds to March at Republican and Democratic HQs; 100+ in Non-Violent Civil Disobedience Planned at Capitol WASHINGTON, May 17 /PRNewswire/ -- Major AIDS service and advocacy groups from
GlaxoSmithKline and Boehringer Ingelheim Agree to Assess the Development of Important HIV Medicines for the Developing World: PRNewswire - May 16, 2004; INGELHEIM, Germany , LONDON and PHILADELPHIA, May 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (GSK) and Boehringer Ingelheim announced today that both companies welcome the United States continued involvement in the global response to HIV/AIDS. GSK and Boehringer Ingelheim have entered into
American AIDS Advocates From AIDS Healthcare Foundation Lead Drive to Curb GSK CEO Garnier's Pay: PRNewswire - May 14, 2004; -- GSK Shareholders to Weigh in on Drug Giant s Poor Performance, Proposed 18.3m pounds Sterling Executive Compensation Package for CEO at Monday s AGM. US Largest AIDS Group to Call on GSK for Accountability, Responsibility & Transparency in Corporate Governance at Press Conference Monday What: Press Conference: U
World Experts Unite in Urgent Effort to Fight Deadly Disease - Up to One Million Child Deaths are Preventable - New Evidence Shows HIV-Infected Children & Infants are Particularly Vulnerable: PRNewswire - May 10, 2004; HELSINKI, Finland , May 10 /PRNewswire/ -- Leaders in the fight against disease today emphasized the importance of preventing unnecessary child deaths from Streptococcus pneumoniae -- a disease currently responsible for killing between 800,000 and one million children every year, mostly in developing countries.
Hoyer Meets With Health, AIDS Groups to Discuss Global AIDS, Other Health Issues: PRNewswire - May 6, 2004; WASHINGTON, May 6 /PRNewswire/ -- House Democratic Whip Steny Hoyer (MD) met with Congresswoman Carolyn Kilpatrick and numerous global health and HIV/AIDS groups today to discuss the need for increased funding and effective implementation of HIV/AIDS treatment and prevention programs. Hoyer released the following state
Bloomberg Joins More Than 30 U.S. Mayors to Declare May 7th AIDS Orphans Day to Support 100 Million AIDS Orphans Expected in 2010: PRNewswire - May 6, 2004; -- Countries and Cities Across the Globe Join in the Effort, Including: Colombia , Brazil , Uruguay , Monaco , Venice, Florence, Cannes, Paris, Brazil,
Tanox Initiates Phase 2 Clinical Trial of TNX-355 for HIV Infection: PRNewswire - May 5, 2004; HOUSTON, May 5 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV). The Phase 2 study is a three-arm, double-blind, placebo-controlled study, which will enroll approxim
New AHF Subsidiary to Serve as Watchdog on Corporate Governance in Healthcare Industry: 'ART' Will Promote 'Accountability, Responsibility & Transparency': PRNewswire - May 5, 2004; -- After Years of Successful Advocacy Targeting Practices of Pharmaceutical Companies like GSK, Abbott, Serono and Roche, AHF Hopes to Bring Accountable, Responsible and Transparent Corporate Governance to All Corporations That Have an Impact on Global Health LOS ANGELES, May 5 /PRNewswire/ -- AIDS Healthcare Foundatio
SANOCHEMIA USA: Operating Activities Commence and HIV-2: PRNewswire - May 4, 2004; VIENNA, Austria , May 4 /PRNewswire/ -- - Sanochemia USA: operating activities commence US approval for HIV 2 confirmation test expected soon Sanochemia Pharmazeutika AG, listed in the Prime Segment of the Frankfurt Stock Exchange, announces the April operational start of its US subsidiary Sanochemia Corporation which
New Hope for Families Dealing With Alzheimer's, AIDS and Age-Related Macular Degeneration: PRNewswire - May 4, 2004; -- Key Health Issues Presented at This Year s National Biotechnology Conference of the American Association of Pharmaceutical Scientists (AAPS) Will be Held May 16-18 in Boston ARLINGTON, Va., May 4 /PRNewswire/ -- Pharmaceutical science leaders from the FDA , research institutions and top pharmaceutical companies will
Medical Services to Form Joint Venture in China: PRNewswire - May 3, 2004; EDMONTON, Alberta, May 3 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has entered into discussions with a Chinese Pharmaceutical Company with an excellent distribution system throughout the People s Republic of China . The purpose of the joint venture
ViroLogic Announces Nationwide Distribution Agreement With Quest Diagnostics for Portfolio of HIV Phenotypic Tests: ViroLogic Becomes Preferred Provider of HIV Phenotypic Testing: PRNewswire - May 3, 2004; SOUTH SAN FRANCISCO, Calif., May 3 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Company has signed an expanded referral testing agreement with Quest Diagnostics (NYSE: DGX), the nation s leading provider of diagnostic testing, information and services. Under the terms of the agreeme
SHOWTIME Supports Gay Pride Month With Special Programming Highlighting Gay Themes and Issues in June: PRNewswire - May 3, 2004; -- Featuring the Premieres of The Opposite Sex: Jamie s Story and Jack NEW YORK, May 3 /PRNewswire/ -- In recognition of Gay Pride Month in June, SHOWTIME is proud to offer its viewers a number of programs featuring gay themes and issues including the premiere of the original documentary The Opposite Sex: Jamie s Story
GSK Loses Another Key Round in AIDS Healthcare Foundation's AZT Patent Piracy Case: Judge Rules in Favor of AIDS Healthcare Foundation on Summary Judgment Motion by GSK in Federal Lawsuit Against British Drug Giant: PRNewswire - May 3, 2004; LOS ANGELES, May 3 /PRNewswire/ -- Late last week, the United States District Court (United States Federal Court for Central District of California Western Division, Case No. CV-03-02792 TJH ex) rejected GlaxoSmithKline s (GSK) motion for summary judgment against AIDS Healthcare Foundation s (AHF) patent piracy lawsuit
National HIV Testing Day to Take Place June 27: 'It's Better to Know' Is Theme for 2004: PRNewswire - May 3, 2004; WASHINGTON, May 3 /PRNewswire/ -- WHAT: National HIV Testing Day, sponsored by the National Association of People with AIDS (NAPWA-US) with support from the federal Centers for Disease Control and Prevention (CDC), is Sunday, June 27. Local health departments and HIV prevention organizations across the country w
L.A. County Health Dept. Bows to Pressure From Bathhouse Owners; Delays Action on Supervisors' Bathhouse Motion, Says AHF: PRNewswire - May 2, 2004; -- After 3 Months, Health Dept. Fails to Bring Ordinance Back to Board of Supervisors; In February, Supervisors Voted in Favor of Motion to Regulate Bathhouses and Sex Clubs; Measure Aims to Improve Testing and Prevention Services at Venues What: Press Conference: On L.A. County Health Dept. s Delay on Bathhouse Ordina
The Immune Response Corporation Obtains $12 Million in Private Placement Financing: PRNewswire - April 30, 2004; CARLSBiAD, Calif., April 30 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company developing immune-based therapies for HIV and select other diseases, announced today that it has entered into agreements to sell through a private placement approximately 6,857,000 shares of
GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004: $250,000 in Research Grants to Be Awarded to Selected Researchers Working Toward Breakthroughs in HIV/AIDS Drug Therapies: PRNewswire - April 30, 2004; RESEARCH TRIANGLE PARK, N.C., April 30 /PRNewswire/ -- GlaxoSmithKline (GSK) is pleased to announce a call for applications for its 2004 Drug Discovery and Development Research Grant Program. GSK will award $250,000 in grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives a
Pfizer Partnership Initiative Helping to Stem HIV/AIDS in Uganda: Update Provided at UN InfoPoverty Conference: PRNewswire - April 30, 2004; UNITED NATIONS, April 30 /PRNewswire/ -- A unique partnership combining medicines, philanthropic support, medical expertise, and other resources with on-the-ground community support is showing signs of progress in battling the HIV/AIDS pandemic in hard-hit Uganda , according to a presentation at the InfoPoverty World C
HIV Drug Market to Grow to More Than $8 Billion by 2013: PRNewswire - April 28, 2004; -- However, Social and Political Issues Constrain the HIV Drug Market, According to a New Study from Decision Resources WALTHAM, Mass., April 28 /PRNewswire/ -- Decision Resources, Inc., one of the world s leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the HIV drug
Concerned Black Men to Address Violence, Drugs and HIV/AIDS at Youth Summit: PRNewswire - April 28, 2004; WASHINGTON, April 28 /PRNewswire/ -- The National Organization of Concerned Black Men, Inc. (CBM) is fighting the epidemic of violence, drugs and HIV/AIDS that is effecting the African-American community in Washington, DC and the nation. Their approach is simple ... talk to the target audience. So on Wednesday, May 5,
Study Reports Triple Nucleoside HIV Regimen Virologically Inferior To Sustiva(R) (Efavirenz) Combined With Two Or Three Nucleosides For Initial Treatment Of HIV-1 Infection: PRNewswire - April 28, 2004; PRINCETON, N.J., April 28 /PRNewswire-FirstCall/ -- For the initial treatment of HIV-1 infection, a regimen consisting of the co-formulated triple nucleoside reverse transcriptase inhibitor (NRTI) TRIZIVIR(R) ( abacavir sulfate, lamivudine and zidovudine; GlaxoSmithKline ) is virologically
AHF to Now Offer Rapid HIV Testing on Mobile Testing Unit In Los Angeles County: Bureaucracy Blamed for One-and-One-Half Year Wait for 20 Minute Test: PRNewswire - April 28, 2004; LOS ANGELES, April 28 /PRNewswire/ -- After a lengthy bureaucratic delay involving differing county, state and CDC regulations and requirements, AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , today will begin offering free, rapid HIV testing services on its mobile testing unit in
Use of TRIZIVIR in the Management of HIV: PRNewswire - April 28, 2004; RESEARCH TRIANGLE PARK, N.C., April 28 /PRNewswire/ -- Preliminary results of ACTG 5095 are published in the April 29 issue of the New England Journal of Medicine, following presentation of these data at the International AIDS Society meeting in July 2003. GlaxoSmithKline provides the following information as backgroun
MedMira Signs Second Experienced China Distributor: 100,000 HIV Tests to be Shipped in Next Week: PRNewswire - April 27, 2004; HALIFAX, N.S., April 27 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) today announced the signing of a second experienced distributor in the People s Republic of China with an initial order of 100,000 MiraWell(TM) Rapid HIV Tests to be shipped within the next week. This additional contract, with
AIDS Healthcare Foundation (AHF) to Rollout Program to Help Florida HIV Positive Minorities Access Care, Services: PRNewswire - April 27, 2004; -- AHF One of Seven Providers Statewide to Join Florida Department of Health in Innovative Minority AIDS Initiative; AHF to Unveil Program in Palm Beach and Broward Counties May 1st WHAT: Press Conference & Teleconference AHF to unveil New HIV Care Linkage Program in Two Hard Hit Florida Communities [Broward
Beyonce to Donate Percentage of Her Proceeds from Verizon Ladies First Tour to Nelson Mandela's 46664 Global Aids Initiative: PRNewswire - April 26, 2004; NEW YORK, April 26 /PRNewswire/ -- International pop superstar Beyonce will donate a percentage of her proceeds from the Verizon Ladies First Tour to Nelson Mandela s 46664 global AIDS initiative. The multi-platinum recording artist has earmarked fifty cents from each ticket sold to the Ladies First Tour to benefit 466
Perry Farrell, Michelle Branch, Damien Rice and Macy Gray Join Music Stars of India at 'One Night for India' Charity Concert, June 8th at UCLA's Pauley Pavilion in Los Angeles: PRNewswire - April 26, 2004; -- Tickets on Sale Friday, April 30 -- Proceeds to Benefit The Global Fund and the American India Foundation LOS ANGELES, April 26 /PRNewswire/ -- Top music acts Perry Farrell, Michelle Branch, Damien Rice, Macy Gray will join top Indian music acts for ONE NIGHT FOR INDIA, a charity concert event to benefit the fight a
Hospital Workers File OSHA Complaint Against Yale-New Haven Hospital, Citing Needlestick Risk: PRNewswire - April 26, 2004; -- Service Employees International Union Charges Switch to Less-Safe Syringe Was Based on Restrictive Contract With Purchasing Group Novation NEW HAVEN, Conn., April 26 /PRNewswire/ -- Citing serious concerns about needle safety at Connecticut s largest hospital, a union representing hospital service workers has filed
AHF Applauds Agreement by Donor Nations for Efficient AIDS Funds Use: PRNewswire - April 25, 2004; LOS ANGELES, April 25 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS organization, with clinics in the US, Africa and Central America hailed today s announcement that donor nations have reached agreement on coordinating their AIDS relief funds for developing world nations. The agreement includes
BET's Rap-It-Up Hosts Teen Health Forum in St. Louis April 30: PRNewswire - April 22, 2004; WASHINGTON, April 22 /PRNewswire/ -- BET s Rap-It-Up, the cable network s national HIV/AIDS public awareness initiative, brings its award-winning campaign to St. Louis Vashon High School on Friday, April 30. Rap-It-Up will host a teen health forum at the high school located on 3035 Cass Avenue at 10:00 a.m. followed by
Hosts, Guests and Public to Enjoy Desserts and Art at AIDS Foundation Fundraiser: PRNewswire - April 22, 2004; COLUMBIA, S.C., April 22 /PRNewswire/ The AIDS BENEFIT FOUNDATION OF SOUTH CAROLINA (ABF) announces Dining With Friends to be held Saturday, April 24, 2004. Dining with Friends is a creative fundraising concept where hosts volunteer to entertain friends in their own homes on April 24, 2004. Hosts make out their guest l
AHF, AIDS Advocates to Protest Norvir Price Hike at Abbott's AGM: Activists Say Drug Giant, 'Getting Fat on AIDS!': PRNewswire - April 22, 2004; -- Will Protest AIDS Drug s 400% Price Hike Before Annual Meeting CHICAGO, April 22 /PRNewswire/ -- The following is being issued by the AIDS Healthcare Foundation: WHAT: Protest over Abbott s 400% Price Hike on Norvir WHEN: FRIDAY, April 23rd 8:00 a.m. - 11:00 a.m. Protest at AGM (media availabilities th
Relentless Government Attacks on Women's Reproductive Rights and Health Drive Hundreds of Thousands to March on Washington: PRNewswire - April 21, 2004; -- Delegations from Around the World to Demand End to Policies that Endanger Women s Lives Ashley Judd, Madeline Albright, Delores Huerta and Dorothy Height Among Speakers for Historic March WASHINGTON, April 21 /PRNewswire/ -- In the face of increasing government attacks and looming threats to women s reproductive hea
Statement by Abner Mason, Founder of AIDS Responsibility Project, on the Unanimous Passage by the Presidential Advisory Council on HIV/AIDS of a Resolution Ensuring Only Drugs Proven to be Safe and Effective Are Bought for Africans: PRNewswire - April 21, 2004; LOS ANGELES, April 21 /PRNewswire/ -- Abner Mason, founder and executive director of AIDS Responsibility Project (ARP), today praised a Presidential advisory committee for passing a resolution (see below) in favor of buying only the highest-quality HIV/AIDS drugs for poor Africans. Recently, the 34 members of the Presi
The Immune Response Corporation Announces Four Abstracts Accepted at Two Prestigious International Scientific Conferences - New Data on HIV Product Candidate, IR103 to Be Presented -: PRNewswire - April 21, 2004; CARLSBAD, Calif., April 21 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company developing immune-based therapies for HIV and select other diseases, announced today that four abstracts related to its product candidates have been accepted for poster presentations at two p
Female Condom Company's HIV Work Recognized: Female Health Company Community Programs Commended in Global Business Awards: PRNewswire - April 21, 2004; CHICAGO, April 21 /PRNewswire-FirstCall/ -- The HIV prevention work of Female Condom developer and manufacturer, the Female Health Company (OTC Bulletin Board: FHCO), has today been recognized in this year s prestigious Business Excellence Awards, organized by the Global Business Coalition (GBC) on HIV/AIDS. The Chicag
U.S. and Foreign Generic Producers Commit to Fight HIV/AIDS: PRNewswire - April 20, 2004; DURHAM, N.C., April 20 /PRNewswire-FirstCall/ -- U.S. pharmaceutical companies have teamed with Indian and South African generic drug makers to attack the HIV epidemic in Africa and the Caribbean. The coalition s goal is to bring combination therapies to African and Caribbean nations at one-fifth of the lowest cost ava
Lipid Sciences' Novel Therapeutic Vaccine Approach for HIV Infection: Data Presented At Keystone Symposium: PRNewswire - April 19, 2004; PLEASANTON, Calif., April 19 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) announced today that preclinical data for its Viral Immunotherapy platform was presented at the Keystone Symposium, HIV Vaccine Development: Progress and Prospects. The data illustrated that Simian Immunodeficiency Virus (SIV, a
'Survivor'-Style Contest Comes to Region, Consumers Compete for $7500 Grand Prize: PRNewswire - April 19, 2004; -- Hifi House, Philadelphia Magazine, and Sony are Giving Away Sony s Best Flat- Panel HDTV to Celebrate Philadelphia Magazine s Design Home 2004 Exhibition; All Proceeds Benefit the Nonprofit MANNA Organization and Victims of HIV/AIDS BROOMALL, Pa., April 19 /PRNewswire/ -- It s part American Idol, part Survivor, par
Abbott Labs: 'Getting Fat on AIDS!' Says AHF: 34-Hour Vigil at Drug Giant's South Pasadena Site to Protest 400% AIDS Drug Price Hike: PRNewswire - April 19, 2004; AHF, Southern California HIV Advocacy Coalition (SCHAC), Bienestar, Whittier Rio Hondo AIDS Project (WRHAP) & HIV/AIDS Patients & Advocates Join In Southland Protest & Vigil WHAT: 34-Hour Protest Vigil at ABBOTT LABS OVER the 400% PRICE INCREASE on NORVIR WHEN: Protest Vigil (media availabilities throughout
ZIAGEN Receives Traditional Approval Status From FDA: PRNewswire - April 16, 2004; At-A-Glance -- The nucleoside analog ZIAGEN has received traditional approval status from the U.S. FDA to treat HIV infection in combination with other antiretrovirals. -- Since receiving accelerated approval in December 1998, more than 500,000 patient years of treatment support the use of ZIAGEN in combination the
Theratechnologies Reports Phase II Results for ThGRF in HIV associated Lipodystrophy: Compound reduces visceral fat with good safety profile: PRNewswire - April 15, 2004; MONTREAL, April 15 /PRNewswire-FirstCall/ - Theratechnologies (TSX:TH) today announced exciting results for its Phase II clinical trial, testing ThGRF in patients with HIV-associated lipodystrophy, a medical condition characterized by body composition changes and metabolic abnormalities. Highlights include a good safet
Cutting Edge HIV/AIDS Monitoring Research Funded by Bristol-Myers Squibb Leads to Significant Cost Savings for African Nations: Public-Private Partnership Reduces Costs to Monitor Disease Progression: PRNewswire - April 15, 2004; NEW YORK, April 15 /PRNewswire-FirstCall/ -- The cost of HIV/AIDS monitoring has long been a barrier to successful treatment in Africa. Now, research funded by SECURE THE FUTURE(R), an HIV/AIDS philanthropic initiative funded by the Bristol-Myers Squibb Company (NYSE: BMY) and the Bristol-Myers Squibb Foundation, has s
ADVENTRX Pharmaceuticals Receives FDA Clearance for HIV Viral Entry Inhibitor to Begin Phase Ib/IIa Human Clinical Trial: PRNewswire - April 15, 2004; SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (OTC Bulletin Board: AVRX) announced today that the Investigational New Drug Application (IND) for its HIV-1 entry inhibitor, BlockAide/CR(TM), received FDA clearance to begin a Phase Ib/IIa human clinical trial. The trial will assess safety,
Canadian Health Groups Take Campaign Against Internet Pharmacies to Washington: PRNewswire - April 14, 2004; WASHINGTON, April 14 /PRNewswire/ -- Canadian health groups today called on the Government of Canada to ban the exportation of pharmaceutical drugs from Canada to the U.S. The groups, who represent the interests of millions of Canadian patients, were in Washington to highlight their concerns with Internet pharmacies, i
The Immune Response Corporation Presents Preclinical Results Supporting Continued Development of New HIV Product Candidate, IR103 - Results Presented at the Keystone Symposium on HIV Vaccine Development -: PRNewswire - April 14, 2004; CARLSBAD, Calif., April 14 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company developing immune- based therapies for HIV and select other diseases, announced today that preclinical data for its newest product candidate, IR103, were presented at the Keystone Symposium o
Canticle Ministries Awards Scholarships to Three High School Students Living With HIV: 'Lighting the Way to a World Without AIDS': PRNewswire - April 14, 2004; WHEATON, Ill., April 14 /PRNewswire/ -- Canticle Ministries is holding its 2nd annual scholarship brunch from 11 a.m. to 2 p.m. Sunday, May 16, at the Marriott UIC, 625 South Ashland Ave., Chicago. A reception takes place at 11 a.m. Brunch will take place at noon, and at 1:30 p.m. the scholarships will be presented.
Medical Services Completes Major Test in the United States: PRNewswire - April 14, 2004; EDMONTON, Alberta, April 14 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pinksheets: MSITF) is pleased to announce that it has completed a major test of its HIV 1&2 test kits in the United States . The samples used in the test were obtained geographically from all over the United States. The indepe
AHF Applauds Feds for Hearings on Abbott Over AIDS Drug Price Hike: PRNewswire - April 14, 2004; -- Drug Giant s Greed Puts Government Research Funding Under the Microscope and May Help Fast Track Legal Importation of Cheaper Canadian Drugs. 400% Price Hike on Norvir Prompts Huge Public Outcry by Doctors and AIDS Activists LOS ANGELES, April 14 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS org
FUZEON(R) to be Widely Available Through Specialty and Retail Pharmacies in the U.S. - Ample Supply Enables Expanded Distribution: PRNewswire - April 14, 2004; NUTLEY, N.J., and DURHAM, N.C., April 14 /PRNewswire-FirstCall/ -- Roche and Trimeris (NASDAQ:TRMS) today announced that FUZEON(R) ( enfuvirtide ), the first and only fusion inhibitor available for the treatment of HIV, will now be available through retail and specialty pharmacies across the U.S. beginning on April 26.
Patients, Pharmacists, Physicians Speak Out Against Risk of Counterfeit Drug Importation: Testimony Before HHS Task Force to Stress Dangers of Imported Medicine: PRNewswire - April 13, 2004; WASHINGTON, April 13 /PRNewswire/ -- On the eve of a Department of Health and Human Services Task Force Public Hearing, the Partnership for Safe Medicines, a nonprofit coalition of more than 40 healthcare and anti- counterfeiting groups, called widespread prescription drug importation an unacceptably dangerous and inhe
Medical Services Receives Additional Test Results For its VScan HIV Test Kit: PRNewswire - April 13, 2004; EDMONTON, Alberta, April 13 /PRNewswire-FirstCall/ -- Medical Services (Pink Sheets: MSITF) is pleased to announce that it has received the independent test results of its VScan HIV 1&2 test kits from Hainan Province in the Peoples Republic of China . The testing showed a 99.7% accuracy in terms of specificity and
Calypte Announces License From CDC for HIV Incidence Test: PRNewswire - April 12, 2004; ALAMEDA, Calif., April 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a company engaged in developing rapid tests for HIV diagnosis and the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved seru
Medical Professionals Lobby for $15 Billion from Bush Administration: PRNewswire - April 9, 2004; DURHAM, N.C., April 9 /PRNewswire/ -- Medical professionals met in Botswana in March to determine generics safety and efficacy and develop a strategy to obtain a substantial amount of the $15 billion in aid the Bush administration has promised to be spent on generics. According to Combating Generics: Pharmaceutical B
Study Shows No Significant Drug Level Interactions in Co-administration of Invirase(R)/Ritonavir with Tenofovir: PRNewswire - April 9, 2004; NUTLEY, N.J. -- Roche today announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase (R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily). T
Abbott Seeks to Suppress AHF's Ads in Gay Papers: Move Seen as Attempt to Silence AIDS Healthcare Foundation's Free Speech & Ongoing Criticism of 400% Price Hike on Norvir: PRNewswire - April 8, 2004; LOS ANGELES -- In a brazen attempt to silence AIDS advocates ongoing criticism of Abbott Laboratories over its recent 400% price hike on the key AIDS drug Norvir , two prominent gay publications are buckling under pressure from Abbott to refuse to run, or significantly alter, a parody advertisement created by AIDS He
Stop Paid Blood Donation, Global Conference Appeals: PRNewswire - April 7, 2004; BEIJING, April 7 /Xinhua-PRNewswire/ -- Legislation is required to tighten control on blood donation and ensure a safer supply, a global conference of blood experts agreed in Beijing today. All blood must be from voluntary, unpaid donors and the support and legal commitment of health authorities will be sought worldwid
Senators DeWine and Clinton Detail Global Report on Children and HIV/AIDS: PRNewswire - April 7, 2004; -- Preserving Our Future -- HIV/AIDS and the World s Children Report is First in a Series Designed to Build Awareness of and Solutions for the AIDS Pandemic WASHINGTON, April 7 /PRNewswire/ -- Members of Congress, business leaders and leaders in the women s and children s rights communities gathered today on Capitol Hi
LIFEbeat Honors Z100 NY's Tom Poleman at Spring Benefit: PRNewswire - April 6, 2004; NEW YORK, April 6 /PRNewswire/ -- LIFEbeat, the Music Industry Fights Aids, will honor radio executive Tom Poleman, SVP Programming for Clear Channel Radio New York (CCRNY) & Program Director at Z100, for his commitment and dedication to the organization at their annual Spring Benefit. The music industry event will
Global Agreement Reached on Generic AIDS Medications: Will President Bush Use Taxpayer Dollars Wisely in Fighting AIDS?: PRNewswire - April 6, 2004; WASHINGTON, April 6 /PRNewswire/ -- A breakthrough plan to provide safe, generically-manufactured AIDS medication to poor countries around the world was announced today by the Global Fund, WHO, UNICEF, and the Clinton Foundation. The announcement was made just as Ambassador Randall Tobias, President Bush s Global AIDS
Cell Research Uncovers Intriguing Clues to `Trojan Horse' Gene in HIV Infection: PRNewswire - April 6, 2004; PHILADELPHIA, April 6 /PRNewswire/ -- Researchers are probing details of how HIV commandeers genes in infected cells to disguise itself from the immune system. The researchers, from The Children s Hospital of Philadelphia, have identified cellular proteins expressed during HIV infection that enable HIV- infected cells
Elizabeth Taylor Gives Grant to AHF's South African 'People's Hope' Clinic: PRNewswire - April 6, 2004; -- Hollywood Legend s Gift Will Enable Ithembalabantu ( People s Hope ) Clinic to Buy One Year of Life-Saving AIDS Drugs for Approximately 100 Additional People LOS ANGELES, April 6 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , which operates clinics in the US, A
Survey Suggests Lack of Awareness Heightens Risk for Sexually Transmitted Diseases: Awareness of Viral Hepatitis Compared to Other Common STDs Ranked Lowest: PRNewswire - April 6, 2004; RESEARCH TRIANGLE PARK, N.C., April 6 /PRNewswire/ -- New survey results unveiled today by the American Social Health Association (ASHA) -- an organization dedicated to preventing sexually transmitted diseases (STDs) -- suggest that lack of awareness may put Americans at risk for contracting STDs. While an overwhelming
AHF Applauds Lower Priced AIDS Drugs for 100 Plus Countries: PRNewswire - April 6, 2004; LOS ANGELES, April 6 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS organization, with clinics in the US, Africa and Central America hailed today s William J. Clinton Presidential Foundation announcement of an agreement to make available the commonly used three-drug anti-retroviral (ARV) regimens
Data Safety Monitoring Board Recommends Dosing of Final Two Patients in VRX496 Phase I Trial: PRNewswire - April 5, 2004; GAITHERSBURG, Md., April 5 /PRNewswire/ -- VIRxSYS Corporation, a private biotechnology company focused on the development of novel genetic medicines for the treatment of serious diseases such as HIV/AIDS, announced today that the independent Data Safety Monitoring Board (DSMB) unanimously recommended that the remainin
AIDS Therapeutic Treatment Now South Africa (ATTN/SA) Activists Applaud Gauteng Government's Rollout of Anti-Retroviral Medications: PRNewswire - April 2, 2004; DURBAN, KwaZulu-Natal, South Africa , April 2/PRNewswire/ -- Finally - after years of public debates, court cases and demonstrations, people living with HIV/AIDS who are dying are finally getting life-saving anti-retroviral medicines in Gauteng. This comes after two of Gauteng s largest hospitals Chris Hani Baragwanath
Calypte Launches International Manufacturing Initiative of its Rapid HIV Type 1 and HIV Type 2 Tests Announces License and Supply Agreement with Adaltis, Inc.: PRNewswire - April 1, 2004; -- Memorandum of Understanding Signed for Initial Manufacturing of HIV-1/2 Rapid Tests in Thailand ALAMEDA, Calif., April 1 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) a company engaged in developing rapid tests for HIV diagnosis and the developer and marketer of the only two FDA
PlanetOut Teams With AIDSmeds.com to Create Groundbreaking HIV/AIDS Resource Centers: Millions of Gay.com and PlanetOut.com Members Gain Access to Leading Treatment Information: PRNewswire - April 1, 2004; SAN FRANCISCO, April 1 /PRNewswire/ -- PlanetOut Partners, Inc., the leading media company providing products and services to the gay and lesbian community worldwide, today announced a partnership with the HIV information provider AIDSmeds.com, a publisher of online HIV treatment information. This resource is now avail
Delta SkyWish(TM) Program Partners With the Elton John AIDS Foundation: SkyMiles(R) program members may donate miles to support HIV/AIDS prevention, education and treatment: PRNewswire - April 1, 2004; ATLANTA, April 1 /PRNewswire-FirstCall/ -- Delta Air Lines (NYSE: DAL) has designated the Elton John AIDS Foundation as the SkyWish Charity of the Quarter. SkyMiles program members may contribute miles to support the organization s efforts to help individuals affected by and those living with HIV/AIDS. We are pleased t
Landmark Bill to Meet Needs of Children Affected by AIDS Passes Key Congressional Committee: PRNewswire - March 31, 2004; WASHINGTON, March 31 /PRNewswire/ -- Today a landmark initiative to help orphans and vulnerable children passed the House Committee on International Relations by unanimous vote. The bill was championed by a bipartisan group of Representatives, including Rep. Henry Hyde (R-IL), Rep. Barbara Lee (D-CA), Rep. Dana Rohrbac
Serono's Serostim(R) Improves Lean Body Mass and Physical Performance in Patients With HIV-Associated Wasting: PRNewswire - March 31, 2004; -- Results of largest study of recombinant human growth hormone in HIV-associated wasting published in current issue of the Journal of AIDS ROCKLAND, Mass., March 31 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA)-Serono s Serostim(R) [somatropin (rDNA origin) for injection] improves lean body mass and phy
Medical Services International to Place Its VScan HIV Rapid Test Kits in Dispensaries in Southeast Asia: PRNewswire - March 31, 2004; EDMONTON, Alberta, March 31 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that its VScan HIV 1&2 rapid test kits will now be carried OTC (Over the Counter) in drugstores in Hong Kong . Our Hong Kong Distributor working with Medical Services staff has sig
Canadian Clinical Trial Investigates REMUNE(R) as a Drug-Sparing Therapy in HIV-Positive Patients: PRNewswire - March 30, 2004; CARLSBAD, Calif., March 30 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to treating and preventing HIV and AIDS through the development of immune-based therapies, announced today the start of a new HIV clinical trial in Canada . REMUNE, the Company
ViroLogic Launches VLink Online System for HIV Resistance Test Reporting: PRNewswire - March 30, 2004; -- Internet Access to Test Results Adds Convenience and Reduces Turnaround Time SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the launch of VLink online test reporting for its comprehensive portfolio of HIV drug resistance assays, PhenoSense GT(TM), Pheno
IPM Will Take Over the Development of Tibotec's Promising Microbicide to Help in the Prevention of the Sexual Transmission of HIV: PRNewswire - March 29, 2004; LONDON, March 29 /PRNewswire/ -- International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson . The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect w
NY State Doubts Abbott's 'Hold Harmless' Claims on Norvir Price Increase: AHF Asks NY AG Spitzer to Launch Inquiry Into Abbott's Statements: PRNewswire - March 29, 2004; LOS ANGELES, March 29 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US which operates medical clinics in the US, Africa, and Central America, and which also provides pharmacy services to over 150 people with HIV/AIDS in New York City, has asked New York Attorney General Eliot Sp
Pursue Strategic Alliances in Difficult Times, New York Consultant Tells National AIDS Conference in Miami: PRNewswire - March 28, 2004; NEW YORK, March 28 /PRNewswire/ -- Innovative solutions are needed to cope with impediments to the delivery of HIV-related healthcare caused by reduced financial resources, a New York consultant will tell participants Monday at the 16th National HIV/AIDS Update Conference being sponsored by the American Foundation for
Medical Services to Participate in the amfAR (American Foundation for Aids Research) National HIV/AIDS Conference in Miami Florida: PRNewswire - March 26, 2004; EDMONTON, Alberta, March 26 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that its will be showcasing its VScan rapid test kits at the upcoming 16th National HIV/AIDS update conference held by The American Foundation for Aids Research (amfAR) in Miami, Florida,
Evotec OAI and Panacos Enter into Medicinal Chemistry Agreement to Design and Optimise Novel Anti-HIV Compounds: PRNewswire - March 25, 2004; HAMBURG, Germany and OXFORDSHIRE, England and GAITHERSBURG, Md., March 25 /PRNewswire-FirstCall/ -- Evotec OAI AG (Deutsche Borse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, and Panacos Pharmaceuticals,
American Airlines Again the Official Airline for AIDS Walk Tarrant County, March 28 in Fort Worth: PRNewswire - March 25, 2004; -- There s Still Time to Register to Walk, or to Sponsor a Walker; All Funds Support the AIDS Outreach Center s Services in North Texas FORT WORTH, Texas, March 25 /PRNewswire-FirstCall/ -- For the ninth consecutive year, American Airlines, with regional affiliate American Eagle, will again serve as the official airlin
GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R): PRNewswire - March 25, 2004; CAMBRIDGE, Mass., March 25 /PRNewswire-FirstCall/-- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received a positive opinion from the European Committee for Proprietary Medicinal Products (CPMP) for Telzir(R) ( f
Human Genome Sciences to Sharpen Focus - Announces Plans to Concentrate on Drugs of Highest Potential: PRNewswire - March 25, 2004; ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that it is sharpening its focus in preparation for the commercialization of the Company s most promising drug candidates. As part of this strategy, the Company plans to reduce the number of drugs in early devel
Lipid Sciences Receives STTR Research Grant From National Institutes of Health (NIH): Vaccine for SARS Virus Focus of Research: PRNewswire - March 25, 2004; PLEASANTON, Calif., March 25 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) announced today that it is the recipient of a STTR (Small Business Technology Transfer) grant awarded by the NIH (National Institutes of Health) for a Virion Solvent Treatment for SARS (Severe Acute Respiratory Syndrome). The ove
AHF Spoofs Abbott's Spin on Huge Norvir Price Hike in New Ad Campaign: PRNewswire - March 24, 2004; -- Parody Ads Blast Abbott for Expanded Greed Over 400% Price Hike on Key AIDS Drug; Ads Will Appear in Windy City Times, Frontiers Newsmagazine, and Washington Blade LOS ANGELES, March 24 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States which operates clinics in
CytRx Corporation, Advanced BioScience Laboratories and University of Massachusetts Announce FDA Acceptance of IND For Unique HIV Vaccine - Phase I trial to begin in Worcester, MA: PRNewswire - March 23, 2004; LOS ANGELES, March 23 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced today that the HIV vaccine formulation developed by the University of Massachusetts Medical School and ABL and funded by the Nation
Medical Services U.S. Live Testing Program for the VScan HIV Test Kit Continues to Show Excellent Results: Medical Services U.S. Live Testing Program for the VScan HIV Test Kit Continues to Show Excellent Results: PRNewswire - March 23, 2004; EDMONTON, Alberta, March 23 /PRNewswire-FirstCall/ -- Medical Services International Inc., (Pinksheets: MSITF) is pleased to announce that it has received the results of its third live testing program in Florida. The results of this current test show that the VScan HIV test kits were 100% accurate. The data being colle
Health Discovery Corporation Announces Agreement with the University of Miami for Biomarker and Pathway Discovery in AIDS Related Dementia: PRNewswire - March 23, 2004; SAVANNAH, Ga., March 23 /PRNewswire-FirstCall/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY) today announced the signing of an Agreement with The University of Miami to use Health Discovery Corporations proprietary and patent protected Fractal Genomics Modeling (FGM) techniques to identify new patterns of
Beckman Coulter Awarded First Tender Through Clinton Foundation Partnership to Supply AIDS Related Products to Developing World: Company Delivers First Shipment of AIDS Tests and Equipment to South Africa: PRNewswire - March 23, 2004; FULLERTON, Calif., March 23 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), announced today it has been awarded the first tender in South Africa for its CD4 monitoring test and COULTER(R) EPICS(TM) XL flow cytometers. The tender is the result of Beckman Coulter s participation with the William J. Clinton P
EraGen Biosciences and Emory University Enter into Collaborative Agreement for HIV Molecular Diagnostics: PRNewswire - March 22, 2004; MADISON, Wis., March 22 /PRNewswire/ -- EraGen Biosciences, a rapidly growing life science company driving a new era in genetic diagnostics and drug discovery announced today they have entered into a collaboration agreement with Emory University supported by an NIH STTR grant to develop a quantitative genotyping system
SHOWTIME's Hit Series SOUL FOOD Tackles HIV/AIDS: PRNewswire - March 22, 2004; NEW YORK, March 22 /PRNewswire/ -- On April 14th, SOUL FOOD will recognize the sensitivity and urgency of the HIV/AIDS issue by airing an episode in which Kenny s brother reveals he is HIV positive. In an effort to better inform viewers about the unique challenges faced by African-Americans with AIDS, SHOWTIME will cre
MedMira Ships 100,000 Rapid HIV Test Kits to China, First of 1.3 Million Kit Order: PRNewswire - March 22, 2004; HALIFAX, March 22 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) today announced that the company has completed an initial shipment of 100,000 MiraWell(TM) Rapid HIV Tests to the People s Republic of China . The shipment is the first portion of an annual commitment of 1.3 million kits from a new d
New Global TB Plan and WHO TB Progress Report to Be Released on World TB Day, March 24th, at Major International TB Meeting in India: PRNewswire - March 22, 2004; Journalist s Briefing and Q&A by Phone From New Delhi - March 23 Noon ET NEW DELHI, India and WASHINGTON, March 22 /PRNewswire/ -- The following is being issued by RESULTS Educational Fund: * New data shows TB epidemic is still growing, especially where HIV is causing TB to skyrocket and in regions with alarming le
Advances in the Treatment of Immunodeficiency Disorders Released at the 2004 AAAAI Annual Meeting: PRNewswire - March 21, 2004; SAN FRANCISCO, March 21 /PRNewswire/ -- Children initially sensitized to an aeroallergen at age 2 years outgrew their sensitization by age 4, according to a study presented today at the 2004 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco. Michael R. Simon, MD, Henry Fo
AHF Praises Assembly Subcommittee for Vote to Restore AIDS Funding To Crucial California Testing Program: PRNewswire - March 18, 2004; In August, DHS Cut $7M From $8M Program to Monitor Effectiveness of AIDS Patients Drug Therapies LOS ANGELES, March 18 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US which operates clinics in the US, Africa and Central America, praised a California Assembly Subcommittee for th
AHF Files Superior Court Action Against Abbott for Unfair Business Practices, False Advertising and Fraud in California: PRNewswire - March 18, 2004; Abbott Labs Hit With False Advertising Lawsuit by AIDS Healthcare Foundation Over AIDS Drug Pricing Claims WHAT:Press Conference & Teleconference Call FILING OF CALIFORNIA STATE COURT COMPLAINT AGAINST ABBOTT LABS OVER FALSE ADVERTISING RE: IMPACT OF AIDS DRUG PRICE INCREASE WHEN:THURSDAY, March18th 2004 LOS ANGE
Medical Services to Ship Additional VScan HIV Test Kits to Europe: PRNewswire - March 18, 2004; EDMONTON, Alberta, March 18 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) announced on January 29, 2004 that it had begun to ship VScan HIV 1&2 rapid test kits to Austria for testing. Today, the Company wishes to advise that based on the results obtained to date and the successfu
Latest Drug Discovery & Development Advances in Antivirals the Focus of Conference to be held March 29-30, 2004 in Cherry Hill, NJ: PRNewswire - March 17, 2004; CHERRY HILL, N.J., March 17 /PRNewswire/ -- The world of antiviral researchers and clinical experts from the pharma & biotech industry will be convening in Cherry Hill, NJ to attend, speak, & exhibit at the 5th International Antiviral Drug Discovery & Development Summit, announces Strategic Research Institu
AHF Blasts GSK Over Expensive New Ad Campaign: PRNewswire - March 17, 2004; -- US Largest AIDS Group Says Almost 2.2 Million People With AIDS Worldwide Could be Saved with the $300 Million That GSK Spent on Network TV Ads Last Year: Just One 30 Second Spot on Law & Order Could Pay for One Year of ARVs for 1,900 People LOS ANGELES, March 17 /PRNewswire/ -- AIDS Healthcare Foundation (AHF),
Health Canada Official to Join IPM, a Global Partnership Developing Microbicides to Protect Women Against HIV: Government Expert seconded to Global Public-Private Partnership: PRNewswire - March 17, 2004; SILVER SPRING, Md. and OTTAWA, March 17 /PRNewswire/ -- The International Partnership for Microbicides (IPM) today announced secondment of a government official to advance a public-private health partnership. Under the terms of the agreement, Martin Methot, Director of the International Health Division, Health Policy a
Jacksonville Faces $300K AIDS Funding Cut by Feds: AIDS Healthcare Foundation Says, 'Don't Cut Care or Meds': PRNewswire - March 17, 2004; -- 40 of 51 Eligible Metropolitan Areas (EMAs) Nationwide Saw Cuts -- Duval County to Lose More Than $300,000 in Federal Ryan White Title One Funding WHAT: Press Conference AIDS Healthcare Foundation Speaks Out on Federal AIDS Funding Cuts in Hard Hit, North East Florida Community WHEN: WEDNESDAY, March 17th 2004 J
Primagen Appoints Distributors for its Retina Products and Services: PRNewswire - March 16, 2004; AMSTERDAM, Netherlands , March 16 /PRNewswire/ -- Primagen Holding B.V. (http://www.primagen.com), a provider of molecular diagnostic tests for infectious diseases, AIDS and cancer, announced today that it has entered into distribution agreements for its Retina(TM) Rainbow products with Farmaplus N.V., having its offic
Global AIDS Alliance: Congressman Jim Nussle Insensitive to Global AIDS Crisis: PRNewswire - March 16, 2004; WASHINGTON, March 16 /PRNewswire/ -- The Global AIDS Alliance today accused Congressman Jim Nussle (R-IA) of being insensitive to millions of people around the world suffering from AIDS. Congressman Nussle led the House Budget Committee last week in reducing funds available for global AIDS and poverty programs by $4.5
Panacos Pharmaceuticals Initiates Phase 1 Clinical Trial of PA-457, the First in a New Class of Oral Anti-HIV Compounds.: PRNewswire - March 16, 2004; GAITHERSBURG, Md., March 16 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has begun a Phase 1 clinical trial of its small molecule HIV drug candidate PA-457. PA-457 has a different mechanism of action than approved HIV drugs and has potent activity against HIV strains resistant to current therap
AHF Medical Staff Urges Abbott Labs to Rescind 400% Price Increase on Key AIDS Drug, Norvir(R): PRNewswire - March 16, 2004; -- Medical Providers & Staff of US Largest AIDS Group Sends Letter to Abbott to Press for Rollback of Pharmaceutical Giant s Recent Five-Fold Price Increase LOS ANGELES, March 16 /PRNewswire/ -- The medical staff of AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US which operates clinics in
Heart Disease, HIV/AIDS and Fitness Should Be Nation's Top Health Priorities, According to New Survey of Gays and Non-Gays: PRNewswire - March 15, 2004; Witeck-Combs Communications/Harris Interactive Survey Also Shows That More Than Half of All Adults Surveyed Think Federal Research on Lesbian and Gay Health is Extremely Important ROCHESTER, N.Y., March 15 /PRNewswire/ -- According to national survey results released today by Witeck-Combs Communications and Harris Inte
Medical Services International's VScan HIV Test Kits to Be Used in Drug Rehabilitation Clinics: PRNewswire - March 15, 2004; EDMONTON, Alberta, March 15 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that Beijing officials have approved the shipping of VScan HIV 1&2 rapid test kits to certain Provincial police departments to start a mandatory testing program for HIV in drug rehabi
Reality Television Stars Launch 'The Reality Cares Foundation' Via The Giving Back Fund: First National Event Will Raise Funds for People Affected by HIV/AIDS: PRNewswire - March 15, 2004; LOS ANGELES, March 15 /PRNewswire/ -- Reality stars of hit television shows such as The Amazing Race, Big Brother, Boy Meets Boy, Real World, and Road Rules have come together to form The Reality Cares Foundation (http://www.realitycares.org) to raise money for people affected by life-threatening diseases such as Alzhe
BET Premieres Third Installment of NAKED TRUTH Documentary Series About HIV/AIDS on March 20: NAKED TRUTH III Examines Attitudes of African-American Sexuality and Sexual Health: PRNewswire - March 15, 2004; WASHINGTON, March 15 /PRNewswire/ -- BET s award-winning HIV/AIDS documentary series continues with the premiere of the poignant and touching NAKED TRUTH III, which examines how attitudes around sexuality and sexual identity affect the sexual health of African Americans, in particular, the rise of HIV infection. Premie
AHF Condemns Abbott Over 20% Pay Hike, $500,000 Bonus Increase for C.E.O. in Wake of Unprecedented Price Hike of AIDS Drug -- Huge Compensation Increase Comes Shortly After Chicago Pharmaceutical Giant's Gouging of AIDS Patients, Drug Company Rivals With 400% Price Increase on Key AIDS Drug, Norvir: PRNewswire - March 15, 2004; LOS ANGELES -- According to a recent Chicago Tribune article, Abbott Laboratories increased Chief Executive Miles White s salary 4.5 percent and his bonus 40 percent in 2003, the company said in its annual proxy filing with the Securities and Exchange Commission. White s total pay was $3.4 million, up 20 percent from 2
JUVEN Added to Abbott Laboratories' Nutritional Product Line for People With Cancer, HIV/AIDS and Wounds/Pressure Ulcers: PRNewswire - March 12, 2004; -- Medical Food Is Designed to Help Reduce Muscle Breakdown and Rebuild Muscle Tissue COLUMBUS, Ohio, March 12 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) Ross Products Division has added JUVEN(R) to its line of nutritional products. Based on a patented blend of three key ingredients -- arginine, glutamin
Chimerix Awarded NIH Grant to Fund Drug Development for Multi-Drug Resistant HIV Infection: PRNewswire - March 11, 2004; SAN DIEGO, March 11 /PRNewswire/ -- Chimerix Inc., a biotechnology company developing orally available, targeted medicines for the treatment of smallpox, multi-drug resistant HIV and hepatitis virus infections, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant under the
Mobious Launches Two New Plasmonic Devices: PRNewswire - March 10, 2004; EXETER, England, March 10 /PRNewswire/ -- - Bulk Refractive Index Compensated Proteomics Array & Highly Multiplexed Label-Free Real-Time PCR Mobious Genomics is pleased to announce the launch of two new technologies. The group has developed a new plasmonic sensing technique that it believes will address the key iss
AHF Applauds Legislators' Vote to Block Proposed Cuts to ADAP, Urges Schwarzenegger to Reverse Position: PRNewswire - March 9, 2004; -- US Largest AIDS Group, Other AIDS Activists Help Hundreds of Californians Living with HIV/AIDS Attend Rally in Sacramento to Protest Cuts & Lobby Legislators LOS ANGELES, March 9 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) the nation s largest AIDS organization which operates free AIDS treatment clinics in
AHF Criticizes GSK for 5% Overall Price Hike on AIDS Drugs: As Cash-Strapped States Look for Ways to Avoid Waiting Lists for ADAP, British Drug Giant's Price Hike Will Cost the US Government $16 Million - Half of This Year's Entire Funding Increase for ADAP: PRNewswire - March 8, 2004; LOS ANGELES, March 8 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US which operates clinics in the US, Africa and Central America, today criticized British drug giant GlaxoSmithKline (GSK) for their recent, across-the-board price increases of roughly 4.9% on their AIDS drugs.
Hispanics Face Significant Disparities in Pharmaceutical Treatment: Study Shows Hispanics Have Less Access to State-of-the-Art Medications; Genetic and Environmental Factors Demonstrate Need for Prescribing Tailored to the Individual: PRNewswire - March 8, 2004; WASHINGTON, March 8 /PRNewswire/ -- Hispanics are less likely to receive or use medications for asthma, cardiovascular disease, HIV/AIDS, mental illness, and pain, according to a new study. These disparities in pharmaceutical treatment are substantial and often persist even after adjustment for differences in income, a
Today's Testimony on AIDS Policy Should be Frank and Honest, says GAA: Congress Should Expect Clarity on Generic Medications: PRNewswire - March 4, 2004; WASHINGTON, March 4 /PRNewswire/ -- In today s testimony before Congress, State Department officials must be frank and honest about US policy on generic AIDS medication, said the Global AIDS Alliance. The official in charge of US efforts to fight AIDS, Ambassador Randall Tobias, will testify this morning before the Hou
Medical Services Invited to Discussions Concerning Mandatory Testing: PRNewswire - March 4, 2004; EDMONTON, Alberta, March 4 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has received an invitation to meet with government officials in Beijing concerning mandatory testing by law enforcement agencies. These meetings will take place the week of March 8
FDA Approves Roche Diagnostics Test for Use in Screening Source Plasma And Organ Donors for HIV-1, the Leading Cause of AIDS: PRNewswire - March 2, 2004; -- Roche s COBAS AmpliScreen HIV-1 Test v1.5 is the first FDA-licensed nucleic acid test that producers of plasma-based therapeutics can use in their own laboratories BASEL, Switzerland , March 2 /PRNewswire/ -- Roche Diagnostics announced today that the United States Food & Drug Administration (FDA) h
BET'S Rap-It-Up Hosts Teen Health Forum in Detroit March 13: PRNewswire - March 1, 2004; WASHINGTON, March 1 /PRNewswire/ -- BET s Rap-It-Up, the cable network s award-winning national HIV/AIDS public awareness initiative, brings its first citywide health forum to Detroit s Southfield Lathrup High School on Saturday, March 13 at 12:00 p.m. Partnering with Rap-It-Up for the community effort are Michigan Sta
Feds Cut AIDS Funding: AHF Tells L.A. County, 'Cut Bureaucracy, Not Care or Meds': L.A. County Loses $3M in Federal Ryan White Title One AIDS Funding: PRNewswire - March 1, 2004; LOS ANGELES, March 1 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS organization with clinics in the US, Africa and Central America-today expressed disappointment at new cuts to federal AIDS funding that will adversely affect 40 of 51 eligible metropolitan areas (EMAs) across the country, i
Treatment With Serostim Decreased Visceral Adipose Tissue in Study of Patients With HIV-Associated Adipose Redistribution Syndrome (HARS): PRNewswire - March 1, 2004; -- Study of patients with HARS published in Journal of AIDS ROCKLAND, Mass., March 1 /PRNewswire-FirstCall/ -- Serono (virt-x SEO and NYSE: SRA) -- Serono s Serostim(R) (somatropin (rDNA origin) for injection) administered daily decreased visceral adipose tissue in patients with HIV-associated adipose redistribution sy
22-Year Analysis Shows Overall Media Coverage of HIV/AIDS Decreasing, but Focus on Global Epidemic Increasing: People Most Affected by HIV/AIDS Are Rarely the Focus of Media Coverage: PRNewswire - March 1, 2004; MENLO PARK, Calif., March 1 /PRNewswire/ -- Are the media experiencing AIDS fatigue? A new Kaiser Family Foundation study examining 22 years of news coverage finds that overall media coverage is decreasing, while the amount of coverage of the global epidemic is increasing. AIDS at 21: Media Coverage of the HIV Epidemic
Female Condom Launched in India: PRNewswire - March 1, 2004; CHICAGO, March 1 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) and its Indian Partner Hindustan Latex Limited (HLL) announced the launch of the Female Condom in India. This initiates the final stage in a four step process to develop the Indian market. Late in 2001, the Company and HLL f
AIDS Healthcare Foundation Supports House Committee's Funding Shift for ADAP: PRNewswire - February 26, 2004; LOS ANGELES, Feb. 26 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) the largest US-based AIDS organization with clinics in the US, Africa and Central America -- issued the following statement regarding the bipartisan approval earlier today in the House Government Reform Committee of Views and Estimates on the Fiscal
Condom Retailer First to Ban Products Containing Nonoxynol-9 Spermicide: PRNewswire - February 26, 2004; PLAINVILLE, Conn., Feb 26 /PRNewswire/ -- CondomDepot.com, one of the nation s leading condom retailers, has announced that they have removed all products containing the popular spermicide nonoxynol-9 from their shelves. They are the first major condom retailer to drop the controversial spermicide from their shelves.
amfAR to Recognize Harvey Weinstein for His Leadership In the Fight Against AIDS: PRNewswire - February 26, 2004; -- Weinstein to be the second recipient of a prestigious award, following its inaugural presentation to legendary MCA Inc. Chairman Lew Wasserman NEW YORK, Feb. 26 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) is proud to announce that it will organize a tribute event later this year for the purpose
Early Treatment for HIV Act (ETHA) Filed in the U.S. House of Representatives: AIDS Death Rate in U.S. Could be Reduced by 60% With Implementation: PRNewswire - February 26, 2004; BOSTON, Feb. 26 /PRNewswire/ -- The Treatment Access Expansion Project (TAEP), a collaborative project of the HIV/AIDS community, health care providers, and the pharmaceutical industry, announced the filing of the Early Treatment for HIV Act (ETHA) today in the U.S. House of Representatives. The bi-partisan bill was fi
How Far Would You Go? Two Vanderbilt Medical Students will Hike 1,723 Miles to Increase Awareness of HIV/AIDS in Nashville: PRNewswire - February 25, 2004; NASHVILLE, Tenn., Feb. 25 /PRNewswire/ -- Two Vanderbilt medical students Joshua Bress and Kevin Elias have committed themselves to hike 1,723 miles of the Pacific Crest Trail (from the Southern edge of California to Oregon) during the summer of 2004 to increase awareness of HIV/AIDS in Nashville, Tennessee. In Novembe
ADVR Granted a United States Patent for the Treatment of AIDS: PRNewswire - February 25, 2004; YONKERS, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it was issued a United States patent (No. 6,696,422) for the treatment of HIV infections with AVR118 as a combination therapy with other HIV drugs. The Centers for Disease Control and Preventio
Woodhull Freedom Foundation and Federation Appoints Director of 'R.E.A.L.' Campaign to Replace Abstinence-Only-Until-Marriage Sex Education With Comprehensive Sexuality Education: PRNewswire - February 25, 2004; WASHINGTON, Feb. 25 /PRNewswire/ -- The Woodhull Freedom Foundation and its sister lobbying organization, the Woodhull Freedom Federation (together referred to as WFF), are proud to announce that Ms. Joy Freeman has agreed to serve as director of its R.E.A.L.: Real Education About Life campaign, promoting the replaceme
Herpes: The Little Secret Shared By Millions: PRNewswire - February 24, 2004; PALM DESERT, Calif., Feb. 24 /PRNewswire/ -- Jennifer is 33, attractive, and popular. Her friends and family ask her why she has not dated in so long, and she seems to shun the men they want to introduce to her. Ronald is 49, kind, good-hearted, not GQ, but attractive enough in his own right. His friends wonder why he
National Organization of Concerned Black Men Tackle Tough Problems with a Warm Heart: PRNewswire - February 23, 2004; WASHINGTON, Feb. 23 /PRNewswire/ -- The National Organization of Concerned Black Men (CBM) is tackling tough, inner city troubles -- with brains not brawn. Through direct interventions in Washington, DC s poorest schools and neighborhoods, CBM is successfully communicating crucial health facts, life skills -- and love
US' Largest AIDS Group Disappointed by President's Announcement on Global AIDS Funding: AIDS Healthcare Foundation's Proposal to Expand Treatment to 34,000 Africans 'Approved' but Not Funded; Other Leading AIDS Care Providers Face Similar Dilemma: PRNewswire - February 23, 2004; -- Over 3 Million People Have Died Since Bush First Pledged $15 Billion to Fight AIDS LOS ANGELES, Feb. 23 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) the largest US-based AIDS organization with clinics in the US, Africa and Central America-released the following statement today from Michael Weinstein, President:
ADVENTRX Pharmaceuticals Announces Notice of Government Grant Received by M.D. Anderson Cancer Center: Funding To Support Research For New Formulations Of EradicAide(TM) Technology To Treat HIV/AIDS: PRNewswire - February 20, 2004; SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (OTC Bulletin Board: AVRX) announced today new research to develop next generation EradicAide vaccine therapy. The University of Texas M.D. Anderson Cancer Center has received notice of a grant from the NIH (National Institutes of Health) in ex
amfAR Awards $1.15 Million for Basic Research Into HIV/AIDS: Grants and Fellowships Target 'Natural Defense Mechanisms': PRNewswire - February 18, 2004; NEW YORK, Feb. 18 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) announced today more than $1.15 million in basic research support for scientists working to increase knowledge about HIV/AIDS, to improve treatment and prevention, and to move the world closer to a possible vaccine. amfAR s new funding
Germany Begins its First AIDS Vaccine Trial, Partnering with IAVI: PRNewswire - February 16, 2004; BERLIN, Feb. 16 /PRNewswire/ -- German scientists, working as part of an international partnership, are beginning the country s first human trial of a vaccine candidate designed to prevent AIDS. A preventive vaccine is widely considered the best hope to stop the epidemic s continuing spread. The trial will be conducted
New Data Suggest Potential for Once-Daily Dosing Regimen of Kaletra(R) (Lopinavir/Ritonavir) in HIV Treatment-Naive Patients: PRNewswire - February 12, 2004; SAN FRANCISCO, Feb. 12 /PRNewswire-FirstCall/ -- New data, presented this week at a scientific meeting in San Francisco, CA, suggest that an HIV treatment regimen based on a once-daily dose of Abbott Laboratories protease inhibitor (PI) Kaletra (R) ( lopinavir /
Landmark Study Evaluates Leading Chronic Hepatitis C Therapy in HIV Patients - Findings offer new hope in combating a major threat to people with HIV -: PRNewswire - February 12, 2004; NUTLEY, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Roche announced today that results from the largest study conducted to date evaluating chronic hepatitis C treatment among patients co-infected with HIV and HCV were presented at the 11th Annual Conference on Retroviruses and Opportunistic Infections. The landmark APRICOT
Mount Sinai Investigator Reports Highest Hepatitis C Therapy Response Rates to Date in Patients Infected with HIV and Hepatitis C: PRNewswire - February 12, 2004; -- Study findings offer new hope for the estimated 300,000 Americans infected with HIV and Hepatitis C New York, Feb. 12 /PRNewswire/ -- A Mount Sinai School of Medicine researcher reported results from a study with a drug combination that showed the highest hepatitis C treatment response rates ever reported in patient
NCHECR Presentation of VIR201 Clinical Results at the 11th International Conference on Retroviruses and Opportunistic Infections: PRNewswire - February 12, 2004; MELBOURNE, Australia , Feb. 12 /PRNewswire/ -- Virax Holdings Limited (ASX: VHL) today advised that its research partner, the Australian National Centre for HIV Epidemiology and Clinical Research (NCHECR) presented data and released results of the recent clinical trial of Virax s immune based therapy VIR201 at the pres
Low Dose Maintenance Therapy With Recombinant Human Growth Hormone May Sustain Previous Serostim(R) Treatment In HIV Positive Patients With HARS: PRNewswire - February 12, 2004; -- New data presented at a recent medical meeting on HIV and infectious diseases Rockland, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Serono, Inc., the US affiliate of Serono (virt-x: SEO and NYSE: SRA), announced new clinical data on Serostim(R) [somatropin (rDNA origin) for injection] as a potential maintenance therapy
Pharmasset Reports Phase 2 HIV Study Results of Reverset(TM): Once-Daily Oral Dose Reduced HIV Viral Load by 1.77 Log(10) copies/mL: PRNewswire - February 11, 2004; ATLANTA, Feb. 11 /PRNewswire/ -- Pharmasset, Inc. today announced results from a Phase 2 study of Reverset, which is being co-developed with Incyte Corporation for the treatment of HIV-infected patients. The data was presented at the 11th Conference on Retroviruses and Opportunistic Infections in San Francisco by clini
GlaxoSmithKline Reaffirms Its Position Against a Frivolous Lawsuit Sponsored By the AIDS Healthcare Foundation: PRNewswire - February 11, 2004; PHILADELPHIA, Feb. 11 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today issued the following statement responding to announcements that the Attorney General of California has filed a brief in support of litigation sponsored by the AIDS Healthcare Foundation (AHF): We are disappointed that the Attorney General has filed
Lipid Sciences' Data: A Model for a New Therapeutic Vaccination Strategy Against HIV Infection: Data Presented at Conference on Retroviruses and Opportunistic Infections: PRNewswire - February 11, 2004; PLEASANTON, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) announced that a poster exhibited at the 11th Conference on Retroviruses and Opportunistic Infections in San Francisco illustrates that a delipidated retrovirus (SIV-Mac251) can elicit a broader and more robust cellular immune res
Abbott Sued for Anti-trust Over Norvir Price Increase By AIDS Healthcare Foundation: US' Largest AIDS Group Files Federal Action Over 400% Price Increase For Norvir While Abbott's AIDS Drug Kaletra Which Includes Norvir - Has No Price Increase: PRNewswire - February 11, 2004; LOS ANGELES, Feb. 11 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , which operates clinics in the US, Africa and Central America, has filed an antitrust and restraint of trade lawsuit yesterday against pharmaceutical giant Abbott Laborator
California AG Supports AHF's Efforts in Lawsuit Against GSK on AZT Patent: PRNewswire - February 11, 2004; -- Attorney General Bill Lockyer Files Amicus Brief in Support of US Largest AIDS Group s Patent Challenge: Friend of Court Asks That GSK s Summary Judgment Motion Be Denied LOS ANGELES, Feb. 11 /PRNewswire/ -- California s Attorney General Bill Lockyer today filed an amicus ( friend of the court ) brief [case # CV03-2
Panacos Pharmaceuticals to Begin Phase 1 Clinical Trial of the First HIV Maturation Inhibitor, PA-457: PRNewswire - February 9, 2004; GAITHERSBURG, Md., Feb. 9 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration ( FDA ) of its Investigational New Drug (IND) application to begin human clinical trials of the Company s lead compound, PA-457. PA-457 is the first in a new
FemmePharma, Inc. and Emory University Team to Identify Topical Microbicides for Drug Development: PRNewswire - February 9, 2004; WAYNE, Pa., Feb. 9 /PRNewswire/ -- FemmePharma, Inc., a prescription pharmaceutical company dedicated to developing drugs for diseases and disorders disproportionately affecting women, has initiated a collaboration with Emory University to study a library of molecules and their respective activity against HIV and other
Generex Appoints Dr. Douglas Powell as Director of Immunobiology - Former Senior Scientist at Millennium Pharmaceuticals to Lead Development of Cancer and Infectious Disease Programs at Company's Subsidiary: PRNewswire - February 9, 2004; TORONTO, Feb. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), announced today the appointment of Douglas Powell, Ph. D., formerly a Senior Scientist at Millennium Pharmaceuticals, Inc., to be Director of Immunobiology at Antigen Express, its immunomedicines subsidiary near Boston. Dr. Powe
Results of Multinational Trial Investigating Pegasys(R) and Copegus(R) in Patients with Hepatitis C and HIV Announced: PRNewswire - February 7, 2004; NUTLEY, N.J., Feb. 7 /PRNewswire/ -- Roche today announced the results of a multinational trial designed to evaluate the safety and efficacy of Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) compared with conventional interferon alfa-2a/ribavirin for the treatment of chronic hepatitis C in patients co-in
Aventis' Dermik Laboratories Announces FDA Acceptance of Filing For Sculptra(TM) to Treat Facial Lipoatrophy: PRNewswire - February 5, 2004; BERWYN, Pa., Feb. 5 /PRNewswire-FirstCall/ -- Dermik Laboratories, the U.S. dermatology arm of Aventis (NYSE: AVE), announced today that the U.S. Food and Drug Administration ( FDA ) has accepted for filing and granted expedited review of the company s Premarket Approval Application (PMA) for SCULPTRA(TM) (injectable p
Medical Services Ships HIV Test Kits to the Caribbean: PRNewswire - February 4, 2004; EDMONTON, Alberta, Feb. 4 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has begun shipping VScan HIV test kits to the Caribbean. On October 28, 2003, Medical Services announced that it had completed all the necessary testing required for the country of
Eaton's Electrical Business to Sponsor 2004 Carnegie Science Center Awards of Excellence: PRNewswire - February 4, 2004; PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- Diversified industrial manufacturer Eaton Corporation (NYSE: ETN) today announced it will be the title sponsor of the 2004 Carnegie Science Center Awards for Excellence, which celebrate outstanding recent achievement in science and technology in Southwestern Pennsylvania. Th
AHF Lauds LA Supervisors' Unanimous Vote in Favor of Motion to Regulate Sex Clubs: PRNewswire - February 3, 2004; -- AIDS Healthcare Foundation Praises BOS Undivided Support of Motion to Increase Regulations at LA County Bathhouses & Sex Clubs. Motion Will Improve Testing & Prevention Services at Venues LOS ANGELES, Feb. 3 /PRNewswire/ -- Advocates from AIDS Healthcare Foundation, the nation s largest AIDS group which oper
Bristol-Myers Squibb, GlaxoSmithKline, and Abbott Dominate the Growing HIV Drug Market: Revenues for GSK's Trizivir Increased 97% Between 2001 and 2002: PRNewswire - February 3, 2004; WALTHAM, Mass., Feb. 3 /PRNewswire/ -- Decision Resources, Inc., one of the world s leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Bristol-Myers Squibb , GlaxoSmithKline (GSK), and Abbott Laboratories dominate the HIV drug market.
LA Supes to Vote on New Regs for Sex Clubs: PRNewswire - February 3, 2004; -- AIDS Healthcare Foundation to Support Yaroslavsky Motion for Director of Health Services & County Counsel to Work on Regulations for Improved Access for HIV & STD Testing and Prevention Services What: Media Availability Supervisors to Vote on Motion to Regulate Bathhouses and Sex Clubs and Better Access for
ADVENTRX Pharmaceuticals Announces Patent Granted for EradicAide(TM) Technology to Diagnose, Prevent and Treat AIDS: PRNewswire - February 3, 2004; SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals (OTC Bulletin Board: AVRX) announced today that its collaborators at the University of Texas M.D. Anderson Cancer Center have been issued United States Patent number 6,656,471 entitled HIV-specific T-cell induction, for a method to diagnose, prevent a
Hip Hop Superstars 'TLC' Urge African Americans to Take Action and Stop Spread of AIDS: AIDS Now Top Killer of African Americans, Incidence Rising Among Women: PRNewswire - February 2, 2004; HOUSTON, Feb. 2 /PRNewswire/ -- Tionne T-Boz Watkins and Rozonda Chilli Thomas of the award-winning music group TLC will speak out about the devastating impact HIV/AIDS is having on the African American community, particularly women, on Feb. 7 -- National Black HIV/AIDS Awareness and Information Day. AIDS is the no. 1
Millennium Water Alliance Applauds Congressional Action on Water Supply Crisis: PRNewswire - February 2, 2004; HOUSTON, Feb. 2 /PRNewswire/ -- The Millennium Water Alliance (MWA) applauds Congress for providing $100 million under the omnibus federal spending bill to address the critical shortage of safe drinking water in developing countries. The Alliance is a consortium of seven humanitarian aid agencies working to achieve saf
South African AIDS Activists Express Frustration As Government Slashes AIDS Budget by Two Thirds: PRNewswire - February 2, 2004; Renewed Hope for Treatment Access in World s Hardest Hit Country Dashed by Gov t Action DURBAN, South Africa , Feb. 2 /PRNewswire/ -- AIDS activists from the advocacy group, AIDS Therapeutic Treatment Now, South Africa (ATTN SA) expressed outrage and frustration over the move by the South African government to cut by t
President's Budget Proposal for AIDS Drug Assistance Program (ADAP) Falls Short Says AIDS Healthcare Foundation: PRNewswire - February 2, 2004; LOS ANGELES, Feb. 2 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS organization, which operates AIDS treatment clinics in the US, Africa and Central America, today released this statement on President Bush s proposed FY 2005 budget. The $35 million increase to the AIDS Drug Assistance Progr
State Medicaid Heads Pressed by AIDS Healthcare Foundation to Demand Guarantees Against Loss Due to Abbott's Recent 400% Price Increase on Norvir: PRNewswire - February 2, 2004; -- US Largest AIDS Group Writes to State Medicaid Directors Urging They Read Fine Print of Abbott s Price Increase on Key AIDS Drug. Despite Pharmaceutical Giant s Assurances, AHF Projects Steep Cost Increases on Norvir To Cash-Strapped Medicaid Programs Nationwide LOS ANGELES, Feb. 2 /PRNewswire/ -- AIDS Healthcare Fo
President's Budget Underfunds AIDS Programs: PRNewswire - February 2, 2004; WASHINGTON, Feb. 2 /PRNewswire/ -- President Bush today proposed a total of $2.7 billion for programs to fight global AIDS, TB and Malaria in 2005. Just 7% ($200 million) of the total would go to the Global Fund, a partnership headed by the US Secretary of Health and Human Services, Tommy Thompson. The amount for the F
Houston Firm Set to Begin Human Trials of New HIV Treatment: PRNewswire - January 30, 2004; HOUSTON, Jan. 30 /PRNewswire/ -- Stratus Research Labs announced today that it will soon begin human trials in Latin America of its treatment, A-221-HIV on patients infected with the HIV virus. Stratus is a privately held company with offices in Houston, Texas, which is developing a promising medication that, to date h
International AIDS Activist Takes Final Steps in 5-Year Global Walk Dr. John Chittick Completes First-Ever Worldwide AIDS Prevention Outreach to Teens in 65 Countries on Six Continents: PRNewswire - January 30, 2004; BOSTON, Jan. 30 /PRNewswire/ -- Dr. John B. Chittick of Boston is set to complete the last steps in his major humanitarian mission to train the world s youth to fight the spread of HIV/AIDS. After successfully completing a series of Global Walks over five years (1999 - 2004), he arrives back in the US on Friday, Januar
CytRx Corporation, Advanced BioScience Laboratories and University of Massachusetts Announce Filing of Investigational New Drug Application for Unique HIV Vaccine: PRNewswire - January 29, 2004; -- Proprietary Technology Licensed to CytRx - LOS ANGELES, Jan. 29 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR), Advanced BioScience Laboratories (ABL) and University of Massachusetts Medical School (UMMS) announced today that ABL has filed an Investigational New Drug Application (IND) with the Food and D
Bayer Diagnostics Receives CE Mark Certification for Its Genotypic HIV Resistance Test: First and Only CE Mark-Approved HIV Resistance Test: PRNewswire - January 28, 2004; TARRYTOWN, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- The Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY) announced today that it has received CE Mark certification for its genotypic HIV resistance testing product -- the TRUGENE(R) HIV-1 Genotyping Kit. The test, cleared by the U.S. F
Community Leaders Rally Behind New HIV Prevention Forums: Private Foundations, Service Organizations and Local Businesses Respond to Rising New HIV Infections and Success of November 16 Event: PRNewswire - January 28, 2004; NEW YORK, Jan. 28 /PRNewswire/ -- From amfAR to Broadway Cares/Equity Fights AIDS to Astor Medical Group, New York City foundations, HIV/AIDS organizations and private businesses are lending support for the upcoming HIV prevention forum entitled The Crystal-Meth - HIV Connection hosted by Harvey Fierstein. In turn, the
MedMira begins opening high-potential market in Caribbean: PRNewswire - January 28, 2004; HALIFAX, NS, Jan. 28 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) today announced the Company s first steps in entering the promising Caribbean healthcare market with its latest product, the MiraWell(TM) Triple Test, in association with Caribbean Medical International (CMI), an established and w
Gov. Schwarzenegger Signs AB 685 (Leno, D, San Francisco), Rapid HIV Testing Bill Sponsored by AIDS Healthcare Foundation: PRNewswire - January 23, 2004; -- AB 685, One of First Bills Signed by New Governor, Will Streamline Training for HIV Testing Counselors WHAT: Press Conference on Signing of Rapid HIV Testing Bill WHEN: Friday, January 23rd 11:00am WHERE: Magnet 4122 18th St. @ Castro, San Francisco WHO: Hon. Mark Leno, (D, San Francisco) California Assembly Member,
Medical Services VScan Rapid Test Kit Approved in Peru: PRNewswire - January 23, 2004; EDMONTON, Alberta, Jan. 23 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that all additional testing of its VScan Rapid HIV test kit have been completed in Peru and the VScan test kit has been approved by the National Institute of Health.
UNDP and Microsoft Announce Technology Partnership to Combat Poverty In Developing Nations: Joint Initiatives Will Help Achieve Millennium Development Goals Through Technology Resources and IT Expertise: PRNewswire - January 23, 2004; DAVOS, Switzerland , Jan. 23 /PRNewswire-FirstCall/ -- The United Nations Development Programme (UNDP) and Microsoft Corp. (Nasdaq: MSFT) today announced a technology partnership to create and implement information and communications technology projects that will help developing countries achieve the Millennium Develop
AIDS Healthcare Foundation, Episcopal Churches, and Honduran Health Ministry Open Second AIDS Clinic: PRNewswire - January 22, 2004; -- Second of Three Planned Clinics Extends Anti-Retroviral Treatment Access To Needy Central Mountain Town of Siguatapeque, Honduras . US Largest AIDS Group Partners With Ministry of Health, Episcopal Diocese of Honduras and Two Dedicated California Churches. LOS ANGELES and SIGUATEPEQUE, Honduras, Jan.
European and U.S. HIV Prescribers Rank Long-term Efficacy and Avoiding Resistance as Top Treatment Goals but Are Divided on Other Important Issues: PRNewswire - January 21, 2004; -- First International AIDS Society Survey Highlights HIV Prescribing Patterns and Priorities STOCKHOLM, Sweden , Jan. 21 /PRNewswire/ -- Prescribers of HIV/AIDS medications in Europe and North America agree that long-term efficacy and avoiding resistance are the primary treatment goals for people living with HIV. How
Trojan "America's #1 Condom" and MyStudentBody.com Team Up to Promote Safer Sex: PRNewswire - January 21, 2004; PRINCETON, N.J. and NEWTON, Mass., Jan. 21 /PRNewswire/ -- Armkel LLC, makers of Trojan(R) brand condoms, has joined forces with the developers of the MyStudentBody.com college health suite, Inflexxion(R), Inc., in an educational alliance to provide colleges with access to MyStudentBody.com STDs (MSB-STDs), an innovati
Epimmune Completes Patient Enrollment in HIV Vaccine Trial: Vaccine Designed to Combat Effects of Virus Mutation: PRNewswire - January 20, 2004; -- Interim Safety and Immunogenicity Results to Be Presented in July 2004 SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today announced that it has completed patient enrollment in the Phase I/II therapeutic HIV vaccine trial of its EP HIV-1090 vaccine candidate. All 10 patients in the fourth
AIDS Healthcare Foundation: President's State of the Union Speech Disappoints Longtime AIDS Advocates: PRNewswire - January 20, 2004; LOS ANGELES, Jan. 20 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS organization, which operates AIDS treatment clinics in the US, Africa and Central America, today released this statement on President Bush s State of the Union message. There is simply no scientific basis for abstinence-onl
Calypte Biomedical Appoints Dr. Richard George as President and CEO and Richard Van Maanen as Vice President of Operations: Experienced Executives to Lead Next Stage of Company's Growth: PRNewswire - January 20, 2004; ALAMEDA, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that it has named Dr. Richard George its new President and CEO and Richard (Dick) Van Maa
BET, Black AIDS Institute and Kaiser Family Foundation Launch The Rap-It-Up/Black AIDS Short Subject Film Competition: PRNewswire - January 20, 2004; -- Submitted Entries Must Focus on HIV-Related Topics, African-American Themes; BET to Televise Winning Selections Around World AIDS Day WASHINGTON, Jan. 20 /PRNewswire/ -- BET, the Black AIDS Institute and the Kaiser Family Foundation, have launched the new Rap-It-Up/Black AIDS Short Subject (Rap-It-Up/BASS) Film Comp
VaxGen Announces Changes to Management and Board: Executives to Pursue Foundation for HIV Vaccine Development; Director Resigns After Accepting Position at Amgen: PRNewswire - January 20, 2004; BRISBANE, Calif., Jan. 20 /PRNewswire-FirstCall/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that three of its senior executives will be leaving the company to pursue the formation of a not-for-profit foundation for the advancement of HIV vaccine research and development. VaxGen was formed in 1995 to develop an HIV
Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir: Published in The Journal of Acquired Immune Deficiency Syndrome (JAIDS): PRNewswire - January 20, 2004; RESEARCH TRIANGLE PARK, N.C., Jan. 20 /PRNewswire/ -- The final 48-week results from the NEAT trial, an open-label, multi-center study evaluating the safety and efficacy of LEXIVA(TM) (fosamprenavir calcium), the protease inhibitor (PI) formerly known as GW433908 (908), in antiretroviral therapy- naive HIV+ patients ve
Orphan Drug Designation Requested for VIRUCORT-50 in the Treatment of Depression in Children HIV: PRNewswire - January 20, 2004; LAS VEGAS, Jan. 20 /PRNewswire/ -- In a letter to the Secretary of Health and Human Services (HHS) Alfred T. Sapse MD (ret) the US representative of Cortisol Research International, SA, an R & D pharmaceutical company in Bucharest, Romania had requested an Orphan Drug Designation for the newly approved drug VIRUCOR
Study From Arizona State University Reveals ProAlgaZyme May Decrease Risk of Stroke or Heart Attack: Algae Extract Degrades Abnormal Fibrin Debris Known to Create Blood Vessel Blockage: PRNewswire - January 20, 2004; TEMPE, Ariz., Jan. 20 /PRNewswire-FirstCall/ -- Health Enhancement Products, Inc. (OTC: HEPI), today announced that an independent study conducted by the Biochemistry Department at Arizona State University concluded that the Company s flagship product, ProAlgaZyme, possesses fibrinolytic properties, required in the bre
Harvey Fierstein to Host Public Forum on Crystal-Meth and HIV Transmission: Forum to Jumpstart a Public Discourse on the Emerging Crystal Meth Epidemic in NYC's Gay Community: PRNewswire - January 19, 2004; NEW YORK, Jan. 19 /PRNewswire/ -- In an effort to uncover and discuss openly the role crystal methamphetamine use plays in HIV transmission, organizers of the Challenging HIV forum series are pleased to announce a public forum that will include Harvey Fierstein as the moderator and Peter Staley among the panelists.
CytRx Transformation Completed as it Focuses On RNAi Technology and HIV Program: PRNewswire - January 16, 2004; LOS ANGELES, Jan. 16 /PRNewswire-FirstCall/ -- In line with its strategy to become a fully integrated drug development company using RNAi technology and DNA-based vaccines, CytRx Corporation (Nasdaq: CYTR) announced today that it will cease funding its existing investments in genomics companies to focus on its core str
Chiron's HIV Vaccine Candidate Begins Clinical Trial in United States: Trial Underscores Importance of Public-Private Partnership - Second-Generation Candidate Employs Novel Approach to Virus: PRNewswire - January 15, 2004; EMERYVILLE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today the initiation of a clinical trial in the United States for its HIV vaccine candidate. The trial, the result of a collaboration between the HIV Vaccine Trials Network (HVTN), funded by the National Institute of Aller
UN Secretary-General Kofi Annan Launches Global Media AIDS Initiative: PRNewswire - January 15, 2004; NEW YORK, Jan. 15 /PRNewswire/ -- As part of the ongoing mobilisation of civil society in the fight against HIV/AIDS, United Nations Secretary-General Kofi Annan today met with leaders of some of the world s leading media organizations to launch a Global Media AIDS Initiative. The Initiative aims to activate media orga
Procleix(R) Ultrio(TM) Assay Receives European CE Mark: First CE-Marked Triplex Nucleic Acid Test for Blood Screening: PRNewswire - January 15, 2004; -- Chiron Expects to Roll Out Assay in European Economic Area (EEA) Early This Year EMERYVILLE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today that the Procleix(R) Ultrio(TM) Assay used for the simultaneous detection of human immunodeficiency virus type 1 (HIV-1), hepatitis
Red Cross Homeless and Transportation Programs to be Transferred to Experienced Local Agencies: PRNewswire - January 15, 2004; NEW YORK, Jan. 15 /PRNewswire/ -- The American Red Cross in Greater New York (ARC/GNY) today announced that it will transfer its homeless services and transportation services programs to two highly qualified New York City providers. The homeless services program will be transferred to the Children s Rescue Fund and the
Latest Antiviral Findings Featured at the Only-Focused Anti-Infective Congress, Mar 29-30 Cherry Hill NJ: PRNewswire - January 14, 2004; CHERRY HILL, N.J., Jan. 14 /PRNewswire/ -- The world of antiviral researchers and clinical experts from the pharma & biotech industry will be convening in Cherry Hill, NJ to attend, speak, & exhibit at the 5th International Antiviral Drug Discovery & Development Summit announces Strategic Research Institute
Beckman Coulter Signs Agreement With Clinton Foundation to Offer AIDS Testing to the Developing World: PRNewswire - January 14, 2004; FULLERTON, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), during a press conference held today at the William J. Clinton Presidential Foundation in New York City, signed an agreement to participate in a program to supply HIV and AIDS-related products to certain developing countries. Throug
World's Largest Supplier of Donated Medical Goods Opens Twin Cities Facility: Senator Coleman on Hand to Help Welcome Project C.U.R.E. to Minnesota: PRNewswire - January 13, 2004; SAINT PAUL, Minn., Jan. 13 /PRNewswire/ -- Project C.U.R.E., the world s largest supplier of donated medical supplies and equipment to developing nations, today celebrated the grand opening of its new Saint Paul facility, located at 178 E. Ninth Street, and welcomed support from the Twin Cities medical community. Since
CytRx Initiates Broad RNAi Program to Develop Novel Therapies for Treating Major Diseases Associated With CMV: PRNewswire - January 13, 2004; LOS ANGELES, Jan. 13 /PRNewswire-FirstCall/ -- Further expanding its collaboration with a world pioneer in RNA interference (RNAi) technology, CytRx Corporation (Nasdaq: CYTR) today announced it has signed a new agreement with the University of Massachusetts Medical School (UMMS) under which CytRx will fund research at
World-class AIDS Vaccine Researcher Emilio Emini Joins IAVI: PRNewswire - January 13, 2004; NEW YORK, Jan. 13 /PRNewswire/ -- Emilio A. Emini, Ph.D., a globally recognized expert in AIDS and vaccines, has joined the International AIDS Vaccine Initiative (IAVI) as Senior Vice President and Chief of Vaccine Development. Dr. Emini will oversee IAVI s partnership programs to develop a vaccine to prevent HIV infec
Viacom and Kaiser Family Foundation's Know HIV/AIDS Campaign to Premiere Year Two On Super Bowl Sunday: PRNewswire - January 12, 2004; * 2004 commitment of ad placement value estimated at $200 million 40 targeted PSAs to run across television, radio and outdoor media * TV shows incorporate HIV/AIDS storylines and special programming * The 2004 campaign builds on the success of Year One: 44% of adults surveyed either recognized the KNOW HIV/AIDS brand
Rochester Start-up Offers Groundbreaking Discovery in HIV Research - OyaGen Pioneers New Class of Drugs That Focus on HIV Editing Enzyme: PRNewswire - January 12, 2004; ROCHESTER, N.Y., Jan. 12 /PRNewswire/ -- Trillium Group and the University of Rochester Medical Center (URMC) today announced that the University Technology Seed Fund will invest in the formation of OyaGen, Inc., a start-up company at work on a new class of HIV drugs that may enable the body s own immune system to virt
AIDS Rapid Test Bill Among First on Gov. Schwarzenegger's Desk, Reports AIDS Healthcare Foundation: PRNewswire - January 12, 2004; AB 685 (Leno, D, San Francisco) Streamlines Training for HIV Testing Counselors. Bill Sponsor AIDS Healthcare Foundation Urges Signature. LOS ANGELES, Jan. 12 /PRNewswire/ -- A bill intended to jumpstart a stalled rapid HIV testing program will be among the first to land on California Governor Arnold Schwarzenegger s d
Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JPMorgan Healthcare Conference: PRNewswire - January 12, 2004; CAMBRIDGE, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan Healthcare Conference in San Francisco. The Company also provided preliminary results from the Phase II study of pralnacasan in ost
AIDS Healthcare Foundation: California AIDS Cuts Threaten Lives Instead Of Cutting Waste: PRNewswire - January 9, 2004; LOS ANGELES, Jan. 9 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS organization, today called Governor Arnold Schwarzenegger s budget proposal to close California s AIDS medication program to new patients, a bad idea that both threatens lives and saves no money. Today s budget proposal caps
Pataki's State of the State Again Ignores AIDS: PRNewswire - January 7, 2004; NEW YORK, Jan. 7 /PRNewswire/ -- Governor Pataki s annual State of the State Address has again failed to acknowledge the expanding HIV/AIDS epidemic in New York, which continues to be a public health emergency in communities of color, low-income neighborhoods, and among other vulnerable populations. While we are mindfu
Gen-Probe Receives FDA Approval for Vaginal Self-Collection Kit for the APTIMA COMBO 2(R) Assay: PRNewswire - January 6, 2004; SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today announced that it has received Food and Drug Administration ( FDA ) approval for the APTIMA(R) Vaginal Swab Specimen Collection Kit, the first kit that enables patients to self-collect vaginal swab specimens to be tested for Chlamyd
GenVec and the National Institutes of Health (NIH) Expand Manufacturing Contract to Include Late-Stage Clinical Manufacturing for HIV Vaccine: PRNewswire - January 6, 2004; GAITHERSBURG, Md., Jan. 6 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC), a biopharmaceutical company, announced today an additional expansion of its multi-year subcontract with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of He
U.S. FDA Approves INVIRASE(R) Boosted With Ritonavir for Use in Treatment of HIV/AIDS: New Dosing Strategy Offers Potent Option in Combination with Other Anti-HIV Drugs: PRNewswire - January 6, 2004; NUTLEY, N.J., Jan. 6 /PRNewswire/ -- Roche today announced U.S. Food and Drug Administration ( FDA ) approval of its protease inhibitor INVIRASE(R) (saquinavir mesylate 1000 mg) for use with ritonavir (100 mg) in combination regimens for the treatment of HIV infection. This new dosing strategy increases ( boosts ) bloo
Antiviral Drug, Valacyclovir, Reduces Genital Herpes Transmission Between Sexual Partners by 50 Percent: PRNewswire - January 2, 2004; SEATTLE -- An international team of researchers finds that taking a single daily dose of an approved antiviral drug known as valacyclovir can reduce the transmission of genital herpes to uninfected partners by 50 percent. The results are published in the Jan. 1 issue of the New England Journal of Medicine. The team
Results of Pivotal Study for GlaxoSmithKline's VALTREX Published In New England Journal of Medicine: First and Only Anti-Viral Proven to Reduce Sexual Transmission of an STD: PRNewswire - January 1, 2004; RESEARCH TRIANGLE PARK, N.C. -- GlaxoSmithKline today announced the publication of results from a clinical trial evaluating VALTREX(R) (valacyclovir HCl), an oral antiviral, in the reduction of transmission of genital herpes , in the Jan. 1 edition of the New England Journal of Medicine. VALTREX significantly reduced t

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2004. AEGiS.